



Shifa
International
Hospitals Ltd.

QUALITY SERVICE

for Humanity





18 May 2017

Dr. Manzoor H. Qazi
Chief Executive Officer
Shifa International Hospitals Ltd.
Pitras Bekhari Road, Sector H-8/2
Islamabad, 41000
Pakistan

Dear Dr. Manzoor H. Qazi:

Joint Commission International (JCI) Accreditation has reviewed the Initial Hospital Survey Report of 13-18 May 2017 for Shifa International Hospitals Ltd. It is with great pleasure that I inform you of the decision to grant ACCREDITATION to Shifa International Hospitals Ltd. Congratulations to you, and all the other leaders and staff for achieving this recognition of your commitment to provide quality care on an ongoing basis.

The citizens of Pakistan should be proud that Shifa International Hospitals Ltd. is focusing on this most challenging goal – to continuously raise quality to higher levels.

Once again congratulations on this significant achievement.

Sincerely,

Paul Chang, MD, MBA, MPH, CPHQ, FACHE
Vice President, Accreditation, Standards and Measurement
Joint Commission International

Headquarters
1515 West 22nd Street
Suite 1900
11th Floor, Room 2923
United States
Voice: +1 (303) 299-7800
Fax: +1 (303) 267-7800

Amsterdam
Voice: +31 (0) 20 294 499
Fax: +31 (0) 20 294 266

Asia-Pacific Office
15th Floor
Singapore Land Tower
3 Raffles Place
Singapore 048623
Voice: +65 6422 7268
Fax: +65 6426 8114

Middle East Office
P.O. Box 57000
Mail 77, 2nd Floor
Dubai Healthcare City
UAE
Voice: +971 4 29 4996
Fax: +971 4 29 4995

Shifa International Hospitals Ltd.

Islamabad, Pakistan

has been

Accredited

by



JOINT COMMISSION INTERNATIONAL

which has evaluated this **Hospital** and found it to meet the international health care quality standards for patient care and organization management.

Effective 19 May 2017 through 18 May 2020


J. Thomson Kirby, FACHE
Chair


Paul Wilson
President, Chief Executive Officer

© 2014

Joint Commission International is a division of Joint International Business, Inc. an affiliate of The Joint Commission.

Contents



Company
Information

05

Board of
Directors

06

Chairman's
Review

08

Vision, Mission, Values	04	Shifa Obstetrics/Gynaecology	36
Company Information	05	Shifa Pathology and Laboratory Medicine	37
Board of Directors	06	Shifa - Services Under One Roof	38
Chairman's Review	08	Shifa Consultants	40
Office of the Chief Executive Officer	10	Office of the COO	66
Office of the Medical Director	12	Shifa Senior Management Team	67
Director Medical Services	14	Shifa Radiology	70
Director Surgical Services	16	Shifa Nursing	71
Director PGME & CME	17	Shifa Faisalabad Hospital	72
Shifa Heart Center	20	Shifa G-10 Hospital	73
Shifa Cancer Center	24	Awards and Achievements	
Shifa Neurology Center	26	JCIA Glimpses	74
Shifa Urology & Kidney Transplant Center	30	Shifa Consulting Services Pvt. Ltd.	76
Shifa Liver Transplant / Hepatobiliary & Pancreatic Surgery	31	Shifa CSR Initiatives	77
Shifa Gastroenterology	32	Shifa Tameer-e-Millat University (STMU)	78
Shifa General Surgery	33	Shifa Foundation (SF)	79
		Tameer-e-Millat Foundation (TMF)	80

Office of the Chief
Executive Officer

10

Directors'
Report

93

JCIA
Glimpses

74

Acknowledgement	81	Cash Flow Statement	122
Notice of the 30 th AGM	83	Statement of Changes in Equity	123
Notice of the 30 th AGM (Urdu)	88	Notes to the Financial Statements	124
Statement of Material Facts	89	Consolidated Financial Statements	158
Directors' Report	93	Auditors' Report to the Members	159
Directors' Report (Urdu)	106	Consolidated Balance Sheet	160
Statement of Value Addition	107	Consolidated Profit & Loss Account	162
Six Years at a Glance	108	Consolidated Statement of Comprehensive Income	163
Horizontal Analysis	110	Consolidated Cash Flow Statement	164
Vertical Analysis	112	Consolidated Statement of Changes in Equity	165
Statement of Compliance with CCG	114	Consolidated Notes to the Financial Statements	166
Review Report to the Members	116	Pattern of Shareholding	202
Auditors' Report to the Members	117	Disclosure in Connection with the Pattern of Shareholding	204
Balance Sheet	118	Form of Proxy	
Profit & Loss Account	120		
Statement of Comprehensive Income	121		

Our Vision

To be the region's leader by providing quality healthcare services

Our Mission

Healthcare with compassion for all

Our Values

Compassion, Commitment,
Teamwork, Quality, Respect and
Accountability

Our Strategic Priorities

Physician Partnership and Enhanced
Clinical Quality Provide Seamless/Easy
Access Care Delivery Financial Strength/
Viability Strategic Growth



Company Information

Board of Directors

Dr. Habib-Ur-Rahman
Dr. Manzoor H. Qazi
Mr. Muhammad Zahid
Dr. Mohammad Salim Khan
Mr. Shafquat Ali Chaudhary
Shah Naveed Saeed
Mr. Qasim Farooq Ahmad
Dr. Samea Kauser Ahmad
Syed Ilyas Ahmed
Prof. Dr. Shoab Ahmed Khan

Chairman
CEO
Director
Director
Director
Director
Director
Director
Director
Director

Audit Committee

Shah Naveed Saeed
Dr. Habib-Ur-Rahman
Dr. Samea Kauser Ahmad
Syed Ilyas Ahmed

Chairman
Member
Member
Member

Human Resource & Remuneration Committee

Dr. Habib-Ur-Rahman
Dr. Manzoor H. Qazi
Shah Naveed Saeed

Chairman
Member
Member

Chief Operating Officer

Mr. Aziz A. Jan

Chief Finance Officer

Syed Muneer Hussain

Company Secretary

Mr. Muhammad Naeem

Head of Internal Audit

Mr. Muhammad Saeed

Auditors

M/s Grant Thornton Anjum Rahman

Legal Advisor

M/s Bashir Ahmad Ansari & Company

Bankers

Meezan Bank Limited
Al Baraka Bank (Pakistan) Limited
Faysal Bank Limited
Askari Bank Limited
Dubai Islamic Bank Limited
Habib Bank Limited
MCB Bank Limited
First Habib Modaraba

Registered Office

H-8/4, Islamabad

Share Registrar

M/s Corplink (Private) Limited
Wings Arcade, 1-K, Commercial,
Model Town, Lahore



Board of Directors



Dr. Manzoor H. Qazi
(CEO)



Dr. Habib-Ur-Rahman
(Chairman)




Mr. Muhammad Zahid
Director



Dr. Mohammad Salim Khan
Director



Shah Naveed Saeed
Director




Mr. Shafquat Ali Chaudhary
Director



Mr. Qasim Farooq Ahmad
Director



Dr. Samea Kauser Ahmad
Director



Syed Ilyas Ahmed
Director



Prof. Dr. Shoab Ahmed Khan
Director

Chairman's Review



Dr. Habib-Ur-Rahman

Healthcare is serious business especially so in running a large tertiary care hospital where a million patients are served every year in all specialities involving intricate diagnostic procedures and complex surgeries. It needs total commitment of the Board and senior management as well as extreme dedication by more than 4000 team members to perform at international standards of patient safety and delivery of services.

Healthcare is serious business especially so in running a large tertiary care hospital where a million patients are served every year in all specialities involving intricate diagnostic procedures and complex surgeries. It needs total commitment of the Board and senior management as well as extreme dedication by more than 4000 team members to perform at international standards of patient safety and delivery of services.

We put ourselves to test by inviting intense scrutiny by JCI this year. This gave an impetus to intensify our focus on continuous quality improvement. Alhamdulillah! we achieved the Gold Seal of Approval. Pursuit of excellence is a never-ending journey. I congratulate Shifa team for earning this honor.

Operationally your Company enters a new phase. We are investing in a vision of growth. Building more hospitals, venturing into new fields of healthcare services, developing innovative IT infrastructure for hospitals are some examples of our initiatives. Land acquisitions and related activities are in progress. Competition for providing services in large cities is intensifying while smaller towns remain underserved. We have to strike a balance in this scenario. We are targeting bed capacity directly owned or operated by Shifa International to reach 1000 beds in next 3 years. This is expected to bring operational efficiency in arranging hospital supplies and equipment as we serve more communities.

Our subsidiary Shifa Consulting Services has been engaged in providing much needed professional advice to industries, charitable organizations and businesses in planning, building, equipping and commissioning clinics and hospitals. We relish the position of being a national resource in this field. It is a good business opportunity to enhance shareholder value. Past two years have witnessed a keen overseas investor interest in our domestic health sector. Political stability will remain a pre-requisite to sustain that favorable view.

Our endeavors in the field of education are integral part of our corporate philosophy. We bank on precious resource of highly qualified clinical faculty and cutting edge technology to prepare future generation of radiologists, pathologists, medical and surgical specialists, nurses, pharmacists, physical therapists and competent technicians in allied fields to maintain excellence in patient care. Our sponsorship of Shifa Tameer-e-Millat University aims to ignite unquenchable spirit of inquiry in young minds who will lead the professional in coming decades. These promising men and women discover a passion for science and compassion for humanity in working environment of Shifa International Hospitals.

As an institution we continue our quest for equality, hard work and the flourishing of all. As before, we have toiled diligently to assure ethical business practices, safety at work, wellbeing of our proud and dedicated workforce and for environmental protection. There is no letup in assuring management performance and financial controls. This is our contribution towards the goal of a healthy and prosperous Pakistan.

Next pages contain some details of our activities and accomplishments during the year under review.

Office of the Chief Executive Officer



Dr. Manzoor H. Qazi

JCIA has been the biggest milestone achieved since the inauguration of Shifa International Hospital.

A giant leap! I would like to thank the Board members and all the employees, management and consultants, who worked with full commitment, dedication and professionalism to bring this honor and prestige to our country & Shifa International Hospital. With this we are standing among the top quality institutions of the world.

In our last annual report we had mentioned:

“The most important and ambitious target which we are working at present is to get accreditation from “Joint Commission International”. This is an International accrediting body which testifies to the excellence in quality of healthcare delivery. This is a test of all 4000+ employees. We plan to achieve this target in the next 12 months... Insha-Allah!”

And Alhamdulillah! We are pleased and proud to inform you that Shifa International Hospital has received the prestigious Gold Seal of Approval from Joint Commission International (JCI) on May 18, 2017. Worldwide (outside USA) around 950 hospitals have received this Accreditation. This seal accredits the International Standards of Excellence in Quality and Safety. Every area of the hospital was inspected, whether that was directly related to patient care or indirectly or support area. Nursing, Medical, Radiology, Pharmacy, Laboratory, Building, FNSD, Physiotherapy, Medical Records and all other areas were inspected and found to meet the highest standards of quality and safety.

This has been the biggest milestone achieved since the inauguration of Shifa International Hospital. A giant leap! I would like to thank the Board members and all the employees, management and consultants, who worked with full commitment, dedication and professionalism to bring this honor and prestige to our country & Shifa International Hospital. With this we are standing among the top quality institutions of the world.

This year is also special to us, as we have entered into our 25th Year of operations. There has been a consistent growth, both in infrastructure as well as financial, year after year. Over two decades of quality service and commitment have given us National and International recognition. We are the hospital of the choice in the region.

Yes there are challenges, and these challenges keep us energized. The biggest challenge is the availability of a trained healthcare workforce. To address this, Shifa International Hospital and Shifa Tameer-e-Millat University together are working towards training of young doctors, nurses and paramedical staff. After completion of training some of them leave us, for better opportunities internationally and nationally. We take it positively, as they are having a positive impact on healthcare in other hospitals. This also is consistent to our mission.

Quality service is not limited only to accurate diagnosis and efficient treatment, equally important is the respect and dignity of the patient. At Shifa we are making an extra effort to address both these aspects of quality. Patient satisfaction is the most critical measure of quality at Shifa International Hospital.

We have a strong desire that other hospitals in Pakistan should also improve their quality and receive JCI Accreditation. We are reaching out to those hospitals both in public and private sectors and guiding them in implementing quality standards and effective monitoring mechanism, so that they can also meet the tests of quality and safety.

Our sister organizations Shifa Tameer-e-Millat University, Shifa Foundation and Tameer-e-Millat Foundation are also growing and making a significant impact on society both in healthcare provision and education.

We do realize that with the constantly changing healthcare dynamics, economic and geopolitical situation, we have to move on and expand. The organizations which stop growing, start declining. We are pursuing an aggressive growth and expansion policy, both nationally and internationally. To have nationwide impact on quality of healthcare is also our mission. Within the next few months, we will be sharing with you some good and some great news... Insha-Allah!

I would again like to thank all the employees, management and staff of Shifa International Hospital and its sister organizations who have provided services with full commitment and dedication. Their persistent efforts have made Shifa International Hospital a pride of Pakistan. We pray to Almighty to help us and guide us as we move on this mission of continual improvement in the quality of healthcare across the region.

Thank you

Office of the Medical Director



Dr. M. Salim Khan

The entire clinical operations at Shifa International Hospital are directly guided by Medical Director (MD) to ensure best practices and compliance with the hospital policies and procedures for achieving the best possible patient care. Office of the MD works in close collaboration of the five directors namely Director Medical Services, Director Surgical Services, Director Critical Care Services, Director Clinical Research and Director PGME & CME in their respective areas and clinical chiefs in the areas of Radiology, OBS & Gyne, Surgery, Medicine, Pediatrics, Anesthesia & Pain Medicine and Pathology & Lab Medicine. This arrangement is meant to ensure that our patients are served well with quality and accountability and are given best possible patient experience. Medical Director reports to and takes guidance from Office of the Chief Executive Officer.



Dr. Mian Amjad Sohail
Director Medical Services



Dr. Arif Malik
Director Surgical Services



Dr. Darakhshan Jabeen
Director PGME & CME



Dr. Ghulam Siddiq Khan
Chief of Surgery



Dr. Syed Nayer Mahmud
Chief of Medicine



Dr. Shazia Fakhar
Chief of OBS & Gyne



Dr. Muhammad Ashraf
Chief of Anaesthesia
& Pain Medicine



Dr. Ejaz A. Khan
Chief of Pediatrics



Dr. Imran Nazir Ahmad
Chief of Pathology



Dr. Aamir Iftikhar Malik
Director Critical Care Services



Dr. M. Ayaz Mir
Director Clinical Research



Dr. Atif Rana
Chief of Radiology

Director Medical Services



During the last year each department in Medicine and Allied has contributed significantly towards development of services. Every department worked very hard to improve processes and quality of care. Their efforts in this regard lead to gaining accreditation by Joint Commission International.

The Department of Medicine is inclusive of three Clinical Divisions: Internal Medicine, Cardiology and Gastroenterology. Besides, a range of Clinical Sections are tailoring their services to patients' specific requirements, which include, Allergy & Immunology, Dermatology, Endocrinology, Nephrology, Neurology, Radiation Oncology, Medical Oncology, Palliative Care, Psychiatry, Pulmonology & Critical Care, Rheumatology, Neonatology, Infectious Diseases, Physical Medicine ,& Rehabilitation, Emergency Medicine, and Executive Physical & Employee Health Clinic.

Patients are received in the Outpatient Clinics and Emergency Department, where their medical needs are promptly and thoroughly addressed, with patients who require further care admitted and managed through in-hospital care management. Top quality care is provided through highly qualified consultants who have extensive national and international experience in their respective fields. Emergency care teams in the form of Code Blue Team and Rapid Response Team have saved countless lives of patients who are suspected at risk of cardiopulmonary arrest.

Medicine & Allied runs OPD clinics of all specialties on daily basis and the number of OPD appointments completed by every department is increasing every year.

Consultants in all Medicine and Allied departments have heavily invested their time and resources in developing and providing challenging and structured training programs. The aim is to provide best possible training to physicians so they may be able to achieve their post-graduate qualifications.

Emergency Department

Emergency Department provides 24 hours service, with round the clock senior physician coverage. Emergency Department has its own post-graduate training, one of the few in Pakistan and recognized internationally.

Department of Pediatrics

Department of Pediatrics provides services ranging from primary care facility, 24 hour emergency care,

rehabilitation and sub-specialty services catering to specific pediatric needs. Department of Pediatrics is supported by Neonatal ICU and Pediatric ICU to manage critically ill patients.

Endocrinology section

Endocrinology section at SIH offers services in wide range of Endocrinology diseases, as Diabetes and Thyroid diseases are common in this part of the country.

Division of Cardiology

Division of Cardiology leads one of the most renowned heart centers in Pakistan. Shifa Heart Center provides comprehensive specialized services which are further supported by its Cardiac Care Unit. SIH has one of the most comprehensive heart health centers, with examples of services including timely balloon angioplasty, coronary angiography, and implantable cardiac defibrillators.

Division of Internal Medicine

Division of Internal Medicine provides extensive management services for all adult patients, collaborating with other physicians and medical staff to deliver multidisciplinary care. Medical ICU and Medical Step Down facilities are available for critically ill patients. Further specialized services are provided for Geriatric Care and Palliative Care patients, which is the first end-of-life care service provided within the region.

Division of Gastroenterology

Division of Gastroenterology has been steadily expanding its range of services, which includes Endoscopy and ERCP suites. It provides supporting services to Liver Transplant program.

Department of Nephrology

Department of Nephrology. Dialysis Unit with 24 hour service. Furthermore, dialysis services have been extended to Shifa International G-10 as well.

Department of Neurology

Department of Neurology offers a wide array of neurophysiology services and has an array of achievement to its credit. These include, first dedicated Stroke Unit in the region providing thrombolysis.

Infection Control Department

Infection Control Department at SIH ensures Infection Prevention & Control throughout the hospital. Hospital's Infection Control Committee (ICC) meets every month to ensure that infection control measures are being taken at all levels of clinical practices. ICC advises clinicians and other health care workers on proper use of antibiotics, infection control practices and other measures. The committee monitors health care associated infections, which have dropped significantly during the past year.

Department of Oncology

Department of Oncology provides comprehensive care with latest technology facilities. Shifa Cancer Center provides services in three main domains: Medical oncology, Hematology oncology and Radiation Oncology. The Bone Marrow Transplant Program has so far performed more than 100 bone marrow transplants.


Laboratory at SIH

The Laboratory at SIH is a comprehensive full range service and reference laboratory dedicated to provide timely and high quality results. There are nine subspecialties such as Chemical Pathology, Hematology, Flow Cytometer, Histopathology, Blood Transfusion Services, Molecular Diagnostic Lab, Phlebotomy, Cytogenetic, Immunology lab and Microbiology Laboratory which are working under the umbrella of Department of Pathology. The Laboratory at Shifa International Hospital supports the physicians for efficient and appropriate diagnosis of complicated diseases.

Director Surgical Services



Growth in Radiology Procedures (2016-17)



The surgical services at Shifa comprise of 16 specialties with 93 Physicians & Surgeons and 21 Operating rooms. The department of Surgery has added new consultants in Interventional Radiology, Pain Management and Orthopedics in the past year and continues to explore avenues to bring latest expertise and technologies in all specialties.

The Director Surgical Services coordinates & oversees delivery of high quality, safe, patient & family centered surgical services.

The surgical services at Shifa comprise of 16 specialties with 93 Physicians & Surgeons and 21 Operating rooms. The department of Surgery has added new consultants in Interventional Radiology, Pain Management and Orthopedics in the past year and continues to explore avenues to bring latest expertise and technologies in all specialties.

In the year 2016-2017, over 16,985 surgeries were performed with more than 139,000 outpatient visits and around 22,000 IPD admissions.

Radiology department is at the forefront of adding latest technology for improved diagnostic facilities to our patients. We have added new state of the art Ultrasound machines (GE-Voluson-E6 & Aplio-500) with 3D & 4D Obstetrical scan.

The exceptional image quality helps in diagnosing various anomalies not detected by normal machines, ability to do Elastography for Liver tumors, Breast cancer and Thyroid tumors. The Aplio-500 U/S machine with shear wave & stress Elastography will help in grading of liver diseases. With this technology it will be possible to give better qualitative & quantitative information to diagnose effectively in Obstetrics/gynecology, Surgery, Liver transplant, Oncology, ENT & Medicine.

New state of the art 3-D Mammography machine

(Hologic, USA) with stereotactic breast biopsy table has been commissioned. Efficient & better image quality compared to 2-D mammography gives physician's ability to detect early breast cancer. We are also pleased to announce that hospital imaging has been made available on PACS and on LCD monitors in the ORs thus having significant cost savings and ease of availability during procedures.


Shifa is leader in Living donor Liver transplantation. With over 522 transplantations to date our program has survival rates comparable to international rates. Liver transplant & HPB surgery fellowship program at Shifa is imparting training in this specialty to future surgeons.

The Labor & delivery ward has been renovated with 4 delivery rooms, 12 monitored beds including rooms for emergency triage & eclampsia/pre-eclampsia room. For the first time in Shifa, two Modular ORs (HT group, Germany) have been completed and commissioned.

Quality indicators in all areas of surgical services are being monitored to maintain accreditation with JCI. These indicators will help us improve the quality of patient care and achieve future endeavors at Shifa.

Quality improvement measures have also been undertaken in the Operating rooms where pre-operative consent, correct surgical site marking & Time-Out by the entire team before start of procedure has been implemented. We are striving to improve the first case on-time start to improve the OR efficiency.

Director PGME & CME





Postgraduate Medical Education at Shifa International Hospital has experienced considerable growth, innovation and transformation in recent years.

A road map has been developed with a view to improve Medical Education and Training. Improving medical education has been a step worth taking, as we have largely been able to address the changing health care needs of individuals and society. The future of medical education demands that we embrace inter-professional education, innovation in health care delivery, high quality care with safe practices and medical education that is competency-based and integrated across the medical education continuum.

The key strategic objectives identified are to:

1. Promote educational excellence
2. Enhance quality and patient safety
3. Provide operational support
4. Build partnerships- Historically what we could accomplish independently has now become a collaborative effort, there by utilizing each other's strengths and providing unique learning opportunities of training. In this regard a number of elective positions have been secured for our learners through partnership both with national and international institutions.

Through the alignment of our goals and objectives we will ensure the preparedness of our future physicians to progress along the continuum of training, meet the requirements of the physicians of tomorrow and the diverse communities that they will serve.



CONTINUING MEDICAL EDUCATION (CME)

Our CME programs provide opportunities for physicians and allied health care professionals to improve their practice via evidence-based educational activities that focus on advances in medicine, medical technology and biomedical research as well as changes in the health care environment.

WHY CME?


As a Post Graduate institution, we are committed to provide medical education to medical students, residents and physicians on our faculty and in the community.

We promote a vibrant and supportive shared learning community for health care professionals. In addition to disseminating knowledge, our programs foster positive professional relationships, supporting communication and enhancing the potential for productive collaborations. These networks are increasingly vital as treatment methodologies and technologies evolve rapidly.

We also provide a structured forum for CME course planners and presenters. They can demonstrate their expertise and their commitment to advance standards of care, and share ideas for maximizing programs' success.

MILESTONES ACHIEVED

- CME assessment report
- CME contact hour transcript
- CME e-certificate for RSS activities
- CME attendance management system (RSS)
- CME mega event's website
- Event closing report & registration report
- Online registration & payment system
- CME e-calendar





Cancer Center

شفا کیمر سنٹر

Shifa Heart Center

Heart Diseases – National Scenario

An estimated 30 to 40 percent of all deaths in Pakistan are due to cardiovascular diseases (CVD), claiming around 200,000 lives every year. Coronary heart disease is now the leading cause of death in Pakistan. At least 12 Pakistanis die every hour due to heart attack. Major risk factors include tobacco and alcohol use, high blood pressure and cholesterol, obesity, diabetes, physical inactivity, stress and unhealthy diet.

SIH Services

Shifa International Hospital takes pride in having a full time dedicated team of Foreign Qualified and Trained Cardiologists, Cardiac Surgeons, Anesthetists & Intensivists, making it one of the best hospitals for Cardiac Care and Surgery in the area.

Cardiology department provides comprehensive clinical services, offering a range of diagnostic and therapeutic facilities: Computerized ECG, Exercise Tolerance Test (ETT), 24 Hours ECG (Holter Monitoring), 2D, M Mode, Color Doppler Transthoracic Echo, Transesophageal Echo, Dobutamine Stress Echo, Carotid Doppler Scan, Peripheral Arterial and Venous Doppler, Temporary Pacemaker Implantation, Permanent Pacemaker

Implantation (single + dual chamber), Peripheral / Renal Angiography, Pulmonary Angiography, Carotid Angiography, Coronary Angiography and PTCA with Stent Implantation (Percutaneous Coronary Angioplasty).

Cardiac Surgery

Cardiac Surgery offers sophisticated sub-specialized fields such as Aortic Root surgery, Thoracoabdominal Aortic surgery, Valve repair, Adult Congenital Cardiac surgery and Pediatric Cardiac surgery. In Coronary revascularization (CABG), we are the only center which offers the latest technique of Total Arterial Revascularization which has proven superior long term survival compared to the conventional vein graft operations.

In Thoracic Surgery we undertake the complete spectrum and currently are offering minimal access tumor resection, lung volume reduction, empyema surgery and diagnostic procedures. Cosmetic correction of chest wall deformities, diagnosis and resection of mediastinal tumor and Video Assisted Thoracoscopic Surgery (VATS) for pneumothorax, pleural effusions diagnosis and therapy are also being performed.



Achievements

- 24/7/365 Chest Pain Team
- In last 12 months Door to Balloon Time Less than 90 Minutes
- More than 32,000 cardiology procedures
- More than 14,000 OPD visits

Future Plans

Shifa Heart Center aims to be one of the first institutions in Pakistan to offer:

- Percutaneous Valve Replacement
- Extracorporeal Membrane Oxygenation (ECMO) service for pediatric patients
- Cardiac assisting devices
- Cardiac and Lung transplantation

- Minimally Invasive Vein Harvest
- Initiation of a cutting edge Residency program
- We are also planning to start a Diploma in Cardiovascular Nursing in collaboration with Shifa School of Nursing
- National Integrated Anticoagulation Service (NIACS): We take pride in successfully initiating and developing a comprehensive anticoagulation service in collaboration with our Hematology department

This comes at a time when anticoagulation is still an unregulated and unmonitored therapy in most developing countries, including Pakistan. We provide stringent INR monitoring in an appropriate dosing facility. We also administer low dose warfarin to the patients.



Patient Experiences

at Shifa



Patient: Syed Arshad Ali Shah

City: Khewra

Clinic: ENT

Consultant: Dr. Sarim H. Lodhi

I am 46 year old and work at a private firm. I had an unfortunate road accident in which I was badly injured and my ear drums were torn. I have had a surgery at Shifa and I'm recovering fast. Shifa has all the qualities and facilities expected at a tertiary care hospital. Even in the middle of the night the staff is a bell away. I'm so happy with how they treat me. And I must say I love the food. Before this I had been to a private hospital in Rawalpindi for my father's treatment but was extremely disappointed.



Patient: Iftikhar Hussain

City: Rawalpindi

Clinic: Medicine

Consultant: Dr. Muhammad Ashraf

I have been coming to Shifa since 90's and recently have been admitted too. Without a doubt Shifa is always my first and only choice. What brings me here is that patients are treated with warm-heartedness and the best of treatments. Illness and health is from Allah but Alhamdulillah I feel half cured after coming here. Since its inception Shifa has grown a lot and so has its responsibilities. May it continue to grow.



Patient: Sohail Yaseen

City: Dadyal, Azad Kashmir

Clinic: Oncology

Consultant: Dr. M. Ayaz Mir

I am a patient of Leukemia and coming to Dr Ayaz since the start. The doctor and his staff are very cooperative. I'm doing well by the grace of Allah. To all other cancer patients my advice is to keep the will power strong and fight the disease with a face up. Life and death is in Allah's hands.



Patient: Salman Khan Lodhi

City: DHA, Islamabad

Clinic: Neurology

Consultant: Dr. Raja Farhat Shoaib

It's almost been a decade I'm coming to Shifa. I've recently visited the Neurology Department after a mild stroke. Dr Farhat welcomed me with such love I felt I had completely recovered. My son was taking me to a well known hospital in Rawalpindi but I insisted and 'came running back to Dr Farhat'. I was so touched by his politeness that I advised my son, who himself works at a famous public hospital in the capital, to keep his attitude like Dr Farhat.



Patient: Muhammad Taimoor Ilyas

City: Pindi Gheb

Clinic: Ophthalmology

Consultant: Dr. M Amer Raza Awan

I injured my eye 6-7 years ago and it affected my eyesight, I regret not paying attention then. Lately my eyesight has become a lot weaker but I'm lucky I found Dr Amer in this desperate time. I've been diagnosed with TB in the eyes. He explained all the minute details and the process of tests has been very smooth too.



Patient: Faisal Khan

City: Abbottabad

Clinic: Pulmonology

Consultant: Dr. Aftab Akhtar

I'm 29 and came to Shifa in January 2016 after a severe chest pain. Dr Aftab has proved an angel for me. I'm recovering very fast. I'm completely satisfied with the treatment and undoubtedly say 'come to Shifa if you want SHIFA'. I pray for the doctor and his staff's long life.



Patient: Sajjad Ahmed

City: Islamabad

Clinic: Allergy and Immunology

Consultant: Dr. Athar Niaz Rana

I've been coming to Shifa during my Liver transplant. Recently I had an allergic reaction after eating an unwashed peach at work and I visited Dr Athar. He is very cooperative and makes patients feel so comfortable. He also gave me his contact number without asking so that I can call him whenever needed. Doctors don't normally do that.



Patient: Muzammil Niazi

City: Rawalpindi

Clinic: Liver Transplant

Consultant: Dr. Faisal Saud Dar

First of all thanks to Almighty Allah, it feels like I have been given a second chance to life through the amazing service being provided by the talented team at Shifa International Hospital. I intend to cherish this opportunity and spend time with my loved ones.

Shifa Cancer Center

Cancer – National Scenario

Among the non-communicable diseases, cancer is the leading cause of death in Pakistan. There were 14.1 million new cancer cases (majority being from the economically developing countries) and 8.2 million cancer deaths in 2012 worldwide. The most prevalent cancers in Pakistan include breast, cervix uteri and colorectal.

Shifa Cancer Center


Cancer does not mean Death. Precise treatment by experts at well-equipped facilities can make a huge difference. Shifa Cancer Center is one of the only two JCI accredited centers in the region and we offer state of the art services and care to our patients.

The Center provides comprehensive **Medical Oncology** care for solid tumors and hematological malignancies, including radiology diagnostics, pathology evaluation and chemotherapy by experts trained at best US centers.

Department of Radiation Oncology at Shifa is the first radiation therapy center in private sector in the country. It was one of the first to introduce and implement SOPs for radiation therapy including Simulation, Customized Shielding Blocks, Computerized Treatment Planning and Port Films for Treatment Verification. Presently we provide 2DRT (Two dimensional Radiation Therapy), 3DCRT (Three dimensional Conformal Radiation Therapy), IMRT (Intensity Modulated Radiation Therapy) and Arc and Rotational Radiation Therapy. Moreover, the department is equipped with a state of the art Liner Accelerator and CT Simulator (Wide Bore). The latter is used for accurate visualization of tumors and normal tissues in each individual patient for accurate targeting of tumors and protection of normal tissues.

Bone Marrow Transplant

This program at Shifa is a unique program that has transformed the lives of dozens of patients. Since its inception in 2009, the program has performed more than 100 Autologous and Allogeneic Bone Marrow/ Stem Cell Transplants including Matched sibling and



Haplo-identical (half-match) Transplants for lymphoma, leukemia, myeloma and selective solid tumors such as Germ Cell Tumors. The program is registered with CIBMTR in the USA to report outcomes data. We have a team trained at best centers in the world including a pediatric arm and currently are in an expansion phase due to stellar reputation for taking most challenging cases in region.

- Expand our pediatric transplant program to malignant disease in addition to Thalassemia and Aplastic Anemia
- Develop a dedicated Leukemia Unit
- Expand clinical research with ongoing clinical trials to improve access to novel targeted therapies being offered in Europe & USA

Future Plans

- Install a High Dose Rate (HDR) Unit to provide BRACHYTHERAPY (Internal Radiation), to be used in Gynecologic, Head & Neck, Esophagus, Prostate Cancer etc.
- Develop RAPID ARCTherapy, which will allow us to deliver IMRT in very short time (5-10 mints) thereby increasing patient comfort



Even the rich are hungry for love, for being cared for, for being wanted, for having someone to call their own. Mother Teresa

Shifa

Neurology Center

Neurological Diseases – National Scenario

More than 20 million people — 10 percent of the total population — suffer from brain and neurological diseases. An estimated 9.1 million Pakistanis suffer from stroke in the country. There are less than 10 trained stroke specialists in the whole country.

SIH Services

Shifa Neurology Center consists of a specialized team of certified, highly trained and experienced neurologists, surgeons, nurses and technicians who diagnose and treat various neurological illnesses. Our Neurophysiology services include Nerve Conduction Studies (NCS), Electromyography (EMG), Electroencephalography (EEG), Video EEG monitoring, all types of evoked potentials (somatosensory, brainstem auditory, visual) and polysomnography.

In our Stroke Unit, a fully comprehensive stroke care pathway is operational with hyperacute care. We are the only center in northern Pakistan to offer IV tPA for hyperacute stroke. Since the inception of stroke center in 2015 we have treated more than 60 acute ischemic stroke patients by administering tPA. There is also

an established 10 bed facility to manage stroke and neurological rehabilitation at Shifa G-10 Islamabad.

Our Neurology Residency Program comprises of vigorous training for future leaders in clinical and academic neurology. Two of our graduates have completed post-graduation stroke fellowship and have developed an independent stroke unit in Balochistan.

Neurosurgery

Neurology at Shifa compliments the Neurosurgery and thus Shifa becomes patient's ultimate choice. Our neurosurgery department promises services of international standards. Surgical Intensive Care Unit and Neuro Step Down facilities are available for taking care of critical and postoperative patients.

Our center is also involved in Continuous Community Awareness Program. The center celebrates designated awareness days for common neurological diseases and has put efforts in developing patient awareness materials for Stroke, Alzheimer's, Parkinson's disease, Epilepsy and Multiple Sclerosis.



Achievements

- First dedicated Stroke Unit in the region providing thrombolysis
- First dementia patient registry
- First registry for maternal and fetal complications in pregnant epileptic women
- Movement disorder clinic
- More than 40 research papers in several renowned international and national indexed medical journals
- Workshops for paramedics to manage stroke and neurological emergencies

Future Plans

We are working to establish:

- Specialized clinics for epilepsy and TIA
- Endovascular treatment pathway for acute ischemic stroke in collaboration with department of Interventional Radiology
- Vascular Neurology Fellowship
- Community orientated satellite clinics
- Telestroke services



Patient Experiences

at Shifa



Patient: M. Asad Iqbal

City: Wah Cantt

Clinic: Dental

Consultant: Dr. Syed Hamid Nasr

I have had a few procedures done at Shifa Dental Clinic earlier and since my experience was great I have come again for dental implant. I must appreciate the staff and environment here. I pray more similar Institutions are built around the country for everyone's convenience.



Patient: Dr. M. Zubair

City: Quetta

Clinic: Kidney Transplant

Consultant: Dr. Saeed Akhter

I had polycystic kidney disease since 11-12 years. Suddenly my renal profile deteriorated and my doctor in Quetta referred me here for transplant. I contacted Dr Saeed and the team at Shifa and went through a transplant in January this year. Dr Saeed is no doubt one of the best surgeons in Pakistan. The system developed at Shifa kidney Transplant is remarkable and so is the team's coordination. One thing that must be appreciated is that the post transplant follow up at Shifa is like no other.



Patient: Arfeen Bibi

City: Haripur

Clinic: Obs/Gyne

Consultant: Dr. Nabia Tariq

I am 27 years old and have had C-section earlier. This time my case was very complicated and the hospitals I went to refused to take up my case. I was then fortunately referred to Dr Nabia. On my first visit she had given me much hope and I went through C-section after a few days. Alhamdulillah everything went well and Allah blessed me with a beautiful baby girl.



Patient: M. Inaam Jaan

City: Mardan, KPK

Clinic: Gastroenterology

Consultant: Dr. Farzana Shafqat

I've been getting treatment at Shifa since 7-8 years. Before coming here I went through a lot of distress. I was continuously losing weight in addition to other complications and doctors in Mardan couldn't diagnose my disease. I even went through a surgery. I took medication for TB for 14 months only to find out I never had TB. After coming to Dr Farzana I was diagnosed with Ulcerative Colitis. Treatment followed quick recovery and I was finally at peace. I am coming for follow up now. Dr Farzana digs out every little detail about the patient, asks a lot of questions including dietary routine and gives the time required. The patient actually feels the doctor is concerned.



Patient: M. Ahmad Babar s/o Fauzia Babar

City: Islamabad Clinic: Pediatrics Consultant: Dr. Shehla Chaudhry

Ahmad was delivered at Shifa two years back. He was born immature and needed critical care at the NICU. After Allah I don't have words to thank Dr. Shehla the way she took him out of a life/death situation. I pray from the heart for her and her children's health. I still come for follow ups. I see people coming to Shifa from far flung areas. It must be so mentally and physically stressful for them but they come here since they feel satisfied here.



Patient: Masood ul Hassan Niazi

City: Mianwali Clinic: Cardiology Consultant: Dr. Yusuf Hassan

I've been coming to Shifa since it was established. I am diabetic and a heart patient and have been to a few doctors here. Presently I'm seeing Dr Yusuf and I'm very much satisfied with him.



Patient: Tahira Jabeen

City: Faisalabad Clinic: Endocrinology Consultant: Dr. Osama Ishtiaq

I'm diabetic and visit Dr Osama every 6 months. He always gives enough time. I can also call him up whenever I have any query. Me and my brothers who are also diabetic feel satisfied only with him. Staff is also cooperative, Alhamdulillah. I believe the patients should also cooperate with them and understand the staff has a hectic routine and have to deal with all sorts of patients.



Patient: Abdullah Alvi s/o Ummara Alvi

City: Jaddah, Saudi Arabia Clinic: Orthopedics Consultant: Dr. Aamer Nabi Nur

Abdullah had developed Osteomyelitis. We initially visited a Pediatrician here at Shifa who referred us to Orthopedics. Without any unnecessary tests and delay Dr Aamer suggested a minor surgery. It was because of his experience and competency. My son had been admitted at the hospital for a week after the surgery. I remember it was Ramadan and considering the fact that Abdullah was only 5 then, the staff had been extra cooperative. He was many times reluctant to get injections but the staff put an extra effort to calm him down.

When I was young, I admired clever people. Now that I am old, I admire kind people.
Abraham Joshua Heschel, Philosopher

Shifa

Urology & Kidney Transplant Center

Urological & Kidney Diseases – National Scenario

Pakistan ranks at number eight in the world in kidney diseases. 20,000 Pakistanis die of kidney failure every year. Chronic Kidney Disease (CKD) is rapidly growing in Pakistan due to late diagnosis, high volume of kidney stone disease and increasing number of patients with diabetes and high blood pressure. Consuming poor quality food, low water intake, self-medication and excessive use of medicine, obesity, diabetes and hypertension lead to kidney damage.

SIH Services

Urology & Kidney Transplant Center, one of the busiest departments of Shifa, ensures a multidisciplinary care approach for patients with rare and complex urological diseases common in adults and children too. Experienced and well trained urologists including a full time pediatric urologist provide their services for the treatment of acute and chronic urological conditions.

We are equipped with state of the art lithotripter and provide facility to all age groups. Ancillary help of general anesthesia has made lithotripsy possible even

in young children including infants. Our treatment options include: Endourology, Pediatric urology, Laparoscopy, Reconstructive surgeries, Urological oncology and Urogynecology.

Kidney Transplant

Treatment of kidney failure is either hemodialysis or kidney transplant, whereas dialysis offers an excellent short term cure, transplant is the option which gives the best chance of a good long term quality of life. The Center has become a comprehensive unit with the provision of kidney transplantation. Our success rates in this field are comparable to international level.

Achievements

- 431 kidney transplants

Future Plans

Looking forward, we are working to equip our surgical armamentarium with LASER for stones and other endourological procedures.



Shifa

Liver Transplant / Hepatobiliary & Pancreatic Surgery

Liver & Pancreatic Diseases – National Scenario

Liver cirrhosis is a leading cause of liver failure. 10 percent of population unfortunately suffers from liver cirrhosis, making it one of the most important health issues of the country. Out of approximately 200 million people, five percent (10 million) are infected with hepatitis C virus and more than two million may need liver transplantation at some stage of the disease to save their lives. Pancreatic diseases also have devastating complications as most of the patients with severe pancreatitis also develop kidney failure, respiratory failure, heart failure, sepsis and abdominal collections which can eventually lead to death.

SIH Services

Shifa is proud to be a leader in Living Donor Liver Transplantation in Pakistan. With a multidisciplinary approach by a competent team comprised of hepatobiliary and liver transplant surgeons, anesthesiologists, intensive care facility along with trained nursing staff and skilled technicians, we offer comprehensive care for liver, pancreas and biliary pathologies. Other than providing adult and pediatric Living Donor Liver Transplantation services, we perform all major pancreatic surgeries.

Our transplant and hepatobiliary experience has been recognized at national and international forums for showing excellent results that are comparable to international standards. We are constantly striving hard to maintain our status as the leading National Liver and Pancreatic Surgery unit.

Achievements

- More than 500 Liver transplant surgeries
- Frequent publications in well recognized international journals

Future Plans

We plan to continue serving the nation by providing state of the art health care facilities for liver and pancreatic diseases. Our aim is to expand the program in order to serve a greater number of patients and to be able to contribute in research by way of publications. We also hope to be able to assist other centers in establishing sustainable programs for liver transplantation and pancreatic services.



Shifa Gastroenterology

Gastroenterology Diseases – National Scenario

According to estimates over 20 million people in Pakistan are infected with Hepatitis B and C. This means every 20th person in the country is suffering from chronic hepatitis. The number of gastrointestinal cancers including esophageal, gastric and colon cancers are also on the rise.

SIH Services

Gastroenterology department at Shifa has come a long way since its inception 20 years ago. With constant up gradation and expanding services we serve as a choice destination for patients with gastrointestinal and liver diseases from all across the country. Our services include: Diagnostic and therapeutic Esophago gastro duodenoscopy (EGD) and Colonoscopy. Flexible proctosigmoidoscopy, Esophageal dilatation, PEG insertion, Esophageal varicos band ligation (EVBL), Esophageal varicossclerotherapy, Diagnostic and therapeutic endoscopic retrograde Cholangiopancreatography (ERCP) and Removal of Stones and Dilatation of stricture of biliary / pancreatic system.

Achievements

The gastroenterology department is providing supporting services to Liver Transplant program. The GI consultants are providing services to pre and post liver transplant patients. The department is performing almost 1000 endoscopic procedures per year.

Future Plans

In near future we plan to provide services like:

1. Argon plasma coagulation
2. Video capsule endoscopy
3. Endoscopic Ultrasound (EUS)



Shifa

General Surgery

General Surgery Diseases – National Scenario

An estimated 40 million individuals in Pakistan suffer from high blood pressure, 32 million from heart disease, 24 million from obesity, 18 million from high cholesterol and eight million from diabetes. The mortality figures are also quite alarming with close to 2000 Pakistanis losing their lives to a preventable non-communicable disease every day. The disability figures are just as bad with approximately 100 people undergoing amputations per day due to diabetes and trauma, and another 100 going on dialysis every day, mostly due to diabetes induced renal failure.

SIH Services

The Department of General Surgery provides compassionate and high quality comprehensive surgical consultations and care in many subspecialties including; colon and rectal surgery, trauma and burn, pediatric surgery, endocrine surgery, bariatric surgery and multidisciplinary hepatobiliary & pancreatic surgery. By using latest techniques, we strive to provide best treatment in routine and complex surgical conditions. We offer cost effective solutions to patients with collaborative and multidisciplinary approach in the following types of surgical procedures.

1. General surgical procedures
2. Oncologic/ Cancer Surgery

3. Bariatric Surgery (surgical weight loss)
4. Vascular Surgery
5. Colorectal Surgery

Achievements

MDMs (Multi-disciplinary meetings) have been regularly established to cater for all types of cancers and difficult diseases to jointly plan the best possible management.

The faculty is engaged in research activities as well. Many papers have been presented in the national as well international conferences. The department has also produced a number of publications.

Shifa General Surgery is the only department in the region offering latest techniques of VAAFT (Video-assisted Anal Fistula Treatment) for peri-anal complex fistulae and EPSiT (Endoscopic Pilonidal Sinus Treatment) for pilonidal sinus disease. Laparoscopic VMR is another established procedure for obstructed defecation.

Future Plans

The department intends to establish a one-stop dedicated multi-disciplinary breast clinic with state-of-the-art facilities under one roof.



Patient Experiences

at Shifa



Patient: Mahnoor Iqbal

City: Mirpur, Azad Kashmir Clinic: Dermatology Consultant: Dr. Aamna Batool Khan

I developed severe acne on forehead and cheeks. I also have scars and pigmentation. Dr Aamna initially treated my Acne which is almost controlled now. She is now working on the scars and pigmentation and I have all the confidence in her expertise. I had been to a lot of doctors earlier but it is only after coming to her I've recovered so much in 4 months. I'm very happy!

Patient: M. Adeel Bashir

City: London, United Kingdom Clinic: Surgery Consultant: Maj. Gen. (R) . M. A. Hashmi



It's been a year I am suffering from Hemorrhoids. After multiple appointments with the GP and taking medicines there was no sign of recovery. I finally urged the GP to refer me to a Specialist since my routine life was disturbed because of the illness. I was referred to Surgery but only to experience delayed appointments and by that time I was not in a state to wait anymore. My appetite was disturbed and I was losing weight. I finally decided to come to Pakistan for the treatment. In the first appointment, Dr Hashmi has suggested a surgery day after tomorrow. He thoroughly explained me about the procedure and complications. The staff has been very good to me and the overall procedure was smooth.

Patient: M. Mustafa Farrukh

City: Islamabad Clinic: Psychiatry Consultant: Dr Maryam Saeed Khan



When it comes to work ethics and dedication to ones job, I say this from experience since I've been to at least 5-6 other therapists in the twin cities, Dr Maryam rates the highest. She is actually concerned about her patients and gives enough time. I at times get very anxious and the first time I came to her I was feeling that way. She told me she could listen to me then but rather told me to come the next with a proper appointment because she genuinely wanted to treat me and give proper time. That's the kind of attitude a caregiver needs to have. It takes me an hour to drive to Shifa and I have to pay more than many other places but it's worth it all.

Patient: M. Naeem

City: Lahore Clinic: Nephrology Consultant: Dr. Syed Farhat Abbas



I've been coming to Dr Farhat since 4-5 years and I'm on dialysis since Dec 2015. Before coming here my health was not stable but ever since I am being treated by Dr Farhat I've only felt better.

Patient: Tasmia Baakir d/o Baakir Ali

City: Gujrat Clinic: Rheumatology Consultant: Dr. Zafarullah



My daughter Tasmia was coming back from her 9th grade exam when she fell while getting off the vehicle. She said all her joints hurt badly, she couldn't move or eat. We took her to Dr Zafarullah. She was diagnosed with Juvenile Dermatomyositis. After 3 years of treatment and Medication she has now completely recovered. I will always pray for Dr Zafar Ullah for after Allah he has proved to be a blessing for my daughter.



Shifa Obstetrics/Gynecology

Obs/Gyne Diseases – National Scenario

Around 30,000 women die every year in Pakistan because of pregnancy-associated complications that put the maternal mortality rate to about 178 per 100,000 live births. Complications of miscarriages/abortions accounted for 10 to 12 percent of maternal deaths.

SIH Services

Shifa International Hospital's Obstetrics/Gynecology department has been established since the beginning of its inception. The department has progressively expanded in terms of level of care and provision of services. Shifa International Hospital has now achieved the status of a referral center from other tertiary care hospitals for all major and advanced gynecological surgeries and emergencies due to the facilities it provides. Currently we have 29681 patients in outpatient department, 2259 gynecological surgeries, 1503 vaginal deliveries and 1314 C-sections per year.

Achievements

The outpatient department has been renovated with incorporation of daycare facility with 5 beds for

the obs/ gyne patients. State of the art Colposcope has been added to outpatient facility as a diagnostic tool. The labor and delivery unit has been reformed and renovated with state of the art equipment to improve patient care. Three modular operation theaters are being used as obstetric operating rooms to timely facilitate the obstetric emergencies. A well baby nursery has been established on B3 floor to facilitate the Post natal/ Post operative mothers and neonates. Minimal invasive surgery has been started in the gynecological field which is replacing the open surgery for most of the gynecological cases and most of the common gynecological procedures are now being performed laproscopically like hysterectomy, cystectomy, adhesiolysis and sterilization. Laproscopic myomectomy procedure will be started soon after availability of morcellator.

Future Plans

- IVF center for assisted Reproductive Therapy like IUI, IVF and ICSI.
- Outpatient hysteroscopy for evaluation of menstruation irregularity.
- Expanding satellite OPD services in Rawalpindi/ Islamabad.



Shifa

Pathology and Laboratory Medicine

The core objective of Department of Pathology & Laboratory Medicine at Shifa International Hospital is to achieve excellence by meeting international quality and technology standards and benchmarks. One of the core areas of focus is continuous and on-going product and capacity development by increasing lab tests portfolio to cater to a broader population of health care professionals and patients. The operational capability and efficiency is also continuously monitored and improved by reducing Turn-Around-Time (TAT), introducing Point of Care Testing (POCT) facilities through-out the hospital, managing a robust lab set-up for ER services and overseeing rigorous supply-chain-management system to obtain latest equipment and quality lab supplies, etc. The Department has come a long way by developing technical capabilities and strategies in the following sub-specialties:

1. CHEMICAL PATHOLOGY
2. HAEMATOLOGY
3. FLOW CYTOMETRY LAB
4. HISTOPATHOLOGY_w
5. BLOOD TRANSFUSION SERVICES
6. MOLECULAR DIAGNOSTIC LAB
7. CYTOGENETICS LABORATORY
8. IMMUNOLOGY LABORATORY
9. MICROBIOLOGY LABORATORY



Shifa
Services Under One Roof



Orthopedics Center



Rehabilitation



Ophthalmology



Plastic Surgery



Ear, Nose & Throat



Dental Clinic



**Anesthesia & Pain
Medicine**



Internal Medicine



Pediatrics

یہ خدا کا حکم ہے کہ جو شخص اس سے محبت کرتا ہے، وہ اپنے بھائی سے بھی محبت کرے۔ (حضرت عیسیٰ علیہ السلام)



Critical Care & Pulmonary Medicine



Allergy & Immunology Medicine



Psychiatry



Rheumatology



Dermatology



Infectious Disease



Nutrition & Dietetics



Pharmacy



Emergency

Consultants

ALLERGY & IMMUNOLOGY

Dr. Athar Niaz Rana



- MBBS, Diplomate American Board of Allergy & Immunology- A Conjoint Board of the American Board of Internal Medicine and the American Board of Pediatrics (1987), Diplomate American Board of Pediatrics (1981)
- Joined Shifa in 2005

Dr. Masooma Saeed



- MBBS, Consultant Anesthesiologist
- Joined Shifa in 2002

Dr. Salman Ahmad Saleem



- MBBS, Member College of Physicians & Surgeons - Anaesthesiology (2001), Fellow College of Physicians & Surgeons - Anaesthesiology (2003)
- Joined Shifa in 2006

ANESTHESIOLOGY

Dr. Shawkat M. Matabdin



- MBBS, Diploma Anesthesia from Royal College of Physicians & Surgeons - Anesthesia, UK (1977)
- Joined Shifa in 1993

Dr. Shahid Javaid



- MBBS, Member College of Physicians & Surgeons - Anaesthesiology (1986), Fellow College of Physicians & Surgeons - Anaesthesiology (1995)
- Joined Shifa in 2013

Dr. Muhammad Ashraf



- MBBS, Fellow College of Physicians & Surgeons - Anaesthesiology (2000)
- Diploma in Anaesthesia, Pakistan (1996)
- Joined Shifa in 2002

Dr. Aitzaz ud Din Khan



- MBBS, Member College of Physicians & Surgeons - Anaesthesiology (2010), Fellow College of Physicians & Surgeons - Anaesthesiology (2011)
- Joined Shifa in 2012

Dr. Brig (R) Muhammad Zameer



- MBBS, Member College of Physicians & Surgeons - Anaesthesiology (1981), Fellow College of Physicians & Surgeons - Anaesthesiology (1995)
- Joined Shifa in 2006

Dr. Shafi Ur Rehman



- MBBS, Consultant Anesthesiologist
- Joined Shifa in 2002

Dr. M. Nasir Ayub Khan



- MBBS, Fellow College of Physicians & Surgeons - Anaesthesiology (2003)
- Diploma in Medical Education, UK (2009)
- Joined Shifa in 2005

Dr. Suresh Kumar



- MBBS, Member College of Physicians & Surgeons - Anaesthesiology (2005), Fellow College of Physicians & Surgeons - Anaesthesiology (2012)
- Joined Shifa in 2012

ANESTHESIOLOGY Contd.

Dr. Jehanzeb Malik



- MBBS, Fellow of Faculty of Anesthesia Royal College of Surgeons, Ireland (1992)
- Joined Shifa in 2015

Dr. Muhammad Umar Fazal



- MBBS, Fellow College of Physicians and Surgeons- Anesthesia (2014),
- Joined Shifa in 2017.

CARDIOLOGY

Dr. Muhammad Nazir Awan



- MBBS, Fellow College of Physicians and Surgeons- Anesthesia (2005), Diploma in Anesthesia, Pakistan (1997)
- Joined Shifa in 2013.

Dr. Habib-ur-Rahman



- MBBS, Diplomate American Board of Internal Medicine (1985), Diplomate American Board of Cardiovascular Disease (1989)
- Joined Shifa in 1993

Dr. Mohammad Hassan Farooq



- MBBS, Fellow College of Physicians and Surgeons- Anesthesia (2012)
- Joined Shifa in 2013.

Dr. Mohammad Asad A. Saleem



- MBBS, Diplomate American Board of Internal Medicine (2001), Diplomate American Boards of Cardiovascular Diseases and Electrophysiology (2004)
- Joined Shifa in 2006

Dr. Muhammad Nafees Ul Hassan



- MBBS, Fellow College of Physicians and Surgeons- Anesthesia (2014).
- Joined Shifa in 2014.

Dr. Muhammad Abdul Azim



- MBBS, Fellow College of Physicians & Surgeons - Medicine (1996), Fellow College of Physicians & Surgeons - Cardiology (2002)
- Joined Shifa in 2010

Dr. Muhammad Imran Shahzad



- M.D (2003), Fellow College of Physicians and Surgeons- Anesthesia (2014).
- Joined Shifa in 2014.

Dr. Saeedullah Shah



- MBBS, Member Royal College of Physicians, UK (1996)
- Joined Shifa in 2012

Shifa Consultants

CARDIOLOGY Contd.

Dr. Yusuf Hassan



- MBBS, Member Royal college of Physicians, UK (1993), Diplomate American Boards of Internal Medicine (2008), Cardiovascular Diseases (2009) and Interventional Cardiology (2010)
- Joined Shifa in 2012

CARDIAC SURGERY

Dr. Shafqat Hasan



- MBBS, Fellow Royal College of Surgeons, England - General Surgery (1992), Fellow Royal College of Surgeons, Glasgow - General Surgery (1993), Fellow Royal College of Surgeons Glasgow - General Surgery (1993), Fellow Royal College of Surgeons, UK - Cardiothoracic Surgery (2001)
- Joined Shifa in 2015

Dr. M. Tauqeer Akbar



- MBBS, Fellow Royal College of Physicians, Edinburgh - Cardiothoracic Surgery (2009), Fellow Royal College of Physicians - Cardiothoracic Surgery (2010), Member Royal College of Surgeons, Edinburgh (2000), Fellow Faculty of Anaesthetists, Royal College of Surgeons Ireland (1998)
- Joined Shifa in 2011

Dr. Faridullah Khan



- MBBS, Fellow Royal College of Surgeons, Edinburgh (1992)
- Joined Shifa in 2009

DERMATOLOGY

Dr. Rasheed Chaudhry



- MBBS, Diploma Dermatology, Pakistan (1974)
- Joined Shifa in 1998

Dr. Ahsan Hameed



- MBBS, Fellow College of Physicians & Surgeons - Dermatology (1990)
- Joined Shifa in 2003

Dr. Aamna Batool Khan



- MBBS, Fellow College of Physician & Surgeons - Dermatology (2010), Member College of Physicians & Surgeons (2011)
- Joined Shifa in 2011

Dr. Rushqia Mukhtar



- MBBS, Fellow College of Physician & Surgeons - Dermatology (2010), Member Royal College of Physicians, UK (2009)
- Joined Shifa in 2014

DENTAL SURGERY

Dr. Imtiaz Ahmed



- Bachelor of Dental Surgery, Master of Science - Orthodontics (1985), Master of Science - Prosthetic Dentistry, London (1989), Fellow Royal Australasian College of Dental Surgeons (1993)
- Joined Shifa in 2007

DENTAL SURGERY Contd.

Dr. Syed Hamid Nasr



- Bachelor of Dental Surgery, Fellow Dental Surgery, Royal College of Physician & Surgeons, England - Oral Surgery (1992)
- Joined Shifa in 2007

Dr. Anwar Ali Shah



- Bachelor of Dental Surgery, Ph. D, UK - Orthodontics (2001), Fellow Dental Surgery, Royal College of Physician & Surgeons, Edinburgh (2001), Fellow Dental Surgery, Royal College of Physician & Surgeons Ireland (Orthodontics-2005), Fellow Dental Surgery, Royal College of Physician & Surgeons England - Orthodontics (2009), Member Royal College of Surgeons England - Orthodontics (2005)
- Joined Shifa in 2013

Dr. Noeen Arshad



- Bachelor of Dental Surgery, Master of Science - Orthodontics (1998), Diplomate American Board of Pediatric Dentistry (2004)
- Joined Shifa in 2000

Dr. M. Azhar Sheikh



- Bachelor of Dental Surgery, Fellow Royal College of Surgeons - Dental Surgery (1995), Masters in Dental Surgery (1987)
- Joined Shifa in 2010

Dr. Nadia Aman



- Bachelor of Dental Surgery, Fellow College of Physicians & Surgeons- (Operative Dentistry-1990)
- Joined Shifa in 2010

Dr. M. Israr



- Bachelor of Dental Surgery, Master of Science - Oral Surgery, UK (2000), Fellow Dental Surgery, Royal College of Physician & Surgeons, Glasgow (2000), Fellow of Faculty of Dentistry in Oral Surgery with Oral Medicine, Royal College of Surgeons, Ireland (2005)
- Joined Shifa in 2015

Dr. Adil Shahnawaz



- Bachelor of Dental Surgery, Fellow College of Physicians & Surgeons, Pakistan - Operative Dentistry (2012)
- Joined Shifa in 2016

EMERGENCY

Dr. Abdus Salam Khan



- MBBS, Diplomate American Board of Internal Medicine (2014)
- Joined Shifa in 2009

Dr. Khawaja Junaid Mustafa



- MBBS, Member College of Emergency Medicine (2011)
- Joined Shifa in 2012

Dr. Huma Husnain



- MBBS, Member College of Emergency Medicine (2011)
- Joined Shifa in 2012

Shifa

Consultants

EMERGENCY Contd.

Dr. Ahmed Fawad Khan



- MBBS, Member Royal College of Physicians, UK (2011)
- Joined Shifa in 2012

Dr. Syeda Sobyia Owais



- MBBS, Diplomate American Board of Pediatrics (2014)
- Joined Shifa in 2014

Dr. Sidra Tahir



- MBBS, Member Royal College of Physicians and Surgeons, UK (2010),
- Fellow Royal College of Emergency Medicine, UK (2016).
- Joined Shifa in 2016.

ENDOCRINOLOGY

Dr. Nasim Yusuf



- MBBS, Certificate Specialist of the Province of Quebec - Internal Medicine and endocrinology (1973)
- Joined Shifa in 1995

Dr. M. Tayyab Badshah



- MBBS, Diplomate American Board of Endocrinology, Diabetes & Metabolism (2010), Diplomate American Board of Internal Medicine (2016)
- Joined Shifa in 2013

Dr. Osama Ishtiaq



- MBBS, Fellow College of Physician & Surgeons - Diabetes, Endocrinology & Metabolism (2008), Fellow College of Physician & Surgeons - Internal Medicine (2004), Member College of Physicians & Surgeons (2003)
- Joined Shifa in 2009

Dr. Umar Yousaf Raja



- MBBS, Member Royal College of Physicians – General Medicine, UK (2006), Member Royal College of Physicians -Diabetes & Endocrinology, UK (2010), Certificate of Completion of Training in Internal Medicine & Diabetes & Endocrinology (2013)
- Diploma in Dermatology, UK (2004)
- Joined Shifa in 2016

Dr. Sheraz Khan



- MBBS, Member Royal College of Physicians, UK – General Medicine (2004), Certificate of Completion of Training in Diabetes & Endocrinology & Internal Medicine, UK (2010), Fellow Royal College of Physicians, Edinburgh (2014), Specialty Certificate Endocrinology / Diabetes (2014)
- Joined Shifa in 2016

ENT

Dr. Zafar Iqbal



- MBBS, Diploma in Otorhinolaryngology (1982)
- Joined Shifa in 1997

Dr. M. Zaffar Rabbani



- MBBS, Member College of Physicians & Surgeons - Otorhinolaryngology (1998), Fellow College of Physicians & Surgeon (2000)
- Joined Shifa in 2001

ENT Contd.

Dr. Sarim H. Lodhi



- MBBS, Fellow Royal College of Surgeons - Otorhinolaryngology, Glasgow (2001)
- Joined Shifa in 2012

Dr. Farzana Shafqat



- MBBS, Fellow College of Physicians & Surgeons - Medicine (1994), Fellow College of Physicians & Surgeons - Gastroenterology (1998), Fellow American College of Physicians & Surgeons - Gastroenterology (1999)
- Joined Shifa in 2003

FAMILY MEDICINE & EMPLOYEE HEALTH

Dr. Bilal Firdaus Khan



- MBBS, Member Royal College of Physicians, UK (2006), Member Royal College of General Practitioners UK (2007).
- Joined Shifa in 2016.

Dr. Muhammad Naseer



- MBBS, Member Royal College of Physicians Edinburgh - Medicine (2005), Member Royal College of Physicians London - Gastroenterology (2010)
- Joined Shifa in 2014

GASTROENTEROLOGY

Dr. Nasir Khokhar



- MBBS, Diplomate American Board of Internal Medicine (1982), Diplomate American Board of Tropical Medicine (1984), Fellow American College of Gastroenterology (2003)
- Joined Shifa in 1993

Dr. Naeem Ullah



- MBBS, Member Royal College of Physicians, Ireland (2005), Certificate of Specialist in Gastroenterology, Ireland (2014), Certificate of Training in Endoscopy, Ireland (2014)
- Joined Shifa in 2015

Dr. Shaheen M. Mufti



- MBBS, Diplomate American Board of Internal Medicine (1987)
- Joined Shifa in 1993

Dr. Shahzad Riyaz



- MBBS, Member Royal College Of Physicians, UK -Internal Medicine (2005). Fellow Royal College of Physicians, UK -Gastroenterology (2016)
- Joined Shifa in 2016.

Dr. Saeed Zameer



- MBBS, Diplomate American Board of Internal Medicine (1993), Diplomate American Board of Gastroenterology (2003)
- Joined Shifa in 2008

GENERAL SURGERY

Dr. Ghulam Siddiq



- MBBS, Fellow Royal College of Surgeons Edinburgh (1991)
- Joined Shifa in 1998

Consultants

GENERAL SURGERY Contd.

Maj. Gen. (R) M. A. Hashmi



- MBBS, Fellow Royal College of Surgeons Edinburgh (1970), Member Royal College of Surgeons England and Royal College of Physicians London (1973), Fellow International College of Surgeons (1983), Clinical Fellowship Pediatrics, London (1987)
- Master of Business Administration, USA (1998)
- Joined Shifa in 2003

Dr. Arif Malik



- MBBS, Diplomate American Board of Surgery (2007), Fellow Minimally Invasive Bariatric and Robotic Surgery, USA (2006)
- Joined Shifa in 2008

Dr. Mohammad Amir



- MBBS, Fellow College of Physicians & Surgeons - Surgery (1991), Fellow Royal College of Surgeons Edinburgh - General Surgery (1997)
- Joined Shifa in 2002

Dr. Mohammad Iqbal



- MBBS, Fellow Royal College of Surgeons Edinburgh (1968), Fellow College of Physicians & Surgeons
- Joined Shifa in 2001

Dr. Mohammad Mussadiq Khan



- MBBS, Diplomate American Board of Surgery (1982), Fellow College of Physicians & Surgeons - Surgery (2003)
- Joined Shifa in 1995

Dr. Tahir Hussain



- MBBS, Fellow College of Physicians & Surgeons - General Surgery (1989)
- Joined Shifa in 2003

Dr. Qamar Hafeez Kiani



- MBBS, Fellow College of Physicians & Surgeons - General Surgery (2004), Member Royal College of Surgeons - General Surgery, UK (2007)
- Joined Shifa in 2013

Dr. Nasir Khan



- MBBS, Fellow College of Physicians & Surgeons - General Surgery (2004), Member Royal College of Surgeons - General Surgery, UK (2007)
- Joined Shifa in 2011

Dr. Saeeda Yasmin



- MBBS, Fellow College of Physicians & Surgeons - Surgery (2009), Member College of Physicians & Surgeons - Surgery (2011)
- Joined Shifa in 2014

Dr. Omer Ehsan



- MBBS, Fellow College of Physicians & Surgeons (2002), Fellow Royal College of Surgeons Glasgow (2002), Fellow Royal College of Surgeons - General Surgery, Glasgow (2009)
- Joined Shifa in 2015

Dr. M. Iqbal Khan



- MD, Fellow Royal College of Physicians & Surgeon of Glasgow (1992), Fellow Royal College of Surgeons, UK (1992), Diploma in Vascular Surgery, UK (1995), Masters in Health Professional Education (2010)
- Joined Shifa in 2015

HEMATOLOGY & ONCOLOGY

Col. (R) Dr. Saleem Siddiqui



- MBBS, Fellow Royal College of Physicians Canada (1971), Diplomate American Board of Internal Medicine (1972), Diplomate American Board of Medical Oncology (1973)
- Joined Shifa in 2000

Dr. Kamran Rashid



- MBBS, Diplomate American Board of Internal Medicine (2002), Diplomate American Board of Hematology (2005), Diplomate American Board of Oncology (2006)
- Joined Shifa in 2007

Dr. Saira Hassan



- MBBS, Diplomate American Board of Hematology (2009), Diplomate American Board of Medical Oncology (2009)
- Joined Shifa in 2012

Dr. Muhammad Ayaz Mir



- MBBS, Diplomate American Board of Internal Medicine (2007), Diplomate American Board of Hematology (2010), Fellow American College of Physicians (2011)
- Joined Shifa in 2016

INFECTIOUS DISEASES

Dr. Mahmud H. Javid



- MBBS, Diplomate American Board of Internal Medicine (2000), Diplomate American Board of Infectious Diseases (2001)
- Joined Shifa in 2013

INTERNAL MEDICINE

Dr. Mazhar A. Mufti



- MBBS, Diplomate American Board of Internal Medicine (1988)
- Joined Shifa in 1993

Dr. Mian Amjad Sohail



- MBBS, Diplomate American Board of Internal Medicine (1998), Diploma in Cardiology, UK (1990)
- Joined Shifa in 1997

Maj. Gen. (R) Dr. Syed T. A. Shah



- MBBS, Member College of Physicians & Surgeons (1968), Member Royal College of Physicians, UK (1973), Diplomate American Board of Internal Medicine (1973)
- Joined Shifa in 1994

Dr. Aamer Nazir Ahmad



- MBBS, Diplomate American Board of Internal Medicine (2002)
- Joined Shifa in 2002

Dr. Wajid Yar Khan



- MBBS, Diplomate American Board of Internal Medicine (1998)
- Joined Shifa in 2007

Consultants

INTERNAL MEDICINE Contd.

Dr. Tahir Iqbal



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (2006), Member College of Physicians & Surgeons - Medicine (2007)
- Joined Shifa in 2010

Dr. Uzma Tahseen



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (2004), Fellow College of Physicians & Surgeons - Critical Care Medicine (2012)
- Joined Shifa in 2006

Dr. Nahid Gull



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (2006)
- Joined Shifa in 2012

Dr. Muhammad Ashraf



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (1996)
- Joined Shifa in 2011

Dr. Iram Shakir Kiani



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (1989), Member Royal College of Physicians - Medicine Ireland (1998), Fellow Royal College of Physicians Ireland (2004)
- Joined Shifa in 2014

Dr. Nadia Saeed



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (2009), Member College of Physicians & Surgeons - Internal Medicine (2010)
- Joined Shifa in 2014

Dr. Shahzad Khan Siddique



- MBBS, Diplomate American Board of Internal Medicine (2008), Diplomate American Board of Geriatric Medicine (2009)
- Joined Shifa in 2016

LIVER TRANSPLANT / HPB-SURGERY

Dr. Faisal Saud Dar



- MBBS, Fellow College of Physicians & Surgeons (2003), Fellow Royal College of Surgeons Ireland (2003), Fellow Liver Transplant/ HPB Surgery, UK (2008), Fellow of European Board in Transplant Surgery (2009)
- Joined Shifa in 2011
- *Sitara-e-Imtiaz-2015*

Dr. Haseeb H. Zia



- MBBS, Fellow College of Physicians & Surgeons - Surgery (2003), Member Royal College of Surgeons, Ireland (2010), Fellowship in Transplant Surgery, Turkey (2010)
- Joined Shifa in 2012

Dr. Nusrat Yar Khan



- MBBS, Fellow College of Physicians & Surgeons (2003), Member Royal College of Surgeons Edinburgh (2007)
- Joined Shifa in 2014

NEPHROLOGY

Dr. Kh. Sayeed Ahmed



- MBBS, Member American Society of Internal Medicine, Fellow Nephrology, New York, USA (1979)
- Joined Shifa in 1993

Dr. S. Nayer Mahmud



- MBBS, Diplomate American Board of Internal Medicine (1996), Diplomate American Board of Nephrology (1998)
- Joined Shifa in 2010

Dr. Syed Farhat Abbas



- MBBS, Fellow College of Physicians & Surgeons - Nephrology (2008)
- Joined Shifa in 2009

Dr. Kiran Khurshid



- MBBS, Diplomate American Board of Internal Medicine (2013), Fellow of Nephrology, University of Pittsburgh (2015)
- Joined Shifa in 2015

Dr. Fareeha Khalil



- MBBS, Diplomate American Board of Internal Medicine (2009), Diplomate American Board of Nephrology (2016)
- Joined Shifa in 2017.

NEUROLOGY

Dr. Arsalan Ahmad



- MBBS, Doctor of Medicine Neurology (2000)
- Joined Shifa in 2003

Dr. Maimoona Siddiqui



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (2002), Fellow College of Physicians & Surgeons - Neurology (2009)
- Joined Shifa in 2007

Dr. Muhammad Azhar Saeed



- MBBS, Fellow College of Physicians & Surgeons - Neurology (2003)
- Joined Shifa in 2011

Dr. Muhammad Amjad



- MBBS, Fellow College of Physicians & Surgeons - Neurology (2010), Member College of Physicians & Surgeons - Medicine (2010)
- Joined Shifa in 2012

Dr. Waseem Tariq Malik



- MBBS, Fellow Royal College of Physicians & Surgeons - Neurology (2011)
- Joined Shifa in 2012

Dr. Rao Sohail Yasin Khan



- MBBS, Fellow College of Physicians & Surgeons - Neurology (2006)
- Joined Shifa in 2009

Shifa Consultants

NEUROLOGY Contd.

Dr. Raja Farhat Shoab



- MBBS, Member Royal College of Physicians & Surgeons Glasgow - Emergency Medicine/Surgery (2007)
- Joined Shifa in 2014

NEUROSURGERY

Dr. Inayatullah Khan



- MBBS, Fellow Royal College of Surgeons Ireland (1992), Fellow Royal College of Surgeons - Neurosurgery, Ireland (2001)
- Joined Shifa in 2002

Dr. Muhammad Nadeem



- MBBS, Fellow College of Physicians & Surgeons - Neurosurgery (2004)
- Joined Shifa in 2005

Dr. Shahid Ahmed Shah



- MBBS, Fellow College of Physicians & Surgeons - Neurosurgery (2009)
- Joined Shifa in 2009

NUTRITION MEDICINE

Dr. Rezzan Khan



- Masters in Food and Nutrition, (USA) (1974), Doctor of Philosophy (1976)
- Joined Shifa in 1996

NUCLEAR MEDICINE

Dr. S. Razaqat Ali Jafri



- MBBS, Masters in Nuclear Medicine (1986), Fellow College of Physicians & Surgeons - Nuclear Medicine (2003)
- Joined Shifa in 2012

Dr. Musab Riaz



- MBBS, Masters in Nuclear Medicine (1996), Fellow College of Physicians & Surgeons - Nuclear Medicine (2009)
- Joined Shifa in 2010

OBS/GYNE

Dr. Mah Parveen Qazi



- MBBS, Member Royal College of Obstetrics and Gynaecology, UK (1969), Fellow Royal College of Obstetrics and Gynaecology, UK (1983)
- Diploma Obstetrics and Gynaecology, London (1967)
- Joined Shifa in 1998

Dr. Nabia Tariq



- MBBS, Fellow College of Physicians & Surgeons - Obs/ Gyne (2000)
- Diploma Obstetrics and Gynaecology (1992)
- Joined Shifa in 2001

Dr. Shazia Fakhar



- MBBS, Fellow College of Physicians & Surgeons - Obstetrics and Gynaecology (2003)
- Diploma Obstetrics and Gynaecology (1998)
- Joined Shifa in 2009

OBS/GYNE Contd.

Dr. Huma Tasleem



- MBBS, Member College of Physicians & Surgeons - Obs/ Gyne (2003), Fellow College of Physicians & Surgeons - Obs/ Gyne (2004)
- Joined Shifa in 2008

Dr. Tasneem Akhtar



- MBBS, Fellow College of Physicians & Surgeons - Obs/ Gyne (2003), Member College of Physicians & Surgeons - Obs/ Gyne (2004)
- Joined Shifa in 2010

Dr. Shaheen Ashraf



- MBBS, Member Royal College of Obstetrics and Gynaecology, UK (2006)
- Registered Diagnostic Medical Sonographer (2009), Registered Diagnostic Cardiac Sonographer (2010)
- Joined Shifa in 2013

Dr. Shahnaz Nawaz



- MBBS, Member Royal College of Obstetricians & Gynaecologists, UK (1994)
- Fellow Royal College of Obstetricians & Gynaecologists, UK (2007)
- Diploma in Advance Obstetric Ultrasound, UK (2004)
- Certification in Colposcopy, UK (2006)
- Joined Shifa in 2015

Dr. Iram Rabbani



- MBBS, Member Royal College of Obstetricians & Gynaecologists, UK (2003)
- Certificate of Completion of Specialist Training, UK (2008)
- Diploma in Colposcopy, UK (2006)
- Diploma in Obstetric Ultrasound from Royal Colleges of Obstetricians & Gynaecologist & Radiologists (2008)
- Joined Shifa in 2015

Dr. Gulshan Ara Saeed



- MBBS, Member College of Physicians & Surgeons, Pakistan (2000), Fellow College of Physicians & Surgeons, Pakistan - Obstetrics & Gynaecology (2002)
- Joined Shifa in 2016

Dr. Ameena Shah



- MBBS, Fellow College of Physicians & Surgeons, Pakistan - Obstetrics & Gynaecology (2003)
- Diploma in Gynaecology/ Obstetrics - Pakistan (1989)
- Joined Shifa in 2014.

Dr. Rizwan Malik



- M.D, Diplomate American Board of Obs/Gyne (2011), Fellow American College of Obs/Gyne, USA (2007)
- Joined Shifa in 2014.

OPHTHALMOLOGY

Dr. Zeba I. Matin



- MBBS, Fellow Royal College of Surgeons - Ophthalmology, Edinburgh (2002), Fellow College of Physicians & Surgeons - Ophthalmology (2000)
- Joined Shifa in 2003

Dr. Farooq Afzal



- MBBS, Fellow Royal College of Physicians & Surgeons - Ophthalmology, Glasgow (1988), Fellow Royal College of Ophthalmologists, UK (1989)
- Joined Shifa in 1997

Shifa Consultants

OPHTHALMOLOGY Contd.

Dr. M. Amer Raza Awan



- MBBS, Fellow Royal College of Ophthalmologists, UK (2011), Fellow Royal College of Surgeons, Edinburgh (2009), Member Royal College of Ophthalmologists, Edinburgh (2005)
- Joined Shifa in 2013

Dr. Sadia Farooq



- MBBS, Member of College of Physicians & Surgeons (2001), Fellow College of Physicians and Surgeon - Ophthalmology (2002), Fellow Royal College of Surgeons - Ophthalmology, Glasgow (2007)
- Joined Shifa in 2006

Dr. Sulman Jaffar



- MBBS, Fellow College of Physicians & Surgeons - Ophthalmology (2006), Fellow Royal College Surgeons Glasgow - Ophthalmology (2010)
- Joined Shifa in 2010

Dr. Ayisha Kausar



- MBBS, Member College of Physicians & Surgeons - Ophthalmology (2007), Fellow College of Physicians & Surgeons - Ophthalmology (2009)
- Joined Shifa in 2014

ORTHOPEDICS

Dr. Aamer Nabi Nur



- MBBS, Fellow Royal College of Surgeons, Ireland - Orthopedic Surgery, Ireland (1995)
- Joined Shifa in 2001

Dr. Sajjad Hasan Orakzai



- MBBS, Fellow Royal College of Surgeons (1998), Fellow Royal College of Surgeons, Ireland - Trauma & Orthopedic Surgery, Ireland (2008)
- Joined Shifa in 2010

Dr. Fahim Khan



- MBBS, Fellow Royal College of Surgeon, Dublin, Ireland - General Surgery (1998), Fellow Royal College of Surgeon, Dublin, Ireland - Trauma & Orthopedics (2007), MSc (Biomechanics), Ireland, (2005), Certificate of Completion of Specialist Training (2008)
- Joined Shifa in 2016

Dr. Sohail Hafeez



- MBBS, Fellow College of Physicians and Surgeons - Surgery (1989), Fellow Royal College of Physicians Edinburgh - Surgery (1991).
- Joined Shifa in 2017.

PAIN MEDICINE

Dr. Navida Zakria



- MBBS, Member College of Physicians and Surgeons (2005) Fellow College of Physicians and Surgeons - Anesthesia (2011),
- Joined Shifa in 2017.

PATHOLOGY

Dr. Imran N. Ahmad



- MBBS, Diplomate American Board of Pathology - Haematology (2011)
- Joined Shifa in 2008

PATHOLOGY Contd.

Dr. Ayesha Junaid



- MBBS, Member College of Physicians & Surgeons - Pathology (2001), Fellow College of Physicians & Surgeons - Hematology (2002)
- Joined Shifa in 2003

Dr. Nadira Mamoon



- MBBS, Fellow College of Physicians & Surgeons - Histopathology (1991)
- Joined Shifa in 2009

Dr. Asna Haroon Khan



- MBBS, Fellow College of Physicians & Surgeons - Histopathology (2004)
- Joined Shifa in 2011

Dr. Tahir Aziz Ahmad



- MBBS, Member College of Physicians and Surgeon - Pathology (1988), Fellow College of Physicians & Surgeons - Medical Microbiology (1988), Member Royal College of Pathologist, UK (1992), Fellow Royal College of Pathologists, UK (2000)
- Joined Shifa in 2014

Dr. Muhammad Usman



- MBBS, Fellow College of Physicians & Surgeons - Microbiology (2005)
- Joined Shifa in 2012

Dr. Shawana Kamran



- MBBS, Fellow College of Physicians & Surgeons, Pakistan – Pathology (2010)
- Joined Shifa in 2014

Dr. Ghazanfar Abbas



- MBBS, Fellow College of Physicians & Surgeons, Pakistan – Chemical Pathology (2014)
- Joined Shifa in 2016

Dr. Zafar Ali



- MBBS, Fellow College of Physicians and Surgeons- Histopathology (2014)
- Joined Shifa in 2014.

Dr. Zujajah Hameed



- MBBS, Fellow College of Physicians and Surgeons- Histopathology (2013)
- Joined Shifa in 2016.

PALLIATIVE CARE

Dr. Aqdas Kazi



- MBBS, Member Royal College of Physicians - Palliative Medicine, UK (2007),
- Joined Shifa in 2015

PEDIATRICS

Dr. Rehana Sayeed



- MBBS, Diplomate American Board of Pediatrics (1985)
- Joined in Shifa 1993

PEDIATRICS Contd.

Dr. Ejaz A. Khan



- MBBS, Diplomate American Board of Pediatrics (1994), Diplomate American Board of Pediatric Infectious Diseases (1997)
- Joined Shifa in 1997

Dr. Musarrat Hussain



- MBBS, Diplomate American Board of Pediatrics (1997)
- Diploma in Child Health (1984)
- Joined Shifa in 1998

Dr. Yawar Najam



- MBBS, Member Royal College of Pediatric, Ireland (1994), Masters in Epidemiology, London, Diploma in Child Health, Ireland (1989),
- Diploma in Management for Doctors (Health Services), Ireland (2002)
- Joined Shifa in 2006

Dr. Iffat Fatima Zaman



- MBBS, Diplomate American Board of Pediatrics, (1990)
- Joined Shifa in 2003

Dr. Munir Iqbal



- MBBS, Diplomate American Board of Pediatrics (1989)
- Joined Shifa in 2002

Dr. Yasir Iqbal



- MBBS, Diplomate American Board of Pediatrics (1995), Fellow American Academy of pediatrics (1997)
- Joined Shifa in 2007

Dr. Mazhar H. Raja



- MBBS, Member Royal College of Pediatrics, UK (1995), Member Royal College of Pediatrics & Child health, UK (1998), Fellow Royal College of Pediatrics & Child Health, UK (2009), Diploma in Child Health (1985)
- Diploma in Child Health (1985)
- Joined Shifa in 2010

Dr. Masood Khan



- MBBS, Diplomate American Board of Pediatrics (1977)
- Diploma in Child Health (1972)
- Joined Shifa in 2010

Dr. Shehla Chaudhry



- MBBS, Member College of Physicians & Surgeons - Pediatric Medicine (2007), Fellow College of Physicians & Surgeons - Pediatric Medicine (2009)
- Joined Shifa in 2011

Dr. Shahid Nazir



- MBBS, Diplomate American Board Paediatrics (1993), Neonatology Board Certification, USA (2003)
- Joined Shifa in 2014

Dr. Syeda Shaheera Hashmi



- MBBS, Member College of Physicians and Surgeons (2005) Fellow College of Physicians and Surgeons- Pediatrics (2009),
- Joined Shifa in 2017.

PEDIATRIC CARDIOLOGY

Dr. Abdul Malik Sheikh



- MBBS, Fellow College of Physicians & Surgeons - Pediatrics (2008), Fellow College of Physicians & Surgeons - Pediatric Cardiology (2013)
- Joined Shifa in 2014

PEDIATRIC CARDIOLOGY Contd.

Dr. Zaheer Ahmad



- MBBS, Member College of Physicians & Surgeons, Pakistan (2004), Member Royal College of Pediatrics & Child Health, UK (2006), Certificate of Completion of Specialist Training, UK (2012), Fellow Royal College of Pediatrics & Child Health, UK (2014)
- Joined Shifa in 2016

PEDIATRIC SURGERY

Dr. Nadeem Akhtar



- MBBS, Masters in Pediatric Surgery (1997)
- Joined Shifa in 2015

Dr. Nasir Aziz Khan



- MBBS, Fellow Royal College of Surgeons, Dublin, Ireland (2002), Certificate of Completion of Specialist Training (2011), European Diploma in Pediatric Surgery, UK (2013)
- Joined Shifa in 2016

PEDIATRIC ICU

Dr. Ata Ullah Khan



- MBBS, Member College of Physicians and Surgeons- Pediatrics (2009), Fellow College of Physicians and Surgeons- Pediatrics (2010).
- Joined Shifa in 2017.

PEDIATRIC ONCOLOGY

Dr. Itrat Fatima



- MBBS, Fellow College of Physicians and Surgeons- Pediatrics (2011)
- Joined Shifa in 2017.

PHYSICAL MEDICINE & REHAB

Dr. Khaula Ashraf



- MBBS, Fellow College of Physicians & Surgeons - Physical Medicine and Rehabilitation (2007)
- Joined Shifa in 2013

PLASTIC SURGERY

Dr. Saleem A. Malik



- MBBS, Fellow Royal College of Surgeons and Physicians - Canada with specialist certificate in Plastic surgery (1975), Diplomate American board of Plastic surgery (1978)
- Joined Shifa in 1999

Dr. Mamoon Rashid



- MBBS, Fellow College of Physicians & Surgeons - Surgery (1990) Fellow Royal College of Surgeons - Surgery, UK (1993)
- Joined Shifa in 2009
- *Sitare-e-Eisaar (Award for courage and sacrifice)-2006*

Dr. Muhammad Ibrahim



- MBBS, Fellow College of Physicians & Surgeons - Surgery (2003), Fellow Royal College of Surgeons - Surgery, Ireland (2003)
- Joined Shifa in 2008

Shifa Consultants

PLASTIC SURGERY Contd.

Dr. Saad ur Rehman



- MBBS, Fellow College of Physicians & Surgeons - Plastic Surgery (2006)
- Joined Shifa in 2013

SURGICAL ICU

Dr. Wasib Ishtiaq



- MBBS, Fellow College of Physicians and Surgeons- Medicine (2012),
- Fellow College of Physicians and Surgeons- Critical Care Medicine (2016)
- Joined Shifa in 2015.

PSYCHIATRY

Dr. Abdul Wahab Yousafzai



- MBBS, Fellow College of Physicians & Surgeons - Psychiatry (2007)
- Diploma in Psychological Medicine (2002)
- Joined Shifa in 2011

Dr. Rizwan Taj



- MBBS, Member Royal College of Psychiatrists, UK (1993)
- Diplomas in Psychological Medicine, Ireland (1992), Management Medical Doctor (1993), and Clinical Psychiatry, Ireland (1994)
- Joined Shifa in 1997

Dr. Maryam Saeed Khan



- MBBS, Member Royal College of Physicians, UK -Psychiatry(2013), Diploma in Clinical Psychiatry, Ireland (2015)
- Joined Shifa in 2016.

Dr. Fawad Kaiser



- MBBS, Member Royal College of Physicians, UK (2001),
- Fellow Royal College of Physicians UK(2011)
- Diplomate American Board of Medical Psychotherapy(1997)
- Joined Shifa in 2001.

Dr. Sehar Ashraf



- MBBS, Fellow College of Physicians & Surgeons - Psychiatry (2013)
- Joined Shifa in 2013

PULMONOLOGY & CRITICAL CARE

Dr. Aftab Akhtar



- MBBS, Diplomate American Board of Internal Medicine, Diplomate American Board of Pulmonary Medicine (2003), Diplomate American board of Critical Care Medicine (2007)
- Joined Shifa in 2008

Dr. Mobeen Iqbal



- MBBS, Diplomate American Board of Internal Medicine (1997), Diplomate American Board of Pulmonary Medicine (1999), Diplomate American Board of Critical Care Medicine (2000)
- Joined Shifa in 2000

Dr. Sohail Naseem



- MBBS, Diplomate American board of Internal Medicine(1997), American board of pulmonary medicine and critical care medicine (2007)
- Joined Shifa in 2013

Dr. Mati ur Rehman



- MBBS, Diploma in Tuberculosis and Chest Diseases (1986), Member college of Physicians & Surgeons (1987), Doctor of medicine (1990)
- Joined Shifa in 2007

PULMONOLOGY & CRITICAL CARE Contd.

Dr. Ghulam Haider Khalid



- MBBS, Fellow College of Physicians & Surgeons - Internal Medicine (1989), Fellow College of Physicians & Surgeons - Chest Diseases (1995)
- Diploma in Tuberculosis and Chest Diseases (1983)
- Joined Shifa in 2009

Dr. Aamir Iftikhar Malik



- MBBS, Fellow College of Physicians & Surgeons, Pakistan - Internal Medicine (1998), Diplomate American Board of Internal Medicine (2002), Diplomate American Board of Pulmonary Medicine (2004), Diplomate American Board of Critical Care Medicine (2005), Diplomate American Board of Sleep Medicine (2009)
- Joined Shifa in 2016

RADIATION ONCOLOGY

Dr. Mohammad Ali Afridi *Sitara-e-Imtiaz*



- MBBS, Diplomate American Board of Therapeutic Radiology (1976)
- Joined Shifa in 1993

Dr. M. Salim Khan



- MBBS, Diploma in Medical Radiotherapy, Royal College of Physicians, London & Royal College of Surgeons, England (1979)
- Fellow of Faculty of Radiologists, Royal College of Surgeons, Ireland (1981)

Dr. Asif Masood



- MBBS, Fellow College of Physicians & Surgeons - Radiation Oncology (2012)
- Joined Shifa in 2013

Dr. M. Furrukh



- MBBS, Fellow College of Physicians & Surgeons - Radiotherapy (1998)
- Diploma Medical Radiology Therapeutics (1993)
- Joined Shifa in 2014

Dr. Uzma Qasim



- MBBS, Fellow College of Physicians & Surgeons - Radiation Oncology (2013)
- Joined Shifa in 2013

RADIOLOGY

Dr. Mohammad Yousaf Ch.



- MBBS, Diplomate American board of Radiology/ Diagnostics (1977)
- Joined Shifa in 2002

Dr. Atif Rana



- MBBS, Diplomate American Board of Radiology/ Diagnostics (2001), Fellowship in Interventional Radiology - Birmingham (2002), Special Fellowship Interventional Radiology - Birmingham (2003)
- Joined Shifa in 2006

Dr. Rashed Nazir



- MBBS, Fellow College of Physicians & Surgeons - Diagnostics Radiology (2003)
- Joined Shifa in 2003

Shifa Consultants

RADIOLOGY Contd.

Dr. Belqees Yawar Faiz



- MBBS, Fellow College of Physicians & Surgeons - Diagnostic Radiology (2009)
- Joined Shifa in 2009

Dr. Sanam Yasir



- MBBS, Fellow College of Physicians & Surgeons - Diagnostic Radiology (2010)
- Joined Shifa in 2013

Dr. Raheela Aqeel



- MBBS, Fellow College of Physicians & Surgeons - Diagnostic Radiology (2010)
- Joined Shifa in 2005

Dr. M. Salman Rafique



- MBBS, Fellow College of Physicians & Surgeons, Pakistan - Diagnostic Radiology (2012)
- Joined Shifa in 2004

Dr. Sana Sayeed



- MBBS, Fellow College of Physicians and Surgeons- Diagnostic Radiology (2013)
- Joined Shifa in 2014.

Dr. Zahid Amin Khan



- MBBS, European Board of Interventional Radiology(2011), Member Royal College of Surgeons, Edinburgh (2004), Fellow Royal College of Radiologists, UK (2009)
- Joined Shifa in 2017.

Dr. Madiha Saeed Wahla



- MBBS, Fellow College of Physicians and Surgeons- Diagnostic Radiology (2009).
- Joined Shifa in 2016.

Dr. Suraya Bano Zafar



- MBBS, Fellow College of Physicians and Surgeons -Diagnostic Radiology (2005)
- Joined Shifa in 2016.

Dr. Salma Gul



- MBBS, Fellow Royal College of Radiologists, UK (2015)
- Joined Shifa in 2016

RHEUMATOLOGY

Dr. Tahir Mahmood Hashmi



- MBBS, Member Royal College of Physicians, UK - Medicine (2008), Member Royal College of Physicians - Rheumatology, UK (2011)
- Masters in Musculoskeletal Sciences, Oxford (2013)
- Joined Shifa in 2014

Dr. Zafarullah



- MBBS, Member Royal College of Physicians, UK (2007), Member Royal College of Physicians & Surgeons, Glasgow (2008), Member Royal College of General Practitioners, UK (2009), Specialty Certificate in Rheumatology, UK (2012)
- Joined Shifa in 2014

UROLOGY

Dr. Saeed Akhter



- Sitara-e-Imtiaz*
- MBBS, Diplomate American Board of Urology (2004)
 - Masters of Public Health, USA (1986)
 - Joined Shifa in 2000

Dr. Kamran Majeed



- MBBS, Fellow Royal College of Surgeons - Edinburgh (1987)
- Diploma in Urology, London (1991)
- Joined Shifa in 2001

Dr. Mian Khalid Akbar



- MBBS, Fellow Royal College of Surgeons Edinburgh - General Surgery (1994)
- Joined Shifa in 2004

Dr. Ijaz Hussain



- MBBS, Fellow College of Physicians & Surgeons - Pediatric surgery (2001), Fellow Royal College of Surgeons, Ireland (2003), Fellow European Board of Pediatric Urology (2007)
- Joined Shifa in 2010

Dr. Faizan Ahmed



- MBBS, Fellow Royal College of Surgeons Glasgow - General Surgery (1991)
- Diploma in Urology, London (1994)
- Joined Shifa in 2007

Dr. Waqas M. Iqbal



- MBBS, Fellow College of Physicians & Surgeons - Urology (2003), Fellow Pediatric Urology, USA (2011), Fellow Endourology and Robotic Urology, USA (2014)
- Joined Shifa in 2013

Dr. Muhammad Ayaz Khan



- MBBS, Fellow College of Physicians & Surgeons - Urology (2005)
- Joined Shifa in 2009

Dr. Athar Khawaja



- MBBS, Fellow College of Physicians & Surgeons - Surgery (2005)
- Joined Shifa in 2012

SHIFA INTERNATIONAL HOSPITALS LTD.

FAISALABAD

Dr. Muhammad Ilyas Shakir



- MBBS, Diplomate American Board of Internal Medicine (2009)
- Joined Shifa in 2012

Dr. Muzzammal Iftikhar



- MBBS, Fellow College of Physicians & Surgeons - Medicine (2015)
- Joined Shifa in 2011

Dr. Tariq Mahmood



- MBBS, Member College of Physicians & Surgeons - Pediatrics (1998)
- Joined Shifa in 2012

Dr. Aliya Hafeez



- MBBS, Fellow College of Physicians & Surgeons - OBS/ Gyne (2012)
- Joined Shifa in 2014

Dr. Maqbool Ilahi Malik



- MBBS, Member College of Physicians & Surgeons - Pediatrics (1984)
- Member Royal College of Physicians - Pediatrics (1997)
- Joined Shifa in 2012

Dr. Asif Sagheer



- MBBS, Fellow College of Physicians & Surgeons - Anesthesia
- Joined Shifa in 2014

Dr. Shahid Rasool



- MBBS, Fellow College of Physicians & Surgeons - Medicine (2001)
- Fellow College of Physicians & Surgeons - Gastroenterology (2006)
- Member American College of Gastroenterology (2006)
- Joined Shifa in 2014

Dr. Muhmmad Zahid Rafiq Gill



- MBBS, Fellow College of Physicians & Surgeons - Otorhinolaryngology (2010)
- Joined Shifa in 2012

Dr. Muhammad Rizwan



- MBBS, Fellow College of Physicians & Surgeons - Medicine (2013)
- Joined Shifa in 2014

Dr. Wakeel Ahmad Herral



- MBBS, Fellow College of Physicians & Surgeons - Neurosurgery (2012)
- Member College of Physicians & Surgeons (2009)
- Joined Shifa in 2014

Dr. Tahir Younas



- MBBS, Fellow College of Physicians & Surgeons - Orthopedics (2000)
- Joined Shifa in 2013

Dr. Saher Shafiq



- MBBS, Fellow College of Physicians & Surgeons - Anesthesia (2012)
- Joined Shifa in 2013

Dr. Mohammed Awais Ashraf



- MBBS, Fellow College of Physicians & Surgeons (2002)
- Joined Shifa in 2014

Dr. Kashif Rafique



- MBBS, Fellow College of Physicians & Surgeons - Nephrology (2015)
- Joined Shifa in 2016

Dr. Khalid Javed Akhtar



- MBBS, Fellow College of Physicians & Surgeons - General Surgery (1990)
- Fellowship in Urology, Singapore (1996)
- Joined Shifa in 2012

Dr. Nayyir Waseem Akhter



- MBBS, DCN London
- M. Phil Neuro (UK)
- Joined Shifa in 2017

Dr. Shahid Saleem



- MBBS, Member College of Physicians & Surgeons - Diagnostic Radiology (2009)
- Fellow College of Physicians & Surgeons - Diagnostic Radiology (2010)

Dr. Irum Siddique



- MBBS, Fellow College of Physicians & Surgeons - Psychiatry (2013)
- Joined Shifa in 2014

Dr. Naeem Asghar



- MBBS, Fellow College of Physicians & Surgeons - Cardiology (2012)
- Joined Shifa in 2012

Dr. Kaneez Fatima



- MBBS, FCPP - Gynaecologist
- Joined Shifa in 2016

Dr. Shaukat Javed



- MBBS, Fellow College of Physicians & Surgeons - Medicine
- Joined Shifa in 2016

SHIFA INTERNATIONAL HOSPITALS LTD.

G-10

Dr. Mohammad Ali Arif



- MBBS, MRCP (UK), FCPS (Medicine)
- Joined Shifa in 2016

Dr. Farhat Arshad



- MBBS, MCPS, FCPS
- Joined Shifa in 2016

Dr. Kokab Gulzar



- MBBS, MCPS, Fellow College of Physicians & Surgeons - Dermatology & Medicine
- Joined Shifa in 2014

Dr. Sumair Naseem Qureshi



- MBBS (PAK), FCPS (PAK)
- Joined Shifa in 2014

Dr. Humera Naz Altaf



- MBBS, Fellow College of Physicians & Surgeons - General Surgery (2009)
- Joined Shifa in 2014

Dr. Kiren Shaheryar



- MBBS, MCPS (Medicine), FCPS (Dermatology)
- Joined Shifa in 2016

Dr. Beenish Nisar



- MBBS, Fellow College of Physicians & Surgeons - Otorhinolaryngology (2013)
- Joined Shifa in 2014

Dr. Sobia S Bajwa



- MBBS, MSC in Clinical Dermatology (UK)
- Joined Shifa in 2014

Dr. Shamaila Burney



- MBBS, FCPS
- Joined Shifa in 2014.

Dr. Mohammad Imran Jamil



- MBBS, FCPS (PAK)
- Joined Shifa in 2015

Dr. Asad ur Rehman



- MBBS, FCPS (PAK)
- Joined Shifa in 2015

Dr. Abdullah



- MBBS, FCPS (PAK)
- Joined Shifa in 2016

Dr. Shujah Mohammad



- MBBS, FCPS (PAK)
- Joined Shifa in 2015

Dr. Qamar Zaman



- MBBS, FCPS (Neurology)
Speciality Certified in
Neurology (U.K)
- Joined Shifa in 2016.

Dr. Gul Nawaz



- MBBS, FCPS (PAK)
- Joined Shifa in 2015

Dr. Irum Rauf



- MBBS, MCPS (Radiology)
- Joined Shifa in 2017.

Dr. Iftikhar Ali Khan



- MBBS, FCPS (PAK)

SHIFA INTERNATIONAL HOSPITALS LTD.

F-11

Dr. Sheikh M. Ilyas



- MBBS, MD (USA)
- Joined Shifa in 2008

Dr. Riffat Jabeen



- MBBS, Member College of Physicians & Surgeons - Family Medicine (2013), Member Royal College of General Practitioners (2011)
- Joined Shifa in 2015

Dr. Nosheen Rizwan



- MBBS, Diploma from Royal College of Physicians & Surgeons - Dermatology (2005)
- Joined Shifa in 2013

Dr. Fibhaa Syed



- MBBS, Fellow College of Physicians & Surgeons - General Medicine (2009), Member Royal College of Physicians - Internal Medicine (2011)
- Joined Shifa in 2013

Dr. Sobia S. Bajwa



- MBBS, Masters in Clinical Dermatology - Kings College London (2013).
- Joined Shifa in 2014

Dr. Ikram ul Haq Qazi



- MBBS, Member College of Physicians & Surgeons - Chest Diseases (1981)
- Diploma in Tuberculosis and Chest Diseases (UK) (1980)
- Joined Shifa in 2008

Dr. Ali Tayyab



- MBBS, Fellow College of Physicians & Surgeons - Ophthalmology
- Joined Shifa in 2010

Dr. Shamsa Rizwan



- MBBS, Fellow College of Physicians & Surgeons - Obstetrics & Gynaecology (1998), Member College of Physicians & Surgeons - Obstetrics & Gynecology (1989)
- Diploma in Obstetrics & Gynecology, Pakistan (1989)
- Joined Shifa in 2009

Dr. Rehmana Waris



- MBBS, Member College of Physicians & Surgeons - Pediatrics (2005)
- Fellow College of Physicians & Surgeons - Pediatrics (2009)
- Diploma in Child Health (2009)
- Joined Shifa in 2015

Dr. Shaheena Rehman Khan



- MBBS, Diploma in Obstetrics & Gynecology from Royal College of Obs/Gyne, UK (2009), Member Royal College of General Practitioner (2013)
- Joined Shifa in 2014

Dr. Ghazala Bashir



- MBBS, Fellow College of Physicians and Surgeons-Obs/Gyne (2004), Member College of Physicians & Surgeons-Obs/Gyne (2004)
- Joined Shifa in 2017

Dr. Ahmad Hasan



- MBBS, Member College of Physicians and Surgeons Edinburgh- Orthodontics (2015),
- Fellow College of Physicians and Surgeons-Orthodontics -(2011)
- Joined Shifa in 2017

Dr. Syed Kaleem Ur Rehman



- MBBS, Member College of Physicians & Surgeons-Pediatrics (2010), Member Royal College of Pediatrics and Child Health (2012)
- Joined Shifa in 2012

Dr. Alia Khalid



- MBBS, Member Royal College of Psychiatrists, UK (2009)
- Joined Shifa in 2017

Dr. Muhammad Yasir Khan



- MBBS, Fellow College of Physicians and Surgeons-Oto-Rhino-Laryngology-(2004)
- Joined Shifa in 2007

Dr. Saira Saad



- MBBS, Member Royal College of Physicians, UK (2012), Fellow College of Physicians and Surgeons- Neurology (2016),
- Joined Shifa in 2017

Office of the Chief Operating Officer



Mr. Aziz A. Jan

Chief Operating Officer (COO) provides leadership to the entire operations and leads the operations teams functioning in multiple areas at Shifa International Hospital. All support and ancillary functions fall under the purview of the COO who guides them and gets optimum output with the help of his operations team.

Best possible patient care and patient experience can only be created when diverse hospital operations are performed in a flawless and synchronized manner. And the product of this synchronization is the best possible patient care. This purpose is achieved through close coordination of the operation teams led by the COO with the clinical teams led by the Medical Director. Chief Operating Officer reports to and takes guidance from the Chief Executive Officer.

Shifa
Senior Management Team





Shifa Radiology

SIH Services

The Radiology department of SIH continues to provide highest standards of care by local and internationally qualified Consultants using state of the art technology and is striving towards operational excellence. The milestones achieved during the last year include following;

- Radiology department is at the forefront of adding latest technology for improved diagnostic facilities to our patients. We have added new state of art Ultrasound machines (GE-Voluson E6 & Applio – 500) with 3D & 4D Obstetrical Scans.
- The exceptional image quality helps in diagnosing various anomalies not detected by normal machines, ability to do Elastography for liver tumors, Breast cancer and Thyroid tumors. The Aplio-500 U/S machine with shear wave and stress Elastography has helped in grading of liver diseases. With this technology it was possible to give better qualitative and quantitative information to diagnose effectively in Obstetrics/ Gynecology, Surgery, Liver transplant, Oncology, ENT & Medicine.
- New state of art 3-D Mammography machine (Hologic USA) with stereotactic breast biopsy table was commissioned and is operational. Efficient and better image quality compared to 2-D mammography has enabled our physicians to detect early breast cancer.
- MRI under proper anesthesia for distress patients/ Peads has been started under complete protocol. This ensures safety of the patient with best imaging results.

IR Services:

SIH is a regional leader in providing best Interventional Radiology services. During the year, many new procedures were initiated which include;

- Catheter Angiography – For patients with severe Renal impairment for whom iodinated contrast agents cannot be used.
- Introduction of Microwave Ablation – In addition to RFA used for thermal ablation, microwave ablation is introduced as a superior technology.
- Introduction of EVAR – Endovascular Aortic Aneurysm Repair (EVAR) was successfully

introduced and all procedures gave good results.

- Prostatic Embolization – New service of Prostatic Embolization was introduced. This procedure is not being offered by any other hospital in the country. This is another benchmark for SIH.

MODALITY	Total Actual Procedures 15-16	Total Actual Procedures 16-17	Remarks
CT Scans	26,173	27,722	
MRIs	11,495	12,001	
Ultrasounds	51,012	54,112	
IRs	2,564	2,649	
Nuclear Medicine	1,530	1,494	
Flourosocopy	3,517	3,263	
Mammography		410	only 2 Qrt

Future Plans

In pursuance of achieving excellence, Radiology department will continue to grow and improve the quality of its services. In near future, addition of following equipments/ machines will be added to the diagnostic inventory;

- 3 Tesla MRI
- 128 slice CT
- Further addition of 3D & 4D Ultrasound machines



Shifa Nursing

Along with doctors, the most important players in patient care are nurses. Their role cannot be overemphasized. As industry leader, Shifa International Hospital believes that any compromise on the quality of nursing can lead to undesired outcome regarding patient care. Shifa International Hospital regularly invests in improving its nursing services to ensure that our patients get the highest possible care and patient experience.

Nursing at Shifa, staffed with over 840 registered nurses and highly qualified nurse leaders is one the best nursing departments in the country. We get our nurses trained, nationally and internationally, to enable them meet the emerging challenges in patient care. This investment in raising nursing standards includes, to name a few, sponsoring nurses training in areas like ICU, ER, cardiology etc. We do sponsor them for Post RN BScN degree programs to enrich their knowledge and skills.

Nursing management has developed key performance indicators and encourages participation of nurses in internal and external audits for quality assurance to promote evidence based practices.

Nursing Education Services Department (NES) regularly offers our nursing staff educational and training programs for continuous professional development and quality management.

Shifa is one of the few hospitals in Pakistan where staff is encouraged to utilize its potential in a safe, supportive and encouraging work environment. We envision to create a center of excellence in nursing services and education.



Shifa

Faisalabad Hospital

In our endeavor to expand the outreach of our quality services, Shifa Faisalabad Hospital was established with an aim to provide state of the art healthcare services to the residents of Manchester of Pakistan — Faisalabad. We have witnessed substantial growth in the number of outpatients, inpatients and utilization of other hospital facilities in recent years.

New Consultants have been inducted in various specialties. These initiatives have also resulted in the increase in revenue of Faisalabad Hospital.

Our diagnostic services at Faisalabad Hospital including CT Scan, MRI and ultrasound have become preferred choice of the locals as well as of consultants for referring their patients.

Faisalabad hospital has started Advance GI Procedures (ERCP, EVBL, Stenting, PEG insertion etc). The hospital has a state of the art Neonatal Intensive Care Unit (NICU) and has also recently established a well-baby unit where we are providing integrated services with advanced technology. The Hospital also runs a busy dialysis unit on a 3-shift rotation.

We are continuously on toes to provide the best quality health care and follow best international practices.



Shifa G-10 Hospital

Acquired towards the end of 2014, Shifa Hospital in G-10 Sector of Islamabad was established with an aim to lessen the burgeoning load on main H-8 campus and take our same quality services to the citizens of the sprawling Islamabad in other areas of the Capital City. It was also to serve as a model for further satellite expansion of our quality services in the twin cities and beyond.

The services provided here include Neurology, Nephrology, Urology and Rehabilitation Center which is specialized for helping stroke patients to achieve mobility and fast recovery. The facility has 30 inpatient beds. The Hospital has a well-established dialysis unit with 14 dialysis machines.

Actively supported by the operational and clinical resources of Shifa H-8, this hospital is serving the community in G-10 and adjacent sectors with quality healthcare services. The proximity to the main campus in H-8 also enables the hospital to transfer patients within no time if needed and thus enhances the patients' confidence. Similarly medical and technical resources of H-8 can reinforce patient care at G-10, whenever required.



Awards & Achievements

Pictorial Glimpses of Our Journey towards JCIA from Survey to Celebrations





Shifa Consulting Services (Pvt.) Ltd. Changing the Industry Culture



Shifa Consulting Services (SCS) pioneers healthcare consulting services in Pakistan. We are the only healthcare planner company in the country backed by a team of professionals with a proven track record at Shifa International Hospitals of over two decades. The purpose of Shifa Consulting Services is to provide comprehensive planning for new and existing healthcare facilities from pre-commissioning planning stage to post-commissioning manage & operate and restructuring services.

Since incorporation, almost three years ago, SCS has successfully delivered healthcare consultancy services to various hospitals based in different cities of Pakistan, including Sialkot, Faisalabad, Lahore, Multan, Mianwali, Rawalpindi and Islamabad

Our Key Strength Areas Includes

- Feasibility, Financial Planning, Clinical Service Planning
- Hospital Planning including Architectural and Structural Planning
- Equipment Planning and Procurement
- Staffing Plan & Recruitment
- Manage & Operate of Existing & New Facilities

- Joint Ventures, Health Facility Value Assessment and Transition Management

Major projects that Shifa Consulting Services is currently working on includes

- Establishment of a multi-speciality Hospital in United Republic of Tanzania
- Sialkot City Hospital; a multi-speciality hospital in Sialkot
- Equipment Procurement and Staffing Services to an Obs/Gyne & Infertility hospital in Islamabad

Major Projects in pipeline includes

- Healthcare City in Sialkot Region
- Multi-speciality Hospital in Dubai, UAE
- Cancer Center of Excellence in Dubai, UAE

Having covered this distance in such a short period of time is not only a proof of our commitment to this journey, but also reflects our unique position in this market. Through these efforts, we are providing a service that will upgrade the quality of healthcare delivery not only locally but internationally.



اہمیت اس بات کی نہیں کہ ہم کسی کو کیا اور کتنا دیتے ہیں، بلکہ اس کی ہے کہ ہم اس میں کتنی محبت شامل کرتے ہیں۔ (مادر ٹریسا)

Shifa CSR Initiatives

Health Awareness & Community Education – Few Glimpses

As a socially-responsible organization, Shifa International Hospital actively supports Shifa Tameer-e-Millat University (STMU), Tameer-e-Millat Foundation (TMF) and Shifa Foundation (SF) as part of its corporate social responsibility. Moreover, Shifa International Hospital gives free/highly subsidized OPD services including consultations and diagnostics to non-affording patients besides dedicating inpatient beds for these patients without any discrimination.

Nevertheless, to practice its belief that health awareness and prevention are the best tools to build a healthier society, Shifa heavily invests in community education and awareness by holding programs like walks, hiking, question answer sessions with specialist consultants, free screening camps and lectures etc. The hospital also publishes a monthly magazine, Shifa News International, for the patient and community education that is widely circulated to libraries across Pakistan, district and tehsil Headquarter government hospitals and individual readers as well.





Shifa Tameer-e-Millat University

www.stmu.edu.pk

Information contributed by:
Prof. Dr. Mohammad Iqbal Khan
Vice Chancellor

Envisioned by the dedicated and quixotic leadership and culminated by the untiring efforts and commitment of Shifa Family, Shifa Tameer-e-Millat University (STMU) is a Federally Chartered General Category University providing research oriented quality education to students from all over Pakistan and across the globe. The prolific collaboration of Shifa International Hospitals, Ltd., Tameer-e-Millat Foundation, and Shifa Foundation that resulted in the modern quality education provider, STMU, is committed to excellence in the development creation and dispersing of knowledge in diverse fields.

Being a multi campus General University, STMU offers a wide range of undergraduate, graduate and doctoral programs to enable the youth to compete both nationally and internationally. To maintain the highest standard, the university is firmly committed to merit from intake of the students to graduation without any compromise or consideration. Highest quality faculty at STMU is entirely devoted to light up the path of future generation and prepare them to overcome all kinds of modern day challenges. Apart from education, training and research, there is a strong focus on character building, and grooming the wholesome personality, keeping in view our religious, ethical and historical heritage.

Shifa Tameer-e-Millat University works within its parameter of charter to create and disseminate knowledge in the fields of Health, Law, Engineering, Business and finance, Basic and Social Sciences. Currently, Shifa College of Medicine, Shifa College of Nursing, Shifa College of Pharmaceutical sciences, College of Rehabilitation Sciences, Allied Health Sciences and College of Business Administration, Psychology, Bio sciences and School of Health Professional Education are the constituent colleges

of STMU. Under and graduate study programs being offered at the University include MBBS, BSN, MSN, MHPE, Doctor of Physical Therapy (DPT), Doctor of Pharmacy (Pharm. D) and BS in Medical Technologies (MS-MT). Moreover, Bachelor courses in professional development for Cancer Care professionals and MBA in Health Services are also offered in STMU besides various diplomas and fellowship programs. STMU also plans to offer Bachelor and Master Programs in Dental Sciences (BDS / MDS), LLB (5-year program), MS in Public Health, BS in Nutrition and BS in Optometry.

Our Research Department contribute significantly in creation of fresh knowledge and innovations particularly in the fields of health science, pharmaceutical sciences, education and clinical sciences.

STMU has developed an excellent teaching and learning environment and has special focus on Professional and Technical Education as it is an instrument of growth & development of any country's economy. Moreover, the university focus on developing industrial linkage and knowledge based economy. We are proud of the well-equipped campus and our ability to add to our student's academic and social skills to allow them to lead in their professional careers. We provide extensive support to our students including mentoring, personal and financial support on merit without any discrimination. The graduates of STMU particularly, Shifa College of Medicine and Shifa College of Nursing are contributing in Medical and Nursing fields through their valuable research contributions both nationally and internationally. Our Alumni have been shining on world arena though their highest level of performance at various institutions all over the world.



Shifa Foundation is a PCP certified not for profit with certification # PCP/2017/473. It was established in 1991 with an aim to shape the future of underprivileged communities by promoting health and development. It specializes in healthcare provision, healthcare quality and patient safety, management of malnutrition, community-based development programs, development of clean drinking water facilities and humanitarian assistance during disasters.

Shifa Foundation outreaches the deserving communities across the country in collaboration with federal and provincial governments and development actors at various levels and provides holistic and sustainable solutions for the underprivileged segments of our society. Shifa Foundation current interventions fall under the following themes:

1. Healthcare Solutions
2. Ensuring Food Security
3. Water, Sanitation And Hygiene(WASH)
4. Climate Change Adaptation and Disaster Risk Management
5. Education And Skill Development
6. Gender Equality and Child Protection
7. Developing Sustainable Partnerships

In the last 25 years, Shifa Foundation has served:

- Over 1.5 million malnourished individuals
- 8.5 million people with health services

Shifa Foundation is operating through its Head office located in Islamabad and International Office located in Chicago Illinois, USA. Moreover, the organization has its provincial and regional offices all over Pakistan.

Mission: to shape the future of the underprivileged communities by promoting health and development.

Vision: A healthy world for all

Core Values: A commitment to innovation, quality, integrity, equity, accountability and acting in an environment friendly manner.



Information contributed by:
Brigadier (R) Rana Zulfiqar Ahmed
Director General

Introduction

Dr. Zaheer Ahmad (late) was a visionary, social entrepreneur and philanthropist whose work in the healthcare and education sector had a compounding impact on our society. After studying and acquiring expertise abroad, Dr. Zaheer returned to Pakistan to “repay his debt” to his homeland. Transforming his visions into “actions”, he founded both Shifa International Hospitals, Ltd. (SIH) and Tameer-e-Millat Foundation (TMF) in 1987. Since then, TMF through non-stop commitment & struggle has established numerous educational institutes – schools, colleges, technical and vocational institutes, computer training centers and Shifa Tameer-e-Millat University. These institutes are spread all across the country including the four provinces, Islamabad, Gilgit Baltistan, and the Federally Administered Tribal Areas (FATA).

Mission Statement

“Tameer-e-Millat Foundation aims to provide quality education to every individual, in all academic and professional disciplines, without discrimination of gender, race, religion, socio-economic status or ethnicity.”

TMF - Human Resource Development and Capacity Building Institute (TMF - HRDCBI)

This new facility was established at TM City of Education, Fateh Jang with aims to conduct cyclic teacher /

principal / staff training through on campus, online and distant learning. It conducted its first Master Trainers Training earlier this year.

Mobile Capacity Building Team (MCBT), a division of TMF-HRDCBI, was also setup to impart training at doorsteps and to reduce inconvenience, dislocation and expenditure. The MCBT is appropriately equipped with curriculum, software & multimedia.

System of Assessment and Evaluation

In order to maintain & improve quality , TMF has restructured formal system of Assessment and Evaluation of schools.

A complete Students’ Assessment Program was planned, developed and executed.

- Assessment and Evaluation Committees (A&ECs) were established to prepare questionnaire for written and oral tests separately.
- After completion of written and oral tests marking, the statistics were analyzed. Class wise and school wise grades were awarded and a complete School Evaluation Report having all positive and negative indicators was prepared and shared with TMF management and School. Schools are also appreciated or suggested the required steps to improve the quality of education in school, particular class or subject.



Review Report

on Board's Overall Performance

As per the requirements of Code of Corporate Governance, the periodic annual evaluation of the Board of Directors of Shifa International Hospitals Limited is being carried out.

During the year under review, the self assessment carried out revealed that the board of directors of the Company have performed their duties diligently and its overall performance was satisfactory.

The board successfully fulfilled its roles and responsibilities in achieving the objectives set by the Company.

The Board of Directors of your Company:


- i) remain engaged in reviewing and implementing corporate governance policies, code of conduct and internal controls.
- ii) regularly monitored management performance / duties to ensure that they are in line with its policies.
- iii) received schedule of board meetings for each year in advance, agendas of all board & its committee meetings in advance and supporting documents in sufficient time to the board and its committee meetings
- iv) had fully involved in strategic planning process and revisions to it resulting from the annual review.
- v) evaluated the hospital's role in improving healthcare awareness to its patients and community.
- vi) fully participated in and made contributions to the decision-making process of the Board.

Acknowledgement

I would like to thank our valued clients, every member of Shifa Family, our business associates and shareholders for being a part of our success. May Allah (SWT) help us in accomplishing our mission further.

On behalf of the Board

ISLAMABAD
September 11, 2017



Dr. Habib-Ur-Rahman
Chairman

FINANCIAL STATEMENTS

For the year ended June 30, 2017

Notice of the 31st Annual General Meeting

Notice is hereby given that the 31st Annual General Meeting of the shareholders of Shifa International Hospitals Limited will be held at the registered office (C-0 Auditorium) of the Company at Sector H-8/4, Islamabad on Friday, October 27, 2017 at 1030 hours to transact the following business:

ORDINARY BUSINESS

- 1- To confirm the minutes of the last Annual General Meeting of the Company held on October 29, 2016.
- 2- To receive, consider and adopt the annual audited accounts and consolidated audited accounts of the Company and its subsidiary for the year ended June 30, 2017 together with the directors' and auditors' report thereon.
- 3- To approve the payment of cash dividend @ Rs. 5.00 per share for the year ended June 30, 2017 as recommended by the directors.
- 4- To appoint auditors for the year ending June 30, 2018 and to fix their remuneration.

SPECIAL BUSINESS

- 5- To consider, and if thought fit, to pass with or without modification the following resolution as special resolution:

"RESOLVED that a private limited company under the name and style of "Shifa CARE (Pvt.) Limited" be incorporated as an associated company.

FURTHER RESOLVED that the Company is hereby authorized to make investment upto Rs. 250 million in the paid-up capital of the said associated company within 5 years from the date of incorporation.

FURTHER RESOLVED that the Chief Executive Officer and/or Company Secretary be and is/are hereby authorized singly or jointly to give effect to these resolutions."

- 6- To consider, and if thought fit, to pass with or without modification the following resolution as special resolution for alteration in Memorandum and Articles of Association, as recommended by the Board of Directors:

"RESOLVED that the Authorized Capital of the Company be and is hereby increased from Rs. 545,379,000/- divided into 54,537,900 ordinary shares of Rs. 10/- each to Rs. 1,000,000,000/- divided into 100,000,000 ordinary shares of Rs. 10/- each.

FURTHER RESOLVED that the new shares when issued shall rank pari passu with the existing shares in all respects/matters.

FURTHER RESOLVED that the Clause V and Clause III of the Memorandum of Association and Articles of Association respectively be altered accordingly.

FURTHER RESOLVED that the Chief Executive Officer and/or Company Secretary be and is/are hereby authorized to do or cause to do or to be done all acts, deeds and things that deems necessary to give effect to these resolutions."

- 7- To consider, and approve the transmission of Annual Audited Accounts to the shareholders at their registered addresses through CD/DVD/USB instead of transmitting the said accounts in hard copies as notified by the Securities & Exchange Commission of Pakistan vide its SRO No. 470(I)/2016 dated May 31, 2016 and if thought fit, to pass with or without modification the following resolution as ordinary resolution:

"RESOLVED that transmission of Annual Audited Accounts to the shareholders through CD/DVD/USB instead of transmitting the same in hard copy be and is hereby approved.

FURTHER RESOLVED that the Chief Executive Officer and/or Company Secretary be and is/are hereby authorized singly or jointly to give effect to foregoing resolution.”

Statement of Material Facts u/s 134 (3) of Companies Act, 2017 is annexed with this notice.

By Order of the Board



MUHAMMAD NAEEM

Company Secretary

ISLAMABAD

September 18, 2017

Notes:

- i) The share transfer books of the Company will remain closed from October 18, 2017 to October 27, 2017 (both days inclusive). No transfer will be accepted for registration during this period. Transfers received in order at the share registrar's office of the Company i.e. M/s Corplink (Pvt.) Limited situated at Wings Arcade, 1-K, Commercial, Model Town, Lahore at the close of business on Tuesday, October 17, 2017 will be considered in time for the purpose of payment of dividend to the transferees.
- ii) A member entitled to attend and vote at this meeting is entitled to appoint another member as his/her proxy to attend and vote for him/her. Proxies in order to be effective must be received at the registered office of the Company at Sector H-8/4, Islamabad, not less than 48 hours before the time of holding the meeting. Proxy form is attached.
- iii) Members are requested to notify any change in their registered addresses immediately.
- iv) CDC shareholders entitled to attend and vote at this meeting must bring their original CNIC or Passport along with the participant's ID numbers and account numbers to prove their identity. In case of proxy, the attested copy of CNIC or passport of the CDC shareholder must be enclosed. Representatives of corporate members should bring the usual documents required for such purpose.
- v) Pursuant to the directive of the Securities & Exchange Commission of Pakistan, CNIC numbers of shareholders are mandatorily required to be mentioned on dividend warrants. Shareholders are, therefore, requested to submit a copy of their CNIC (if not already provided) to the Company's Share Registrar, M/s Corplink (Pvt.) Limited.
- vi) The Company wishes to inform its shareholders that pursuant to section 242 of the Companies Act, 2017 and circular 18/2017 issued by Securities & Exchange Commission of Pakistan, any dividend payable in cash declared by the listed company shall only be paid through electronic mode directly into the respective bank account designated by the entitled shareholder instead of receiving it through dividend warrants. In this regard, shareholders are advised to provide the particulars relating to their name, folio number, bank account number, title of account and complete mailing address of the bank to the Company's Share Registrar. CDC account holders should submit their particulars to their broker (participant)/ CDC.
- vii) Pursuant to the provision of Finance Act 2017, the rates of Income tax from dividend payment under section 150 of the Income Tax Ordinance, 2001 have been revised as under:
 - For filers - 15 %
 - For non-filers - 20 %

All shareholders are requested to make it sure that copy of their valid CNIC/NTN should be available with the Shares Registrar. Please also note that in case of non-availability of CNIC/NTN, the Share Registrar could not check their status and would be constrained to apply tax rate prescribed for non-filers.

- viii) In order to enable the Company to follow the directives of the regulators to determine shareholding ratio of the Joint Account Holder(s) (where shareholding has not been determined by the Principal Shareholder) for deduction of Withholding Tax on dividends of the Company, shareholders are requested to please complete the form (earlier dispatched) to furnish the shareholding ratio, details of themselves as Principal Shareholder and their Joint Holders to the Company's Share Registrar, enabling the Company to compute Withholding Tax of each shareholder accordingly. In the event of non-receipt of the information by October 17, 2017 each shareholder will be assumed to have equal proportion of shares and the tax will be deducted accordingly.
- ix) Pursuant to Notification vide SRO. 787(I)/2014 of September 08, 2014, the Securities and Exchange Commission of Pakistan has directed to facilitate the members of the Company receiving Annual Financial Statements and Notices through electronic mail system (e-mail). We are pleased to offer this facility to our members who desire to receive Annual Financial Statements and Notices of the Company through email in future. In this respect members are hereby requested to send their consent on a standard request form which is available at Company website <http://www.shifa.com.pk/files/finst/Financial-Statements-Request-Form.pdf> duly signed alongwith copy of CNIC/PoA to the Company's Shares Registrar.
- x) If the Company receives consent from members holding 10% or more shareholding, residing in geographical location to participate in the meeting through video conference at least 10 days prior to the date of meeting, the Company will arrange video conference facility.

In this regard, please fill the following and submit at the registered office of the Company situated at Sector H-8/4, Islamabad at least 10 days prior to the date of Annual General Meeting:

I/We _____ of _____ being a member(s) of Shifa International Hospitals Limited, holding _____ ordinary shares as per registered Folio / CDC Account No. _____ hereby opt for video conference facility at _____.

Date

Signature

دی گئی ہدایات کے مطابق جوائنٹ اکاؤنٹ ہولڈرز/ ہولڈرز (جہاں پر نپل شیئر ہولڈرز کی جانب سے شیئر ہولڈنگ کا تعین نہیں کیا گیا) شیئر ہولڈنگ کے تناسب کا تعین کر سکے تاکہ کمپنی کے منافع سے وہ ہولڈنگ ٹیکس کی وصولی کی جاسکے۔ 17 اکتوبر 2017 تک تفصیلات کی عدم دستیابی کی صورت میں ہر شیئر ہولڈر کا شیئر میں برابر کا حق تصور کیا جائے گا اور اسی تناسب سے ٹیکس کی کٹوتی کی جائے گی۔

ix. یکوریٹیز اینڈ ایکسچینج کمیشن آف پاکستان کے نوٹیفیکیشن نمبر 1/2014 (SRO.787(1)) بتاریخ 8 ستمبر، 2014 کے مطابق یہ ہدایات دی گئی ہیں کہ کمپنی کے ممبران کو سالانہ فنانشل سٹیٹمنٹس اور نوٹسز بذریعہ الیکٹرانک میل سسٹم (ای میل) کی سہولت فراہم کی جائے۔ ہمیں اپنے ممبران کو اس سہولت کی پیشکش کرتے ہوئے خوشی محسوس ہو رہی ہے جو آئندہ ای میل کے ذریعے سالانہ فنانشل سٹیٹمنٹس وصول کرنا چاہتے ہوں۔ چنانچہ ممبران سے درخواست ہے کہ وہ اپنی رضا مندی مقررہ درخواست فارم کے ذریعے جو کہ کمپنی کی ویب سائٹ <http://www.shifa.com.pk/files/finst/Financial-Statments-Request-form.pdf> پر دستیاب ہے، دستخط کر کے کمپیوٹرائزڈ قومی شناختی کارڈ/PoA کی کاپی، کمپنی رجسٹرار کو ارسال کریں۔

x. اگر کمپنی کو اجلاس کی تاریخ سے کم از کم 10 دن پہلے ویڈیو کانفرنس کے ذریعے اجلاس میں شرکت کرنے کے لئے کسی جغرافیائی محل وقوع میں رہنے والے 10 فیصد یا اس سے زائد شیئر ہولڈنگ والے ارکان کی طرف سے درخواست موصول ہوتی ہے تو کمپنی ویڈیو کانفرنس کی سہولت کا بندوبست کرے گی۔ اس سلسلے میں، مندرجہ ذیل فارم پر کریں اور سالانہ اجلاس عام کی تاریخ کے کم از کم 10 دن پہلے کمپنی کے رجسٹرڈ دفتر واقع سیکٹر 4/8-H، اسلام آباد میں جمع کرائیں:

میں / ہم _____ ساکن _____ شفا انٹرنیشنل ہسپتال لیڈنگ کے رکن کی حیثیت سے
 عام حصص کا مالک بمطابق رجسٹرڈ فولیو نمبر / سی ڈی سی اکاؤنٹ نمبر _____ ویڈیو کانفرنس کی سہولت بمقام _____
 منعقد کرانے کا انتخاب کرتا / کرتی / کرتے ہیں۔

دستخط

تاریخ

کمپنیز ایکٹ، 2017 کے سیکشن (3) 134 کے تحت سٹیٹمنٹ آف میٹریل فیکٹس اس نوٹس کے ساتھ منسلک ہے۔

بحکم بورڈ



محمد نعیم

کمپنی سیکرٹری

اسلام آباد

18 ستمبر 2017

نوٹس

- i. کمپنی کے شیئر ٹرانسفر کھاتے 18 اکتوبر 2017 سے 27 اکتوبر 2017 (بشمول دونوں دن) بند رہیں گے۔ اس مدت کے دوران کوئی بھی ٹرانسفر، رجسٹریشن کیلئے قبول نہیں ہوگی۔ 17 اکتوبر 2017 بروز منگل کو کاروبار کے اختتام تک کمپنی کے شیئرز رجسٹرار آفس یعنی میسرز کارپ لنک (پرائیویٹ) لمیٹڈ، ونگز آر کیڈ، K-1، کمرشل، ماڈل ٹاؤن، لاہور کو موصول ہونے والی ٹرانسفر کو منافع کی ادائیگی کی غرض سے بروقت تصور کیا جائے گا۔
- ii. ایک ممبر جو اس اجلاس میں شرکت اور ووٹ کا حقدار ہے، اس طرح وہ حقدار ہے کہ وہ دوسرے ممبر کو اپنی پراکسی مقرر کر سکے تاکہ وہ اس کی جگہ اجلاس میں شرکت اور ووٹ استعمال کر سکے۔ پراکسی موثر ہونے کیلئے اجلاس سے کم از کم 48 گھنٹے پہلے کمپنی کے رجسٹرار آفس واقع سیکٹر 4/H-8، اسلام آباد میں وصول ہو جانی چاہئیں۔ پراکسی فارم ساتھ منسلک ہے۔
- iii. ممبران سے درخواست کی جاتی ہے کہ وہ اپنے رجسٹرڈ پتے میں تبدیلی سے فوراً مطلع کریں۔
- iv. سی ڈی سی شیئر ہولڈرز، جو کہ اس اجلاس میں شرکت اور ووٹنگ کے حقدار ہیں، اپنا اصلی قومی شناختی کارڈ یا پاسپورٹ، شریک آئی ڈی نمبر اور اکاؤنٹ نمبر لازمی ساتھ لائیں تاکہ وہ اپنی شناخت کروا سکیں۔ پراکسی کی صورت میں سی ڈی سی شیئر ہولڈر کی تصدیق شدہ قومی شناختی کارڈ یا پاسپورٹ کی کاپی لازمی منسلک ہو۔ کارپوریٹ ممبران کے نمائندگان معمول کے دستاویزات ہمراہ لائیں جو اس مقصد کیلئے ضروری ہوتے ہیں۔
- v. سیکورٹیز اینڈ ایکسچینج کمیشن آف پاکستان کی ہدایات کی روشنی میں کمپیوٹرائزڈ قومی شناختی کارڈ نمبر، ڈیویڈنڈ وارنٹس پر لکھنا لازمی ہے۔ لہذا ممبران سے گزارش ہے کہ وہ موثر شناختی کارڈ کی ایک کاپی (اگر پہلے سے فراہم نہیں کی گئی ہے تو) کمپنی شیئرز رجسٹرار، میسرز کارپ لنک (پرائیویٹ) لمیٹڈ میں جمع کرائیں۔
- vi. کمپنی اپنے شیئر ہولڈرز کو مطلع کرنا چاہتی ہے کہ کمپنیز ایکٹ، 2017 اور سیکورٹیز اینڈ ایکسچینج کمیشن آف پاکستان کی طرف سے جاری کردہ سرکلر 18/2017 کے سیکشن 242 کے مطابق، لسٹڈ کمپنی کی طرف سے اعلان شدہ نقد منافع کی ادائیگی شیئر ہولڈرز کو منافع وارنٹ کے ذریعے موصول ہونے کے بجائے صرف الیکٹرانک طریقہ کار کے ذریعے ان کے نامزد متعلقہ بینک اکاؤنٹ میں براہ راست ادا کی جائے گی۔ اس سلسلے میں شیئر ہولڈرز کو نصیحت کی جاتی ہے کہ وہ اپنے نام، فوٹیو نمبر، بینک اکاؤنٹ نمبر، اکاؤنٹ نمٹل اور بینک کا مکمل پتہ تفصیل کے ساتھ کمپنی شیئر رجسٹرار کو جمع کروائیں۔ سی ڈی سی اکاؤنٹ ہولڈر اپنی درخواست براہ راست اپنے بروکر (شریک) / سی ڈی سی کو جمع کرائیں۔
- vii. فنانس ایکٹ 2017 کے مطابق، انکم ٹیکس آرڈیننس، 2001 کے سیکشن 150 کے تحت منافع کی ادائیگی سے انکم ٹیکس کی کٹوتی کے ریٹس نظر ثانی کے بعد درج ذیل ہے:

- فالٹرز کیلئے 15%
- نان فالٹرز کیلئے 20%

تمام شیئر ہولڈرز سے درخواست ہے کہ ان کی کمپیوٹرائزڈ قومی شناختی کارڈ اور NTN کی کاپی شیئر رجسٹرار کے پاس موجود ہو۔ مزید برآں یہ نوٹ فرمائیں کہ کمپیوٹرائزڈ قومی شناختی کارڈ اور NTN کی کاپی عدم دستیابی کی صورت میں شیئر رجسٹرار ان کی حیثیت کی جانچ پڑتال نہیں کر پائے گا اور مجبور ہو گا کہ ان کیلئے نان فالٹرز کے ٹیکس ریٹس لاگو کرے۔

viii. شیئر ہولڈرز سے درخواست ہے کہ وہ متعلقہ فارم (پہلے سے ارسال شدہ) کمپنی شیئر رجسٹرار کو بھجوائیں، جس میں وہ شیئر ہولڈنگ تناسب اپنی بطور پرنسپل شیئر ہولڈر اور جوائنٹ ہولڈرز کی تفصیل پیش کریں تاکہ اسی تناسب سے ہر شیئر ہولڈر کے انفرادی ود ہولڈنگ ٹیکس کا تعین کیا جاسکے۔ تاکہ کمپنی مگر ان ادارے کی جانب سے

31 واں سالانہ اجلاس عام

بذریعہ نوٹس مطلع کیا جاتا ہے کہ شفا انٹرنیشنل ہسپتال لمیٹڈ کے شیئر ہولڈرز کا 31 واں سالانہ اجلاس عام کمپنی کے رجسٹرڈ آفس (سی زیرو آڈیٹوریم) واقع سیکٹر 4/H-8، اسلام آباد میں بروز جمعہ 27 اکتوبر 2017 دن 10:30 بجے درج ذیل معاملات کے سلسلے میں منعقد ہوگا:

عام کاروبار:

1. گزشتہ سال 29 اکتوبر 2016 کو منعقد کئے گئے کمپنی کے سالانہ اجلاس عام کے منٹس کی توثیق کرنا۔
2. ڈائریکٹرز اور آڈیٹرز کی رپورٹ کے ساتھ اختتامی سال 30 جون 2017 کمپنی اور اس کے ذیلی ادارے کے سالانہ آڈٹ شدہ اکاؤنٹس اور مجموعی آڈٹ شدہ اکاؤنٹس کی وصولی، غور و خوض اور غفلت در آمد کرنا۔
3. اختتامی سال 30 جون 2017 کیلئے ڈائریکٹرز کے سفارش کردہ 5.00 روپے فی شیئر کے حتمی نقد منافع کی ادائیگی کی منظوری دینا۔
4. اختتامی سال 30 جون 2018 کے لئے آڈیٹرز کی تقرری اور ان کے معاوضہ کی منظوری دینا۔

خاص کاروبار:

5. اگر موزوں سمجھا جائے تو درج ذیل قرار داد کو زیر غور لاتے ہوئے خاص قرار داد کے طور پر منظور کیا جائے:

”طے پایا کہ شفا کیئر (پرائیویٹ) لمیٹڈ“ کی طرز اور نام کے تحت ایک پرائیویٹ لمیٹڈ کمپنی ایک منسلک کمپنی کے طور پر تشکیل دی جائے۔ مزید طے پایا کہ کمپنی اس منسلک کمپنی کے قائم ہونے کے 5 سال کے اندر اندر اس کے ادا شدہ سرمائے میں 250 ملین روپے تک کی سرمایہ کاری کرنے کی مجاز ہے۔ مزید طے پایا کہ چیف ایگزیکٹو آفیسر اور/یا کمپنی سیکرٹری اس بات کے مجاز ہیں کہ وہ فرداً یا مشترکہ طور پر ان قراردادوں کو موثر بنائیں۔“
6. اگر موزوں سمجھا جائے تو بورڈ آف ڈائریکٹرز کی سفارش کردہ درج ذیل قرار داد کو کمپنی کے دستور اور کمپنی کے قواعد و ضوابط میں ترمیم کے ساتھ یا بغیر ترمیم کے زیر غور لاتے ہوئے خاص قرار داد کے طور پر منظور کیا جائے:

”طے پایا کہ کمپنی کا منظور شدہ سرمایہ جو کہ -/545,379,000 روپے ہے اور 54,537,900 عام حصص بمالیت -/10 روپے ہے، سے بڑھا کر -/1,000,000,000 روپے جو کہ 100,000,000 عام حصص بمالیت -/10 روپے کرنے کی منظوری دی جانی ہے۔ مزید طے پایا کہ نئے حصص کے اجرا کو ہر لحاظ سے / تمام معاملات میں موجودہ حصص کے ساتھ پاری پاسو کی درجہ بندی دی جائے گی۔ مزید طے پایا کہ کمپنی کے دستور اور کمپنی کے قواعد و ضوابط کی شق نمبر ۷ اور شق نمبر III کو اس کے مطابق بالترتیب تبدیل کیا جائے گا۔ مزید طے پایا کہ چیف ایگزیکٹو آفیسر اور/یا کمپنی سیکرٹری اس بات کے مجاز ہیں کہ وہ خود یا کسی اور کے ذریعے وہ تمام کارروائیاں، اعمال اور اقدامات کریں جن کے ذریعے ان قراردادوں کو موثر بنایا جاسکے۔“
7. اگر موزوں سمجھا جائے تو سکیورٹیز اینڈ ایکسچینج کمیشن آف پاکستان کے آئس آراؤ 2016 (D)/470 مورخہ 31-05-2016 کے مطابق کمپنی کے شیئر ہولڈرز کو سالانہ آڈٹ شدہ اکاؤنٹس ان کے رجسٹرڈ پتے پر پرنٹنگ فارم میں ارسال کرنے کے بجائے سی ڈی / ڈی وی ڈی / یو ایس بی کے ذریعے بھیجنے پر غور کرنے کی منظوری اور اگر مناسب ہو تو، ترمیم کے ساتھ یا بغیر ترمیم کے ساتھ عام قرارداد کے طور پر مندرجہ ذیل قرارداد کو منظور کیا جائے:

”طے پایا کہ کمپنی کے شیئر ہولڈرز کو سالانہ آڈٹ شدہ اکاؤنٹس ان کے رجسٹرڈ پتے پر پرنٹنگ فارم میں ارسال کرنے کے بجائے سی ڈی / ڈی وی ڈی / یو ایس بی کے ذریعے بھیجنے کی منظوری دی جانی ہے۔ مزید طے پایا کہ چیف ایگزیکٹو آفیسر اور/یا کمپنی سیکرٹری اس بات کے مجاز ہیں کہ وہ خود یا کسی اور کے ذریعے وہ تمام کارروائیاں، اعمال اور اقدامات کریں جن کے ذریعے مذکورہ بالا قرارداد کو موثر بنایا جاسکے۔“

Statement of Material Facts

U/S 134(3) of Companies Act, 2017

INVESTMENT IN ASSOCIATED COMPANY

The Board of Directors have approved establishment of an associated company under the name and style of “Shifa CARE (Pvt.) Limited” which will focus on providing IT solutions pertaining to the following:

1. Hospitals providing services from Primary to Tertiary Care
2. Clinics and Nursing Homes
3. Diagnostic Centers
4. Pharmacies
5. Medical Benefits Management Entities

As per requirements of the Companies (Investment in Associated Companies and Associated Undertakings) Regulations, 2012, following information is provided to the shareholders:-

Sr. #	Description	Information Required
(i)	Name of the associated company or associated undertaking alongwith criteria based on which the associated relationship is established.	Shifa CARE (Pvt.) Limited (Proposed) will be associated company of Shifa International Hospitals Ltd. The proposed company is being established in collaboration with CARE (Pvt.) Ltd. Initially the shareholding of both Shifa and CARE shall be 50% of the Paid-up Capital. In future at appropriate time investment shall/may be invited from third parties, however, the equity interest of Shifa shall not be less than 30% of the total equity at any given time.
(ii)	Purpose, benefits and period of investment.	To contribute in equity - to be long term investment.
(iii)	Maximum amount of investment;	Investment upto Rs. 250 million in five years.
(iv)	Maximum price at which securities will be acquired.	At par value of Rs.10/- per share.
(v)	Maximum number of securities to be acquired.	25 million shares in five years.

(vi)	Number of securities and percentage thereof held before and after the proposed investment.	None at present. Afterward – 25 million shares not less than 30 % at any given point of time
(vii)	In case of investment in listed securities, average of the preceding twelve weekly average price of the security intended to be acquired.	Not applicable
(viii)	In case of investment in unlisted securities, fair market value of such securities determined in terms of regulation 6(1).	Not applicable
(ix)	Break-up value of securities intended to be acquired on the basis of the latest audited financial statements.	Not applicable
(x)	Earnings per share of the associated company or associated undertaking for the last three years.	Not applicable
(xi)	Sources of fund from which securities will be acquired.	Internal generation of resources / issuance of right shares
(xii)	Where the securities are intended to be acquired using borrowed funds: (1) Justification for investment through borrowing; and (2) Details of guarantees and assets pledged for obtaining such funds.	Not applicable.
(xiii)	Salient features of the agreement(s), if any, entered into with its associated company or associated undertaking with regards to the proposed investment.	Not applicable.
(xiv)	Direct or indirect interest of directors, sponsors, majority shareholders and their relatives, If any, in the associated company or associated undertaking or the transaction under consideration.	Following will have interest:- (i) Shifa will have equity interest and nomination of directors accordingly. (ii) Spouse of Dr. Shoab A. Khan, independent director on the Board of Shifa International Hospitals Ltd., is the director of CARE (Pvt.) Limited and holds 27.12 % shares of CARE (Pvt.) Limited so Dr. Shoab A. Khan shall be interested in the associated company by virtue of his spouse, being the director and substantial shareholder of CARE (Pvt.) Limited. (iii) Other directors are not interested in this business except as shareholders of the Company.
(xv)	Any other important details necessary for the members to understand the transaction; and	None

(xvi)	<p>In case of investment in securities of a project of an associated company or associated undertaking that has not commenced operations, in addition to the information referred to above, the following further information, is required, namely;</p> <p>(I) Description of the project and its history since conceptualization;</p> <p>(II) Starting and expected dated of completion of work;</p> <p>(III) Time by which such project shall become commercially operational; and</p> <p>(IV) Expected time by which the project shall start paying return on investment.</p>	Not applicable.
-------	--	-----------------

The directors in their meeting held on September 11, 2017 signed the undertaking as required under sub regulation 3 of Regulation 3 of Companies (Investment in Associated Companies or Associated Undertakings) Regulations, 2012 and the duly signed recommendations of the due diligence report shall be available for inspection in the 31st Annual General Meeting of the Company scheduled to be held on October 27, 2017.

AMENDMENTS IN MEMORANDUM AND ARTICLES OF ASSOCIATION

The amendments in Memorandum and Articles of Association of the Company is proposed to enhance the Authorised Capital of the Company from Rs. 545,379,000/- to Rs. 1,000,000,000/-. The enhancement of its authorised capital will enable the Company to issue the right shares / bonus shares and others. The Directors do not have interest, directly or indirectly, in the aforementioned business except to the extent of their shareholding in the paid-up capital of the Company.

The proposed amendments shall be incorporated in the Memorandum and Articles of Association of the Company after the approval of special resolution. All necessary requirements of law will be complied with in this regard, therefore, the proposal for incorporation in Memorandum and Articles of Association of the Company is hereby being placed before the shareholders for their consideration and approval. The comparative statement of existing and proposed alteration in Memorandum and Articles of Association is as under:

Clause No.	Existing Clause	Proposed Clause
V of Memorandum of Association	The Authorised Capital of the Company is Rs. 545,379,000/- (Rupees Five Hundred Forty Five Million, Three Hundred Seventy Nine Thousand only) divided into 54,537,900 shares of Rs. 10/- each with power to increase or reduce the capital.	The Authorised Capital of the Company is Rs. 1,000,000,000/- (Rupees One Billion only) divided into 100,000,000 shares of Rs. 10/- each with power to increase or reduce the capital.
III of Articles of Association	The Authorised Capital of the Company is Rs. 545,379,000 (Rupees Five Forty Five Million Three Hundred Seventy Nine Thousand only) divided into 54,537,900 Ordinary Shares of Rs. 10/- each.	The Authorised Capital of the Company is Rs. 1,000,000,000/- (Rupees One Billion only) divided into 100,000,000 Ordinary Shares of Rs. 10/- each.

TRANSMISSION OF ANNUAL AUDITED ACCOUNTS THROUGH CD/DVD/USB

To give effect to the S.R.O. 470(I)/2016 dated May 31, 2016 issued by Securities & Exchange Commission of Pakistan (SECP), shareholders' approval is being sought to allow the company to circulate the annual audited statements, auditor's report and directors' report etc. (annual audited accounts) to its members through CD/DVD/USB at their registered addresses.

The Company, however, shall place on its website i.e. www.shifa.com.pk a standard request form to enable those members requiring a hard copy of the annual audited accounts instead of through CD/DVD/USB to intimate the Company of their requirement. The Company shall dispatch free of cost hard copy of the annual audited accounts to such members at their registered addresses within one week of receipt of request.

The directors are not interested in this business except as shareholders of the Company.



MUHAMMAD NAEEM

Company Secretary

DIRECTORS' REPORT

OPERATING RESULTS

	2017 ----- (Rupees in 000) -----	2016 ----- (Rupees) -----
Net revenue	9,257,009	8,730,803
Other operating income	136,579	86,760
Operating costs	(8,464,606)	(7,668,538)
Finance costs	(66,389)	(108,997)
Profit before taxation	862,593	1,040,028
Provision for taxation	(256,166)	(279,930)
Profit for the year	606,427	760,098
	----- (Rupees) -----	
Earnings per share-basic and diluted	11.12	14.68

- The above results indicate an overall revenue growth of 6% as compared to corresponding period of the last year. The operating cost has been increased by 10.4% from Rs. 7,669 million to Rs. 8,465 million, which is mainly due to increase in salaries of nursing staff and postgraduate trainees, cost and volume of supplies and medicines consumed, depreciation and rent. Finance cost has been declined because of the repayment of long term loan and reduction in KIBOR. Reason for drop in operating profit margin is attributable to economic crisis in Saudi Arabia and other Middle East countries which forced them to slash job opportunities which in turn reduced the number of candidates who were visiting the Hospital for mandatory medical checkups to fulfill these countries' requirements. Resultantly the revenue in this particular area decreased considerably while comparing the same with previous year. All these factors translated into drop in earnings per share besides increase in Paid-up Capital of the Company in the previous year. Had we not enhanced the paid up capital, the earnings per share would have been Rs. 11.99, as a matter of comparison with the previous period.
- During the year under review earnings per share decreased from Rs. 14.68 to Rs. 11.12.
- The Board is pleased to declare the final cash dividend of Rs. 5.00 per share for the year ended June 30, 2017.
- Company intends to establish a private limited company, which would be the associated company of Shifa International Hospitals Limited (Shifa/Company/Hospital).
- The financial statements, prepared by the management of Shifa, present fairly its state of affairs, the results of its operations, cash flows and changes in equity.
- Proper books of accounts of Shifa have been maintained as required by the Companies Ordinance, 1984.
- Appropriate accounting policies have been consistently applied in preparation of the financial statements and accounting estimates are based on reasonable and prudent judgment.
- International Accounting Standards, as applicable in Pakistan, have been followed in preparation of financial statements.
- The system of internal control is sound in design and has been effectively implemented and monitored.

10. There has been no material departure from the best practices of corporate governance, as detailed in the listing regulations.
11. There are no significant doubts upon Company's ability to continue as a going concern.
12. Being the healthcare industry Shifa faces many risks which include but are not limited to regulatory, competition, business, economic & business environment, operational & credit, financing & liquidity, clinical, information systems security & availability, quality & stability of operational services, availability, recruitment & retention of skilled resources/medical practitioners, frauds, etc. risks. At Shifa we have a robust internal control and risk management system. The Risk Management and Internal Control processes are designed to safeguard the Company's assets and to appropriately address and/or mitigate emerging risks being faced by the Company.
13. During the year under review, Prof. Dr. Shoab Ahmed Khan, Director, has successfully completed the directors' training program that meets the criteria specified by the SECP.
14. Summary of key operating and financial data of last six years has been given on page No. 108.
15. Note 9.4 of the notes to the financial statements reflect the value of investments of gratuity fund account.
16. The matters significant to the subsidiary of the Company i.e. Shifa Consulting Services (Pvt.) Limited have been disclosed in note 1.3 of the Notes to the Consolidated Financial Statements.
17. For the purpose of Code xvi (l) and Code xxiii of the Code of Corporate Governance all the General Managers and above are considered as the executives of the Company besides CEO, COO, CFO, Head of Internal Audit & Company Secretary.
18. During the year under review, Dr. Samea Kauser Ahmad, Director has gifted 2,810,255 shares of the Company to her family members and Mr. Qasim Farooq Ahmad, Director, has acquired 24,860 shares from her sister namely Dr. Samea Kauser Ahmad as gift whereas Dr. Manzoor H. Qazi, Chief Executive Officer has also acquired 434,307 shares of the Company from her daughter namely Miss Komal Manzoor Qazi as gift. No other director, CFO, Company Secretary, Executives and their spouses and minor children carried out the trade in the shares of the Company during the year under review.
19. Progress Report on the utilization of the proceeds of right shares so far is as under:

Particulars	Amount (Rupees in Million)					Total
	4 th Qtr. 2015-16	1 st Qtr. 2016-17	2 nd Qtr. 2016-17	3 rd Qtr. 2016-17	4 th Qtr. 2016-17	
Renovation of Hospital Building/ planning, designing of F-11 facility/Addition & Replacement of Equipment	256.78	111.58	211.22	166.36	294.08	1040.02

20. The Company has put in place a mechanism for the annual evaluation of the performance of its board.
21. During the year under review, four meetings of the Board of Directors and six meetings of the Audit Committee

DIRECTORS' REPORT

were held respectively.

Number of meetings attended by each director is stated below:

Name of Director	No. of Board Meetings Attended	No. of Audit Committee Meetings Attended
Dr. Habib-Ur-Rahman	4	6
Dr. Manzoor H. Qazi	4	N/A
Mr. Muhammad Zahid	4	5 *
Dr. Mohammad Salim Khan	4	5 *
Mr. Shafquat Ali Chaudhary	3	N/A
Shah Naveed Saeed	3	5
Mr. Qasim Farooq Ahmad	2	N/A
Dr. Samea Kauser Ahmad	4	6
Syed Ilyas Ahmed	4	3**
Prof. Dr. Shoab Ahmed Khan	2	N/A

* Mr. Muhammad Zahid and Dr. Mohammad Salim Khan were relieved of as the member of Audit Committee on 28-01-2017 whereafter one meeting of Audit Committee was held during the year under review.

** Syed Ilyas Ahmed was inducted in the Audit Committee of the Company on 25-08-2016 whereafter only three meetings of Audit Committee were held.

22. The pattern of shareholding and additional information regarding pattern of shareholding is given on page No. 202.

23. The present auditors M/s Grant Thornton Anjum Rahman retire at the conclusion of 31st AGM and being eligible have offered themselves for re-appointment. On the suggestion of the Audit Committee, the Board of Directors of the Company recommended the re-appointment of M/s Grant Thornton Anjum Rahman, Chartered Accountants, as the auditors of the Company for the year ending June 30, 2018.

24. All the related party transactions have been approved by the Board of Directors. The Company maintains a full record of all such transactions, along with the terms and conditions.

25. Shifa is on the web and can be accessed at www.shifa.com.pk.

26. During the year under review, the Company's contribution to the national exchequer is as under:

Direct Taxes	Rs. 340.4 million
Indirect Taxes	Rs. 145.7 million
Tax deducted and deposited from suppliers, employees etc.	Rs. 559.7 million
Total	Rs. 1,045.8 million

27. During the year under review, the Company donated Rs. 2.4 million and Rs. 50 million to Shifa Foundation and Shifa-Tameer-e-Millat University (STMU) respectively. Shifa Foundation is not for profit organization, providing medical treatment facilities to indigent and poor patients. The Company considers the Shifa Foundation as its social arm for fulfilling corporate social responsibilities with respect to people and society. Whereas Shifa is one of the sponsors of STMU. Both Shifa College of Medicine and Shifa College of Nursing are its constituent colleges. STMU is also offering various degree programmes which includes Doctor of Physical Therapy, Doctor of Pharmacy, BS (Mechanical Technology), MBA (Health Services), B.Sc. (Medical Lab Technology), M.Sc. (Nursing), etc.

28. The Company in its endeavor to conserve electricity has installed six Heat Exchanger for heating domestic water to be used in Inpatient and Outpatient Departments, energy efficient lights were replaced instead of conventional lights and energy conservation is also pursued through installation of VFDs of 10 KW Motors.
29. Company is mindful towards environmental protection and following measures are taken to ensure the same:
- Emission tests of generators, boilers, chillers & Incinerator.
 - Sewerage water test.
 - Indoor air quality for legionella.
 - A comprehensive waste management flow chart has been prepared & followed.
 - Spill management training has been conducted for all safety coordinators/ housekeeping related staff.
 - All infectious waste has been weighted and 100% disposed off in incinerator safely.
 - Radiation waste and safety is being looked after by the Radiation Safety Committee.
 - In order to maintain the smooth functioning of the Hospital, the Company has prepared a Disaster Management Plan.
30. Shifa recognizes the importance of providing and maintaining a safe and healthy working environment for all. Health & Safety is of equal importance to the efficiency of the hospital and the quality of the services delivered at Shifa. A comprehensive Staff Health & Safety Program has been developed in this regard. The objective is to evaluate the effectiveness of the Staff Health & Safety Program while identifying the areas of improvement and potential risks. The components of staff health and safety program are following:
- i. Provision of necessary medical care benefits
 - ii. Medical monitoring of employees
 - iii. Ongoing activity of screening and immunization for new joiners.
 - iv. Needle stick injury & splashes program
 - v. Workplace violence prevention
 - vi. Medical equipment safety program
 - vii. Radiation safety program
 - viii. Fire safety management program
 - ix. Laboratory safety program
 - x. Kitchen safety
- Protocols of Pakistan Nuclear Regulatory Authority are strictly implemented to ensure that patient and employees are protected from exposure to any harmful radiation.
31. Shifa has non-discrimination policy through which we provide disabled employees with the same opportunities for promotion, career development and training as those offered to other employees.
32. During the year under review we remain engaged in getting Shifa Joint Commission International (JCI) Accredited. Based on the findings of the initial Hospital survey of 13th May, 2017 to 18th May, 2017 and the Decision Rules of JCI, Shifa has been granted the status of ACCREDITED. The pursuit of JCI accreditation was a mutual team effort with a diversified & multi-functional deliverables implemented throughout the Hospital, which includes:
- To ensure compliance with ventilation guidelines, all procedure rooms were re-designed for achieving the positive pressure.
 - For infection control and prevention, a central CSSD distribution set-up was introduced for central sterilization, decontamination, clean processing, sterilization & distribution of supplies.

DIRECTORS' REPORT

- A fire safety program in compliance with international standards was implemented by upgrading the facility in terms of design layout and infrastructure (fixtures and fittings) for preventing any fire outbreak and 100% staff training was ensured to effectively respond to any potential fire incident.
 - Setting-up waste management system with an efficiency cycle of 24 hour for proper waste disposal and a cold storage room for handling, storage, and transportation of the clinical waste as per accredited guidelines.
 - Point of Care Testing services were introduced by the department of Laboratory & Pathology and Medicine at ER & IPD floors for efficient reporting and reducing the turn-around-time.
 - Histopathology & Cytology lab has been fully automated to increase precision & operational efficiency. The latest equipment has been added to Immunology, Microbiology, & Cytogenetic labs.
 - Pharmacy services are further expanded & outreach beyond Shifa premises to cater to a broader population of patient segments. As part of the Corporate partnership program, retail outpatient and inpatient pharmacies are established at medical center & healthcare facility of OGDCL.
 - Food & Nutrition Services were upgraded to improve food storage, cooking, & dispensing facilities as per accredited food hygiene and nutrition guidelines.
33. The Company has a comprehensive Code of Conduct which requires all employees to maintain a work environment which calls for fairness, respect and integrity and to adopt ethical manners. The Code has provisions which include but are not limited to legal compliance, restraint on political activities & soliciting gifts, avoiding conflict of interest, non-discrimination or harassment on the basis of race, color, age, etc., maintaining confidentiality of information, complying with the laws, rules vis-à-vis environmental protection etc. The Code of Conduct is applicable to all the directors, officers, employees, consultants and agents of the Company.
34. Shifa comply with international standards and have taken measures accordingly with respect to the requirements of JCIA and ISO 9001:2008 in order to ensure that our consumer (patients and their families) are protected from any unforeseen harm.
35. For the awareness of general public Company celebrated following days and also offered free seminars:
- Health awareness seminars with relevance to Global Health Days.
 - Breast Cancer Awareness; Content Development (Visual and Print educational tools for female and distribution through multiple mediums.
 - Capacity Building & Education Lectures for Physicians' community (Paeds Cardiology) in Mirpur & Abbottabad.
 - Educational activities for Stroke patients to facilitate their long-term care (educational lectures and seminars).
 - Developing educational and awareness content (Visual & print) on prevalent diseases and health risk factors to empower the general public.
 - Distribution and outreach of the material to the general public by utilizing different communication mediums.
36. Two funds namely Health Care Fund and Education Fund has been created under the head of Social Welfare Activities Committee (SWAC) for providing financial assistance to the employees for them to address their healthcare needs, if required, and for the sponsorship of one male/female child of employees drawing salaries upto Rs. 100,000/- to bear their educational expenses respectively.
37. The detail of the expansion activities during the year under review are as under:
- i. To expand the capacity and operational efficiency, Obs/ Gyne OPD facility was renovated and re-designed to accommodate the newly joined Consultants and to synchronize the patient flow. A new L&D suit was also built to cater to the departmental requirements and to improve the over-all patient experience.

- ii. Three new operating rooms were established to meet-up the requirement of surgical specialties.
- iii. A phase-wise ER expansion and renovation project has been completed to increase the total capacity to 52 beds, and to improve ER triage areas and process flow.
- iv. During the last year, Chemotherapy facility was expanded by adding 15 new beds. At present, the Chemotherapy unit has total capacity of 61 beds. Furthermore, operational capacity of the BMT services has also been increased by aligning Chemotherapy requirements with Pharmacy services.
- v. A new state-of-the art automated laundry plant is operational for proper Linen & Laundry management to prevent and control laundry specific infections.
- vi. A latest Reverse Osmosis plant has been set-up for the Dialysis patients to ensure purity and hygiene of water to avoid contamination which can lead to morbidity and mortality.
- vii. A latest 3D Hologic mammography machine was added to the Radiology Department to facilitate diagnostics needs of women and breast cancer patients.

Company believes that the expansion activities that are in line with the demand of patients shall have a positive impact on the financial health of the Company in the time to come.

38. To improve the access of quality healthcare to the broader population, there is an on-going need to assess and expand technical and operational capacity of the Hospital. Multiple infrastructure projects were conceived and started in 2016 to enhance operational capacity. A few of them are close to completion while others will be completed during the year ending June 30, 2018, which include:

C-Block Expansion & Renovation

- Addition of 21 beds for Medical ICU and step-down units to increase efficiency and capacity of critical care services
- Thirty one private rooms will be added to ease the admission process during higher IPD occupancy.
- In pursuit of the specialized & an improved post-op care, a new ICU facility will be established for the transplant services.
- A medical day care facility will also be constructed to cater to the increasing needs of medical services.
- Expansion of OPD clinics, i.e., General Surgery & ENT, for improving patient experience by seamless provision of services.

F-Block:

- To further upgrade Radiology Diagnostics & Imaging services, a new dedicated area is allocated to the department at F-block.
- To cater to the advanced requirements for the Radiology Diagnostic Interventional procedures, Shifa is investing in cutting-edge technologies. A new and advanced range of equipment will be added soon which includes CT, MRI and separate ultrasound suits and introducing super specialty services in ultrasonography, and an X-ray unit.

Other Projects:

- Pharmacy services will further be expanded by corporate partnership program by setting-up facilities at Medical Centers of other corporate entities.
- The capacity of the hospital facility at Faisalabad will be increased by adding more IPD & Critical care beds.
- A 100 bedded facility at Sialkot is in the design and conception phase. This project will be a unique example of private sector partnership in the healthcare industry on “Operational & Management Model” to enhance access of the masses to the standardized and quality healthcare services.
- To set-up a Center of Excellence & a comprehensive healthcare facility and institute for Neurosciences, approx. 284 kanals of land has been acquired in Islamabad.

DIRECTORS' REPORT

- Capacity Building in Medical Technology (Equipment procurement has been sanctioned);
 - Oncology: Brachytherapy equipment (Internal Radiation Therapy)
 - Operating Rooms: Neurology Imaging & Surgical Navigation system, setting-up a new angiography unit, Lymph node surgery equipment
 - Neurology: A new EEG machine (Neurophysiology lab)
 - ENT: An Audiometry booth for ENT Clinic
- The future product and service development includes starting an;
 - Integrated and comprehensive Breast Cancer Clinic.
 - Additional beds to expand capacity of BMT Unit.
 - Expanding Evening clinic facility by adding up new time slots, specialties, and consultants.
 - Total Lab Automation to achieve workflow efficiency, total process management, and sustainability to generate more accurate and reliable results.
 - Robotic Surgery services with a dedicated OT facility will be started for the surgical intervention, allowing improved procedural efficiency and outcomes.
- We are also exploring opportunities to branch out our services in different cities of Pakistan as well as in Middle East & African Countries.


The Board is obliged to put on record its appreciation for the consultants, management and staff for their untiring efforts to deliver uninterrupted quality healthcare and shareholders, bankers, patients and regulatory bodies for their patronage.

On behalf of the Board



DR. MANZOOR H. QAZI

Chief Executive Officer



DR. MOHAMMAD SALIM KHAN

Executive Director

ISLAMABAD
September 11, 2017

- نئے ٹائم سلاٹس اور سپیشلائیز و کنسلٹنٹس کو شامل کر کے ایوننگ کلینک کی شروعات کی تو سبچ۔
 - کام کے بہاؤ کی کارکردگی، ٹوٹل پروسیس منیجمنٹ، اور استحکام کے لئے مکمل لیب آٹومیشن تاکہ زیادہ درست اور قابل اعتماد نتائج حاصل ہوں۔
 - سرجیکل انٹرویشن کے لئے روبوٹک سرجری کی سروسز ایک مخصوص OT سہولت کے ساتھ شروع کی جائیں گی تاکہ طریقہ کار کی بہتری اور اچھے نتائج حاصل کئے جاسکیں۔
 - ہم پاکستان کے مختلف شہروں اور مشرق وسطیٰ اور افریقی ممالک میں خدمات کو پھیلانے کے مواقع بھی تلاش کر رہے ہیں۔
- بورڈ اعلیٰ معیار کی طبی دیکھ بھال فراہم کرنے کے لئے کنسلٹنٹس، انتظامیہ اور عملے کی بلا تعطل ان تھک کوششوں کو پیش نظر رکھتے ہوئے ان کا ممنون ہے اور شیئر ہولڈرز، مینکوں، مریضوں اور ریگولیٹری اداروں کو ان کی معاونت پر سراہتا ہے۔

منجانب بورڈ

Marjuna Ali Baji

ڈاکٹر منظور ایچ قاضی
چیف ایگزیکٹو آفیسر

Ms. Salim Khan

ڈاکٹر محمد سلیم خان
ایگزیکٹو ڈائریکٹراسلام آباد
11 ستمبر 2017

کمپنی کا خیال ہے کہ مریضوں کی طلب کے مطابق توسیع کی سرگرمیاں کمپنی کی مالی صحت پر مثبت اثر ڈالے گی۔

38. معیاری طبی سہولیات ایک وسیع آبادی کو باہم پہنچانے کے لئے ہسپتال کی تکمیلی اور آپریشنل صلاحیت کا اندازہ لگانے اور اس کو بڑھانے کی ہمیشہ ضرورت ہوتی ہے۔ آپریشنل صلاحیتوں کو بڑھانے کے لئے پیشتر بنیادی ڈھانچوں کے منصوبوں کا 2016 میں تصور اور آغاز کیا گیا ہے۔ ان میں سے کچھ تکمیل کے قریب ہیں جبکہ دیگر مالی اختتامی سال 2018 میں مکمل ہو جائیں گے، جن میں شامل ہیں:

سی بلاک کی توسیع اور بحالی

- ضروری دیکھ بھال کی خدمات کی کارکردگی اور صلاحیت بڑھانے کے لئے میڈیکل آئی سی اور سٹیپ ڈاؤن یونٹس میں 21 بستروں کا اضافہ کیا جائے گا۔
- IPD میں زیادہ رش کی صورت میں ایڈمیشن کے عمل کو آسان بنانے کے لئے 31 پرائیویٹ کمرے شامل کیے جائیں گے۔
- خصوصی اور آپریشن کے بعد کی بہتر دیکھ بھال کے حصول میں، ٹرانسپلانٹ کی خدمات کے لئے ایک نئی آئی سی یو کی سہولت قائم کی جائے گی۔
- طبی خدمات کی بڑھتی ہوئی ضروریات کو پورا کرنے کے لئے میڈیکل ڈے کیئر کی سہولیات بھی تعمیر کی جائے گی۔
- مریض کے تجربے اور خدمات کی ہموار فراہمی کے لئے OPD کلینک، یعنی، جنرل سرجری اور ENT، کی توسیع۔

ایف بلاک:

- ریڈیولوجی تشخیصی اور امیجنگ کی خدمات کو مزید بڑھانے کے لئے ایف بلاک کا ایک حصہ مخصوص کر دیا گیا ہے۔
- ریڈیولوجی تشخیصی انٹرویویشنل طریقہ کار کی جدید ضروریات کو پورا کرنے کے لئے شفا جدید ٹیکنالوجی میں سرمایہ کاری کر رہا ہے۔ نئے اور جدید رینج کے آلات جلد ہی سہولیات میں شامل کر لئے جائیں گے جن میں سی ٹی، ایم آر آئی و علیحدہ الٹراساؤنڈ یونٹ، الٹراسونوگرافی میں سپر سپیشلسٹی خدمات کو متعارف کرانا اور ایکس رے یونٹ شامل ہیں۔

منصوبے:

- فارمی سروسز کو مختلف کارپوریٹ اداروں کے میڈیکل سینٹرز میں کارپوریٹ پارٹنر پروگرام کے تحت قائم کر کے بڑھایا جائے گا۔
- فیصل آباد ہسپتال کی طبی سہولیات کی صلاحیت کو مزید IPD اور انتہائی نگہداشت کے بستروں کی تعداد میں اضافہ کر کے بڑھایا جائے گا۔
- سیالکوٹ میں 100 بستروں کا ہسپتال ڈیزائن اور تصور کے مرحلے میں ہے۔ یہ منصوبہ صحت کی معیاری دیکھ بھال پر عوام کی رسائی کو بڑھانے کے لئے ”آپریشنل اینڈ مینجمنٹ ماڈل“ میں نجی شعبے کی شراکت داری کی ایک منفرد مثال ہو گا۔
- اسلام آباد میں ایک سینٹر آف ایکسیلینس اور جامع صحت کی سہولیات اور نیوروسائنسز کا انسٹی ٹیوٹ قائم کرنے کے لئے تقریباً 284 کنال زمین حاصل کی گئی ہے۔

• میڈیکل ٹیکنالوجی میں کیپسٹی بلڈنگ کے آلات کی خریداری کی منظوری؛

- o آنکولوجی: بریکی تھراپی کا آلہ (اندرونی ریڈی ایشن تھراپی)
- o آپریٹنگ رومز: نیورولوجی امیجنگ اور سرجیکل نیویگیشن سسٹم، ایک نئے انجیوگرافی یونٹ کا قیام اور لفٹ نوڈ سرجری کے آلات
- o نیورولوجی: ایک نئی ای ای جی مشین (نیوروفزیولوجی لیب)
- o ای این ٹی: ای این ٹی کلینک کے لئے ایک آڈیومیٹری بوتھ۔
- مستقبل کی مصنوعات اور سروس کی ترقی کے لئے مندرجہ ذیل کی شروعات بھی شامل ہے؛
 - o انضمام اور جامع چھاتی کے کیسنس کلینک۔
 - o بی ایم ٹی یونٹ کی صلاحیت کو بڑھانے کے لئے اضافی بستر۔

33. کمپنی میں ایک جامع کوڈ آف کنڈکٹ ہے جس میں تمام ملازموں کو کام کے ماحول کو برقرار رکھنے کو ترجیح دی گئی ہے جو منصفانہ، احترام اور سالمیت کا مطالبہ کرتا ہے اور اخلاقی آداب کو اپنانے پر زور دیتا ہے۔ کوڈ میں سیاسی سرگرمیوں کو روکنے اور تخائف لینے، نسل، رنگ، عمر، وغیرہ کی بنیاد پر ہراساں کرنے، معلومات کی رازداری کو برقرار رکھنے، قوانین کی تعمیل، ماحولیاتی تحفظ سے متعلق قوانین وغیرہ شامل ہیں۔ کوڈ آف کنڈکٹ تمام ڈائریکٹرز، افسران، ملازمین، کنسلٹنٹس اور کمپنی کے ایجنٹوں پر لاگو ہوتا ہے۔

34. شفا بین الاقوامی معیاروں پر عمل درآمد کرتا ہے اور اس کے لئے JCIA اور آئی ایس او 9001:2008 کی شرائط کے عین مطابق اقدامات کیے ہیں تاکہ یہ یقینی بنایا جاسکے کہ ہمارے صارفین (مریضوں اور ان کے خاندان) کو کسی غیر متوقع نقصان سے محفوظ رکھا جائے۔

35. عام عوام کے شعور کے لئے کمپنی نے مندرجہ ذیل دنوں اور مفت سیمینارز کا اہتمام کیا:

- متعلقہ عالمی صحت کے دن کی مناسبت سے صحت کے آگہی سیمینار.
- بریسٹ کینسر سے آگہی
- کنٹینٹ ڈویلپمنٹ (خواتین کیلئے بصری اور پرنٹ کے ذریعے تعلیمی ٹولز اور ان کی مختلف ذرائع سے تقسیم)
- میرپور اور ایبٹ آباد میں فزیشن کمیونٹی کی صلاحیت میں اضافے کے لئے تعلیمی لیکچرز۔
- اسٹروک کے مریضوں کی طویل المدت خیال رکھنے کی سہولت کے لئے تعلیمی سرگرمیاں (تعلیمی لیکچرز اور سیمینارز).
- عوام الناس کو بااختیار بنانے کے لئے موجودہ بیماریوں اور صحت سے متعلق خطرے کے عوامل کے لئے آگاہی (بصری اور پرنٹ) مواد کی تیاری۔

36. سماجی ویلفیئر ایکٹیویٹیز کمیٹی کے تحت دو فنڈز ”ہیلتھ کیئر فنڈ“ اور ”ایجوکیشنل فنڈ“ کے نام سے تشکیل دیئے گئے ہیں جو کہ تمام ملازمین کی صحت کی دیکھ بھال میں حسب ضرورت معاونت کریں گے اور جو ملازمین ایک لاکھ روپے تک تنخواہ لے رہے ہیں، ان کے ایک بچہ/بچی کے تعلیمی اخراجات اٹھانے کے لئے مالی معاونت کرے گی۔

37. زیر جائزہ سال کے دوران توسیع کی سرگرمیوں کی تفصیل ذیل میں ہے:

- i. صلاحیت اور آپریشنل کارکردگی کو بڑھانے کے لئے OBS/GYNE OPD کی سہولیات کو نئے شامل ہونے والے کنسلٹنٹس کو ایڈجسٹ کرنے اور مریضوں کے بہاؤ کو مطابقت دینے کے لئے دوبارہ تعمیر کیا گیا تھا۔ ایک نیا L&D بھی ڈیپارٹمنٹ کی ضروریات کو پورا کرنے اور تمام مریضوں کے تجربے کو بہتر بنانے کے لئے تعمیر کیا گیا۔
- ii. سرجیکل سپیشلٹیز کی ضروریات کو پورا کرنے کے لئے 3 نئے آپریٹنگ رومز قائم کیے گئے ہیں۔
- iii. ایک مرحلہ وار ایمرجنسی رومز کی توسیع اور بحالی کی منصوبہ بندی 52 بستروں کی کل صلاحیت بڑھانے کے لئے اور ایمرجنسی ٹریج کی جگہ کو بہتر بنانے اور بہاؤ کے عمل کو بہتر بنانے کے لئے عمل کر دی گئی ہے۔
- iv. گزشتہ سال کے دوران کیموتھراپی کی سہولیات کو 15 نئے بستروں کو شامل کر کے بڑھایا گیا۔ فی الحال کیموتھراپی یونٹ میں 61 بستروں کی کل صلاحیت ہے۔ اس کے علاوہ بی ایم ٹی کی خدمات کی آپریشنل صلاحیت کو فارمیسی خدمات کے ساتھ کیموتھراپی کی ضروریات کے مطابق بھی بڑھا دیا گیا ہے۔
- v. ایک نئے جدید طرز پر خودکار لائڈری پلانٹ آپریشنل ہے تاکہ صحیح لیٹن اور لائڈری منیجمنٹ کی جاسکے اور لائڈری سے وابستہ بیماریوں کی روک تھام اور ان پر قابو پایا جاسکے۔
- vi. ڈائیلیسز مریضوں کے لئے ایک تازہ ترین ریورس اوسموسس پلانٹ قائم کیا گیا ہے تاکہ پانی کی صفائی اور حفظان صحت کو یقینی بنانے کے لئے آلودگی سے بچا جائے جو مریضوں کی بیماری اور موت کا باعث بنتا ہے۔
- vii. خواتین اور چھاتی کے کینسر کے مریضوں کی تشخیصی ضروریات کو سہولت دینے کے لئے ریڈیولوجی ڈیپارٹمنٹ میں ایک تازہ ترین 3D ہولوجک میموگرافی مشین شامل کی گئی۔

30. شفا اس بات کی اہمیت کو جانتا ہے کہ سب کے لئے ایک صحت مند کام کے ماحول کی فراہمی کو یقینی بنایا اور برقرار رکھا جائے۔ ہسپتال کی بہترین کارکردگی اور شفا میں فراہم کی جانے والی خدمات کے معیار کے لئے صحت اور سیفٹی برابر اہمیت کے حامل ہیں۔ اس تناظر میں سٹاف کے لئے ایک جامع صحت اور سیفٹی پروگرام تشکیل دیا گیا ہے۔ اس کا مقصد سٹاف کی صحت اور سیفٹی پروگرام کے موثر ہونے کا اندازہ لگانے کے ساتھ ساتھ بہتری کی جگہوں اور ممکنہ خطرات کی بھی نشاندہی کرنا ہے۔ سٹاف کی صحت اور سیفٹی پروگرام کے اجزاء مندرجہ ذیل ہیں:

- i. ضروری طبی دیکھ بھال کے فوائد کی فراہمی
- ii. ملازمین کی طبی نگرانی
- iii. نئے شامل ہونے والوں کے لئے سکریٹنگ اور امیونائزیشن کی جاری سرگرمیاں.
- iv. نیڈل سٹک انجری اور سپلیشز پروگرام
- v. کام کی جگہ پر تشدد کی روک تھام
- vi. طبی آلات سیفٹی پروگرام
- vii. ریڈی ایشن سیفٹی پروگرام
- viii. فائر سیفٹی مینجمنٹ پروگرام
- ix. لیبارٹری سیفٹی پروگرام
- x. کچن سیفٹی

پاکستان نیوکلیئر ریگولیٹری اتھارٹی کے پروٹوکولز پر سختی سے عمل کیا جاتا ہے تاکہ مریضوں اور ملازمین کو نقصان دہ ریڈی ایشن کے اثرات سے تحفظ فراہم کیا جاسکے۔

31. شفا غیر انتیازی سلوک کی پالیسی پر عمل پیرا ہے جس کے تحت ہم معذور ملازمین کو وہی ترقی کے مواقع، کیریئر میں ترقی اور ٹریننگ فراہم کرتے ہیں جو کہ دیگر ملازمین کے لئے ہیں۔

32. زیر جائزہ سال کے دوران ہم ہسپتال کو جوائنٹ کمیشن انٹرنیشنل (JCI) سے منظور کرانے میں مشغول رہے۔ 13 مئی، 2017 سے 18 مئی، 2017 کے ابتدائی ہسپتال سروے اور JCI کے فیصلہ جاتی اصولوں کے نتائج کے مطابق شفا کو منظور کی کا سٹیٹس دے دیا گیا ہے۔ JCI کی منظوری کے حصول میں باہمی ٹیم کی کوشش کے ساتھ ساتھ ہسپتال میں متنوع اور کثیرالفعال ڈیلیوریبلز کا لاگو ہونا ہے جس میں شامل ہیں:

- وینٹیلیشن ہدایات کے مطابق تعمیل یقینی بنانے کے لئے اور مثبت دباؤ کو حاصل کرنے کے لئے تمام پروسیجر رومز کو دوبارہ ڈیزائن کیا گیا۔
- انفیکشن کے کنٹرول اور روک تھام کے لئے ایک سنٹر CSSD ڈسٹریبیوشن سیٹ اپ کو برائے سنٹرل، ڈی کنٹینمنٹیشن، صاف پروسیسنگ، سٹریلائزیشن اور سپلائز کی تقسیم کار کے لئے متعارف کرایا گیا ہے۔
- موجودہ سہولت کے ڈیزائن اور انفراسٹرکچر (کلیچرز اور فننگز) کو اپ گریڈ کیا گیا ہے تاکہ بین الاقوامی معیار سے مطابقت کے تحت ایک فائر سیفٹی پروگرام کو لاگو کیا جائے تاکہ آگ لگنے والے واقعات کی روک تھام کی جاسکے۔ اس کے علاوہ 100 فیصد سٹاف کی تربیت کی گئی کہ وہ کسی بھی ممکنہ آگ لگنے کے حادثے سے موثر انداز میں نمٹ سکیں۔
- فضلہ تلف کرنے کے لئے 24 گھنٹے کی مہارتی سائیکل کے ساتھ فضلہ مینجمنٹ کے نظام اور ایک کولڈ اسٹوریج روم کا قیام تاکہ کلینیکل فضلہ کی تلفی، ذخیرہ اور نفل و حمل کو منظور شدہ ہدایات کے مطابق کیا جاسکے۔
- لیبارٹری و پیٹھولوجی اور ایمر جنسی و IPD فلورز پر میڈیسن کے ڈیپارٹمنٹ میں پوائنٹ آف کیئر ٹیسٹنگ کی خدمات کو موثر رپورٹنگ اور وقت کے بچاؤ کے لئے متعارف کرایا گیا۔
- ٹھیک نتائج اور آپریشنل کارکردگی کو بڑھانے کے لئے ہسپتال پیٹھولوجی اور سائٹولوجی لیب کو مکمل طور پر خود کار کر دیا گیا ہے۔ جدید آلات بھی امیونولوجی، مائیکروبیالوجی اور سائٹوجینٹک لیبز میں شامل میں کر دیئے گئے ہیں۔
- فارمیسی کی خدمات کو بھی شفا کے احاطے سے باہر پھیلا گیا ہے۔ کارپوریٹ پارٹنرشپ پروگرام کے تحت ریٹیل اندرونی اور بیرونی مریضوں کے لئے فارمیسی اوجی سی ڈی سی ایل کے طبی مراکز میں قائم کی گئی ہے۔
- غذا اور غذائی کی خدمات کو تسلیم شدہ غذا کی حفظان صحت اور غذائی ہدایات کے مطابق کھانے کی اسٹوریج، کھانا پکانے، اور تقسیم کرنے میں بہتری کے لئے اپ گریڈ کیا گیا۔

* (زیر جائزہ سال کے دوران جناب محمد زاہد اور ڈاکٹر محمد سلیم خان کو 28-01-2017 کو آڈٹ کمیٹی کے رکن کے طور پر سبکدوش کر دیا گیا جبکہ اس کے بعد آڈٹ کمیٹی کا صرف ایک اجلاس منعقد ہوا)

** (سید الیاس احمد کو 25-08-2016 کو آڈٹ کمیٹی میں رکن کے طور پر شامل کیا گیا جس کے بعد آڈٹ کمیٹی کے صرف تین اجلاس منعقد ہوئے۔)

22. شیئر ہولڈنگ کا طریقہ کار اور اس سے متعلق اضافی معلومات صفحہ نمبر 202 پر دی گئی ہیں۔

23. 31 ویں اجلاس عام کے اختتام پر موجودہ آڈیٹرز میسرز گرانٹ تھارٹن انجم رحمن دستبردار ہو رہے ہیں اور دوبارہ تعیناتی کی شرط کے مطابق انہوں نے دوبارہ اپنے آپ کو پیش کیا ہے۔ بورڈ آف ڈائریکٹرز نے آڈٹ کمیٹی کی سفارشات پر میسرز گرانٹ تھارٹن انجم رحمن، چارٹڈ اکاؤنٹنٹس کی دوبارہ تعیناتی برائے سال 30 جون 2018 تک کیلئے سفارش کی ہے۔

24. ساری متعلقہ پارٹی معاملات کی بورڈ آف ڈائریکٹرز نے منظوری دے دی ہے۔ کمپنی کے پاس ایسے تمام معاملات کا مکمل ریکارڈ بشمول شرائط و ضوابط موجود ہے۔

25. شفا ویب پر موجود ہے اور www.shifa.com.pk پر قابل رسائی ہے۔

26. زیر جائزہ سال میں کمپنی کی قومی خزانے میں پیش کردہ حصہ درج ذیل ہے:

ڈائریکٹ ٹیکسز ----- 340.4 ملین روپے

ان ڈائریکٹ ٹیکسز ----- 145.7 ملین روپے

سپلائرز، ملازمین وغیرہ سے ٹیکس کٹوتی ----- 559.7 ملین روپے

کل رقم ----- 1045.8 ملین روپے

27. زیر جائزہ سال میں شفا فاؤنڈیشن اور شفا تعمیر ملت یونیورسٹی (STMU) کو کمپنی نے بالترتیب 2.4 ملین اور 50 ملین روپے عطیہ کئے۔ شفا فاؤنڈیشن غیر منافع بخش تنظیم ہے، جو نادار اور غریب مریضوں کو طبی علاج کی سہولیات فراہم کرتی ہے۔ کمپنی شفا فاؤنڈیشن کو عوام اور معاشرے سے متعلقہ سماجی ذمہ داریوں کو پورا کرنے کے لئے اپنا سماجی بازو تصور کرتی ہے۔ شفا STMU کے سپانسرز میں سے ایک ہے۔ شفا کالج برائے میڈیسن اور شفا کالج برائے نرسنگ، دونوں اس کے ملحق ادارے ہیں۔ اس کے علاوہ STMU مختلف ڈگری پروگرامز جیسا کہ ڈاکٹر آف فزیکل تھراپی، ڈاکٹر آف فارمیسی، بی ایس (میکینیکیل ٹیکنالوجی)، ایم بی اے (ہیلتھ سروسز)، بی ایس سی (میڈیکل لیب ٹیکنالوجی)، ایم ایس سی (نرسنگ) وغیرہ بھی کروا رہی ہے۔

28. کمپنی نے بجلی کی بچت کرنے کی غرض سے IPD اور OPD میں ڈومیسٹک پانی کو گرم کرنے کے لئے چھ ہیٹ ایکسچینجر نصب کئے ہیں روایتی لائٹس کو توانائی کی بچت والی لائٹس کے ساتھ تبدیل کر دیا گیا ہے اور VFDs کی تنصیب کے ذریعے 10 کلوواٹ موٹرز کی توانائی بچائی گئی۔

29. کمپنی ماحولیاتی تحفظ کی طرف متوجہ ہے اور اس کو یقینی بنانے کیلئے مندرجہ ذیل اقدامات کیے گئے ہیں:

- جزیٹرز، بوائلرز، چلرز اور انسیریٹرز کے اخراجی ٹیسٹ.
- سیوریج کے پانی کے ٹیسٹ.
- لیجنیلا کے لئے اندرونی ہوا کے معیار کی جانچ پڑتال.
- ایک جامع ویسٹ مینجمنٹ فلو چارٹ بنایا گیا ہو جس کی پیروی کی جاتی ہے۔
- تمام سیفٹی کوآرڈینیٹر/ہاؤس کیپٹنگ سے متعلقہ سٹاف کیلئے سیل مینجمنٹ ٹریننگ کا انعقاد کرایا گیا ہے۔
- تمام انفیکشن زدہ فضلے کا 100 فیصد وزن کرنے کے بعد انسیریٹرز میں تلف کیا جاتا ہے۔
- ریڈی ایشن سے متعلق فضلے اور سیفٹی کی دیکھ بھال ریڈی ایشن سیفٹی کمیٹی کے ذریعے کی جارہی ہے۔
- ہسپتال کے روزمرہ کی کارکردگی کو برقرار رکھنے کے لئے کمپنی نے ایک ڈیزاسٹر مینجمنٹ پلان تشکیل دیا ہے۔

11. چلتے ہوئے کاروباری ادارہ کے طور پر کمپنی کی صلاحیت پر کوئی اہم شکوک و شبہات نہیں پائے گئے۔
12. صحت کی دیکھ بھال کی صنعت کی حیثیت سے شفا کو بہت سے خطرات کا سامنا کرنا پڑتا ہے جن میں ریگولیشن، مقابلہ، کاروباری، اقتصادی و کاروباری ماحول، آپریشنل و کریڈٹ، فنانسنگ و لیکویڈیٹی، کلینیکل، انفارمیشن سسٹم سیکورٹی و دستیابی، معیار و آپریشنل خدمات کا استحکام، ہنر مند افراد کی دستیابی و بھرتی، دھوکہ دہی، وغیرہ کے خطرات شامل ہیں۔ شفا میں مضبوط اندرونی کنٹرول اور خطرے سے نمٹنے کا نظام ہے۔ کمپنی کے اثاثوں کی حفاظت کے لئے اور / یا ابھرتے خطرات سے مناسب طریقے سے نمٹنے کے لئے رسک مینجمنٹ اور اندرونی کنٹرول کے عمل کو ڈیزائن کیا گیا ہے۔
13. ایس ای سی پی کے بتائے ہوئے معیار کے مطابق زیر جائزہ سال کے دوران پروفیسر ڈاکٹر شعیب احمد خان، ڈائریکٹر نے کامیابی سے ڈائریکٹرز ٹریننگ پروگرام مکمل کر لیا ہے۔
14. صفحہ نمبر 108 پر گذشتہ چھ سال کی کلیدی کارروائیوں اور مالیاتی اعداد و شمار کا خلاصہ دیا گیا ہے
15. نوٹس برائے مالیاتی گوشوارے کا نوٹ نمبر 9.4 سرمایہ کاری کی قدر برائے گریجویٹ فنڈ اکاؤنٹ ظاہر کرتا ہے۔
16. کمپنی کے ذیلی ادارے یعنی شفا کنسلٹنگ سروسز (پرائیویٹ) لمیٹڈ کے اہم معاملات کو مشترکہ فنانشل اسٹیٹمنٹس کے نوٹس میں نمبر 1.3 میں بیان کیا گیا ہے۔
17. سی ای او، سی ای او، سی ایف او، ہیڈ آف انٹرنل آڈٹ اور کمپنی سیکرٹری کے علاوہ تمام جنرل مینجرز اور ان سے سینئر افسران کو کوڈ آف کارپوریٹ گورننس کے کوڈ I (xvi) اور کوڈ xxiii کے مقاصد کے تناظر میں کمپنی ایگزیکٹو سمجھا جاتا ہے۔
18. زیر جائزہ سال کے دوران، ڈاکٹر سمیعہ کوثر احمد، ڈائریکٹر نے کمپنی کے 2,810,255 حصص اپنے خاندان کے اراکین کو بطور تحفہ دیئے ہیں اور جناب قاسم فاروق احمد، ڈائریکٹر، نے اپنی بہن ڈاکٹر سمیعہ کوثر احمد سے 24,860 حصص تحفہ کے طور پر حاصل کئے ہیں جبکہ ڈاکٹر منظور ایچ قاضی، چیف ایگزیکٹو آفیسر نے بھی کمپنی کے 434,307 حصص اپنی بیٹی مس کومل منظور قاضی سے تحفہ کے طور پر حاصل کئے ہیں۔ اس کے علاوہ کسی دوسرے ڈائریکٹر، سی ایف او، کمپنی سیکرٹری، ایگزیکٹوز اور ان کے شریک حیات اور نابالغ بچوں نے زیر جائزہ سال کے دوران کمپنی کے حصص میں تجارت نہیں کی۔
19. رائٹ ٹیئرز کی فروخت سے حاصل شدہ رقم کے استعمال کی پیش رفت رپورٹ مندرجہ ذیل ہے:

رقم (روپے ملین میں)						تفصیلات
ٹوٹل	4 th Qtr. 2016-17	3 rd Qtr. 2016-17	2 nd Qtr. 2016-17	1 st Qtr. 2016-17	4 th Qtr. 2015-16	
1040.02	294.08	166.36	211.22	111.58	256.78	ہسپتال کی بلڈنگ کی بحالی / F-11 فیلڈ کی پلاننگ، ڈیزائننگ / طبی آلات میں تبدیلی اور اضافہ

20. بورڈ کی کارکردگی کے سالانہ جائزے کے لئے کمپنی نے طریقہ کار وضع کیا ہوا ہے۔
21. زیر جائزہ سال کے دوران، بورڈ آف ڈائریکٹرز کی چار میٹنگز اور آڈٹ کمیٹی کی چھ میٹنگز بالترتیب منعقد ہوئی تھی۔

ہر ڈائریکٹر کی میٹنگز میں شرکت کا شمار درج ذیل ہے:

بورڈ میٹنگز میں شرکت کا شمار آڈٹ کمیٹی میٹنگز میں شرکت کا شمار

6	4	ڈاکٹر حبیب الرحمن
لاگو نہیں	4	ڈاکٹر منظور ایچ قاضی
* 5	4	جناب محمد زاہد
* 5	4	ڈاکٹر محمد سلیم خان
لاگو نہیں	3	جناب شفقت علی چوہدری
5	3	شاہ نوید سعید
لاگو نہیں	2	جناب قاسم فاروق احمد
6	4	ڈاکٹر سمیعہ کوثر احمد
* 3	4	سید الیاس احمد
لاگو نہیں	2	پروفیسر ڈاکٹر شعیب احمد خان



نتائج و عملی کارکردگی

2016	2017	
----- (روپے 000 میں) -----		
8,730,803	9,257,009	خالص آمدنی
86,760	136,579	دیگر آمدنی
(7,668,538)	(8,464,606)	آپریٹنگ لاگت
(108,997)	(66,389)	فنانس لاگت
1,040,028	862,593	منافع قبل از ٹیکسیشن
(279,930)	(256,166)	فراہمی برائے ٹیکسیشن
760,098	606,427	منافع برائے سال
----- (روپے) -----		
14.68	11.12	فی شیئر آمدنی - بنیادی اور ڈائلیوٹڈ

- مندرجہ بالا نتائج گزشتہ سال کی اسی مدت کے مقابلے میں 6 فیصد کی مجموعی آمدنی کی بڑھوتری ظاہر کرتے ہیں۔ اس سے آپریٹنگ لاگت 7,669 ملین روپے سے بڑھ کر 10.4 فیصد اضافے کے ساتھ 8,465 ملین روپے ہو گئی جو کہ بنیادی طور پر نرسنگ سٹاف اور پوسٹ گریجویٹ ٹرینینگ کی تنخواہوں میں اضافہ، دواؤں کی مہیا کردہ حجم اور لاگت، ڈیپریسییشن اور کرائے میں اضافے کی وجہ سے ہے۔ فنانس لاگت کی کمی کی وجہ طویل مدتی قرضوں کی واپسی اور KIBOR میں تنزلی ہے۔ آپریٹنگ منافع مارجن میں کمی کا سبب سعودی عرب اور دیگر مشرق وسطیٰ کے ممالک میں اقتصادی بحران شامل ہے جس کی وجہ سے وہاں پر ملازمت کے مواقع کم ہوئے اور ان ممالک میں جانے والے امیدواروں کی لازمی طبی جانچ پڑتال میں کمی واقع ہوئی۔ نتیجتاً خصوصی طور پر اس مدت میں آمدنی میں پچھلے سال کی نسبت کافی کمی واقع ہوئی۔ یہ تمام عوامل علاوہ ازیں ادا شدہ سرمائے میں اضافہ، فی شیئر آمدنی میں کمی کا باعث بنے۔ اگر ہم نے ادا شدہ سرمائے کو بڑھایا نہ ہوتا تو پچھلے سال کی نسبت اس سال فی شیئر آمدنی 11.99 روپے ہوتی۔
- زیر جائزہ سال کی فی شیئر آمدنی 14.68 روپے سے کم ہو کر 11.12 روپے ہو گئی ہے۔
- بورڈ کو یہ بتاتے ہوئے خوشی ہو رہی ہے کہ اختتامی سال 30 جون 2017 کا حتمی نقد منافع 5.00 روپے فی شیئر مقرر ہوا ہے۔
- کمپنی ایک پرائیویٹ لمیٹڈ کمپنی قائم کرنے کا ارادہ رکھتی ہے جو کہ شفاء انٹرنیشنل ہسپتال لمیٹڈ (شفاء / کمپنی / ہسپتال) کی منسلک کمپنی ہو گی۔
- شفاء کی مینجمنٹ کی تیار کردہ مالیاتی گوشوارے ان کے کاروباری معاملات، ان کے آپریشنز کے نتائج، نقدی گوشوارے اور کاروبار میں تبدیلی کی اصل حالت کو پیش کر رہے ہیں۔
- شفاء کے کھاتوں کو باقاعدگی سے کمپنیز آرڈیننس، 1984 کے مطابق برقرار رکھا گیا ہے۔
- مالیاتی گوشواروں کے تیار کرنے میں مناسب پالیسیوں کا مسلسل اطلاق کیا گیا ہے اور اکاؤنٹنگ تخمینوں کی بنیاد مناسب اور دانشمندانہ فیصلے ہیں۔
- مالیاتی گوشواروں کے بنانے میں، پاکستان میں قابل عمل بین الاقوامی اکاؤنٹنگ سینڈرز کو ملحوظ خاطر رکھا گیا ہے۔
- اندرونی کنٹرول کا نظام بہترین خود خال پر بنایا گیا ہے، موثر طور پر لاگو کیا گیا ہے اور موثر کیا جاتا ہے۔
- لسٹنگ ضوابط کے مطابق کارپوریٹ گورننس کے بہترین طریقوں کو مد نظر رکھتے ہوئے ان سے روگردانی نہیں کی گئی۔

Statement of Value Addition






	2017		2016	
	Rs. in '000'	%	Rs. in '000'	%
Value added				
Total Revenue inclusive of other income	9,393,588		8,817,563	
Supplies and other operating costs	4,895,494		4,467,404	
Total value added	4,498,094		4,350,159	
Value allocated To employees				
Salaries, wages and other benefits	3,386,716	75	3,053,772	70
To Government				
Income tax, sales tax and federal excise duty etc	401,866	9	403,896	9
To society				
Donation	52,400	1	50,000	1
To providers of capital				
Dividend to shareholders	163,614	4	336,388	8
Finance cost of borrowed funds	50,685	1	82,393	2
	214,299	5	418,781	10
Retained in the Company				
	442,813	10	423,710	10
Total value allocated	4,498,094	100	4,350,159	100



- Salaries, wages and other benefits
- Income tax and sales tax
- Donation
- Dividend to shareholders
- Finance cost of borrowed funds
- Retained in the Company

Six years at a Glance

		2017	2016	2015	2014	2013	2012
PERFORMANCE							
Operating profit margin	%	10.04	13.16	11.95	12.95	13.74	11.72
Net profit margin	%	6.55	8.71	7.19	7.27	7.30	5.86
Return on equity	%	15.50	25.60	25.72	26.72	27.10	21.99
Return on assets	%	11.99	15.97	14.47	14.14	13.90	11.20
Asset turnover	Times	1.19	1.21	1.21	1.09	1.01	0.96
CAPITAL MARKET/CAPITAL STRUCTURE ANALYSIS							
Market value per share (year end)	Rs.	330	300	250.50	144.58	44.86	30.94
Breakup value per share	Rs.	76	67.52	44.64	37.40	31.42	25.28
Market price to breakup value	Times	4.34	4.44	5.61	3.87	1.43	1.22
Earnings per share	Rs.	11.12	14.68	10.52	9.20	7.68	5.16
Price earning ratio	Times	29.68	20.44	23.81	15.72	5.84	5.99
Dividend per share (total)	Rs.	3	6.5	3	3	1.5	1.5
Dividend yield/effective dividend rate	%	0.91	2.17	1.20	2.07	3.34	4.85
Interest cover	Times	13.99	10.54	5.57	4.33	3.84	3.46
Debt : equity	Ratio	11:89	19:81	34:66	44:56	52:48	54:46
LIQUIDITY							
Current ratio		0.97	1.37	0.87	0.93	1.66	1.04
Quick ratio		0.76	1.16	0.66	0.69	1.29	0.76
HISTORICAL TRENDS							
FINANCIAL POSITION							
----- (Rupees in '000') -----							
Authorized capital		545,379	545,379	545,379	545,379	545,379	545,379
Share capital		545,379	545,379	505,138	505,138	505,138	505,138
Capital reserve		1,046,025	1,046,025	40,000	40,000	40,000	40,000
Unappropriated profit		2,553,295	2,090,865	1,709,813	1,344,260	1,042,248	731,802
Share holders' equity		4,144,699	3,682,269	2,254,951	1,889,398	1,587,386	1,276,940
Surplus on revaluation of PP&E		726,760	742,191	751,182	760,176	583,373	590,552
Non current liabilities		581,874	927,597	1,290,733	1,608,133	2,118,224	1,663,787
Current liabilities		2,295,152	1,842,642	1,822,423	1,597,824	968,684	1,128,439
Total		7,748,485	7,194,699	6,119,289	5,855,531	5,257,667	4,659,718
Property, plant and equipment (PP&E)		5,457,545	4,606,615	4,485,977	4,034,090	3,616,518	3,469,388
Intangible		10,585	-	-	-	-	-
Long term investment		18,120	18,000	18,000	-	-	-
Long term deposits		45,273	39,677	38,129	40,651	31,041	22,066
Current assets		2,216,962	2,530,407	1,577,183	1,483,316	1,610,108	1,168,264
Non current asset held for sale		-	-	-	297,474	-	-
Total		7,748,485	7,194,699	6,119,289	5,855,531	5,257,667	4,659,718
OPERATING RESULTS							
Net revenue		9,257,009	8,730,803	7,410,022	6,393,105	5,315,589	4,451,781
Operating costs		(8,464,606)	(7,668,538)	(6,579,618)	(5,622,197)	(4,625,532)	(3,944,838)
Other income		136,579	86,760	55,288	56,894	40,540	14,812
Operating profit		928,982	1,149,025	885,692	827,802	730,597	521,755
Finance cost		(66,389)	(108,997)	(158,914)	(191,229)	(190,279)	(150,800)
Provision for taxation		(256,166)	(279,930)	(193,768)	(172,017)	(152,166)	(110,161)
Profit after taxation		606,427	760,098	533,010	464,556	388,152	260,794
CASH FLOW SUMMARY							
Net cash flows from operating activities		1,037,835	1,033,182	1,158,863	962,854	670,655	504,482
Net cash used in investing activities		(1,323,953)	(498,613)	(534,181)	(829,793)	(404,875)	(987,042)
Net cash flows from/(used in) financing activities		(514,959)	398,912	(485,424)	(385,228)	190,915	784,743
Changes in cash & cash equivalent (C&CE)		(801,077)	933,481	139,258	(252,167)	456,695	302,183
Cash & cash equivalents at beginning of year		1,582,690	649,702	510,612	763,546	306,452	4,216
Effect of exchange rate change on C&CE		(419)	(493)	(168)	(767)	399	53
Cash & cash equivalents at end of year		781,194	1,582,690	649,702	510,612	763,546	306,452



Horizontal Analysis

	2017		2016	
	Rs in '000'	17 Vs. 16 %	Rs in '000'	16 Vs. 15 %
BALANCE SHEET				
SHARE CAPITAL & RESERVES				
Share capital	545,379	-	545,379	8
Capital reserve	1,046,025	-	1,046,025	2,515
Unappropriated profit	2,553,295	22	2,090,865	22
Shareholders' equity	4,144,699	13	3,682,269	63
Surplus on revaluation of PP&E	726,760	(2)	742,191	(1)
Non current liabilities	581,874	(37)	927,597	(28)
Current liabilities	2,295,152	25	1,842,642	1
Total	7,748,485	8	7,194,699	18
ASSETS				
Property, plant and equipment (PP&E)	5,457,545	18	4,606,615	3
Intangible	10,585	100	-	-
Long term investment	18,120	1	18,000	-
Long term deposits	45,273	14	39,677	4
Current assets	2,216,962	(12)	2,530,407	60
Non current asset held for sale	-	-	-	-
Total	7,748,485	8	7,194,699	18
PROFIT & LOSS ACCOUNT				
Net revenue	9,257,009	6	8,730,803	17.8
Operating costs	(8,464,606)	10	(7,668,538)	16.5
Other income	136,579	57	86,760	57
Operating profit	928,982	(19)	1,149,025	29.7
Finance cost	(66,389)	(39)	(108,997)	(31)
Provision for taxation	(256,166)	(8)	(279,930)	44
Profit after taxation	606,427	(20)	760,098	43

* An overall revenue growth of 6% as compared to last year. Reason for drop in revenue growth is attributable to economic crisis in Middle East countries forced them to slash job opportunities which in turn reduced the number of candidates who were visiting the Hospital for mandatory medical checkups to fulfil these countries' requirements. Resultantly the revenue in this particular area decreased considerably while comparing the same with previous year.

** Operating cost has been increased by 10% to Rs. 8,465 million from Rs. 7,669 million, which is mainly due to increase in salaries, wages & benefits of nursing staff and postgraduate trainees, cost and volume of supplies and medicines consumed, increase in depreciation and rent etc.

2015		2014		2013		2012	
Rs in '000'	15 Vs. 14 %	Rs in '000'	14 Vs. 13 %	Rs in '000'	13 Vs. 12 %	Rs in '000'	12 Vs. 11 %
505,138	-	505,138	-	505,138	-	505,138	-
40,000	-	40,000	-	40,000	-	40,000	-
1,709,813	27	1,344,260	29	1,042,248	42	731,802	33
2,254,951	19	1,889,398	19	1,587,386	24	1,276,940	17
751,182	(1)	760,176	30	583,373	(1)	590,552	(1)
1,290,733	(20)	1,608,133	(24)	2,118,224	27	1,663,787	127
1,822,423	14	1,597,824	65	968,684	(14)	1,128,439	10
6,119,289	5	5,855,531	11	5,257,667	13	4,659,718	35
4,485,977	11	4,034,090	12	3,616,518	4	3,469,388	28
-	-	-	-	-	-	-	-
18,000	100	-	-	-	-	-	-
38,129	(6)	40,651	31	31,041	41	22,066	114
1,577,183	6	1,483,316	(8)	1,610,108	38	1,168,264	62
-	(100)	297,474	100	-	-	-	-
6,119,289	5	5,855,531	11	5,257,667	13	4,659,718	35
7,410,022	16	6,393,105	20	5,315,589	19	4,451,781	30
(6,579,618)	17	(5,622,197)	22	(4,625,532)	17	(3,944,838)	34
55,288	(3)	56,894	40	40,540	174	14,812	15
885,692	7	827,802	13	730,597	40	521,755	8
(158,914)	(17)	(191,229)	0.5	(190,279)	26	(150,800)	30
(193,768)	13	(172,017)	13.04	(152,166)	38	(110,161)	1
533,010	15	464,556	20	388,152	49	260,794	1

Vertical Analysis

	2017		2016	
	Rs in '000'	%	Rs in '000'	%
BALANCE SHEET				
SHARE CAPITAL & RESERVES				
Share capital	545,379	7	545,379	8
Capital reserve	1,046,025	13	1,046,025	14
Unappropriated profit	2,553,295	33	2,090,865	29
Shareholders' equity	4,144,699	53	3,682,269	51
Surplus on revaluation of PP&E	726,760	9	742,191	10
Non current liabilities	581,874	8	927,597	13
Current liabilities	2,295,152	30	1,842,642	26
Total	7,748,485	100	7,194,699	100
ASSETS				
Property, plant and equipment (PP&E)	5,457,545	70.4	4,606,615	64
Intangible	10,585	0.2	-	-
Long term investment	18,120	0.2	18,000	0.3
Long term deposits	45,273	0.6	39,677	0.6
Current assets	2,216,962	28.6	2,530,407	35.1
Non current asset held for sale	-	-	-	-
Total	7,748,485	100	7,194,699	100
PROFIT & LOSS ACCOUNT				
Net revenue	9,257,009	100	8,730,803	100
Operating costs	(8,464,606)	91.4	(7,668,538)	87.8
Other income	136,579	1.5	86,760	1.0
Operating profit	928,982	10.1	1,149,025	13.2
Finance cost	(66,389)	0.7	(108,997)	1.3
Provision for taxation	(256,166)	2.8	(279,930)	3.2
Profit after taxation	606,427	6.6	760,098	8.7

2015		2014		2013		2012	
Rs in '000'	%	Rs in '000'	%	Rs in '000'	%	Rs in '000'	%
505,138	8	505,138	9	505,138	10	505,138	11
40,000	1	40,000	1	40,000	1	40,000	1
1,709,813	28	1,344,260	23	1,042,248	20	731,802	16
2,254,951	37	1,889,398	33	1,587,386	31	1,276,940	28
751,182	12	760,176	13	583,373	11	590,552	12
1,290,733	21	1,608,133	27	2,118,224	40	1,663,787	36
1,822,423	30	1,597,824	27	968,684	18	1,128,439	24
6,119,289	100	5,855,531	100	5,257,667	100	4,659,718	100
4,485,977	73	4,034,090	69	3,616,518	69	3,469,388	74.5
-	-	-	-	-	-	-	-
18,000	0.3	-	-	-	-	-	-
38,129	0.7	40,651	1	31,041	0.6	22,066	0.5
1,577,183	26	1,483,316	25	1,610,108	30.4	1,168,264	25
-	-	297,474	5	-	-	-	-
6,119,289	100	5,855,531	100	5,257,667	100	4,659,718	100
7,410,022	100	6,393,105	100	5,315,589	100	4,451,781	100
(6,579,618)	88.8	(5,622,197)	88	(4,625,532)	87	(3,944,838)	88.6
55,288	0.7	56,894	1	40,540	0.7	14,812	0.3
885,692	11.9	827,802	13	730,597	13.7	521,755	11.7
(158,914)	2.1	(191,229)	3	(190,279)	3.6	(150,800)	3.4
(193,768)	2.6	(172,017)	2.7	(152,166)	2.8	(110,161)	2.5
533,010	7.2	464,556	7.3	388,152	7.3	260,794	5.8

Statement of Compliance with the Code of Corporate Governance

Shifa International Hospitals Limited - Year Ended June 30, 2017

This statement is being presented to comply with the Code of Corporate Governance contained in Listing Regulation No. 35 of Pakistan Stock Exchange for the purpose of establishing a framework of good governance, whereby a listed company is managed in compliance with the best practices of corporate governance.

The Company has applied the principles contained in the CCG in the following manner:

1. The Company encourages representation of Independent non-executive directors and directors representing minority interests on its board of directors. At present the board includes:

Category	Names
Independent Directors	Shah Naveed Saeed Syed Ilyas Ahmed Prof. Dr. Shoab Ahmed Khan
Executive Directors	Dr. Manzoor H. Qazi Mr. Muhammad Zahid Dr. Mohammad Salim Khan
Non-Executive Directors	Dr. Habib-Ur-Rahman Mr. Shafquat Ali Chaudhary Mr. Qasim Farooq Ahmad Dr. Samea Kauser Ahmad

The independent directors meet the criteria of independence under clause i (b) of the CCG.

2. The directors have confirmed that none of them is serving as a director on more than seven listed companies, including this Company.
3. All the resident directors of the Company are registered as taxpayers and none of them has defaulted in payment of any loan to a banking company, a DFI or an NBFIs or being a member of a stock exchange, has been declared as a defaulter by that stock exchange.
4. No causal vacancy occurred in the Board during the year ended June 30, 2017.
5. The Company has prepared a "code of conduct" and has ensured that appropriate steps have been taken to disseminate it throughout the Company along with its supporting policies and procedures.
6. The Board has developed a vision/mission statement, overall corporate strategy and significant policies of the Company. A complete record of particulars of significant policies along with the dates on which they were approved or amended has been maintained.
7. All the powers of the Board have been duly exercised and decisions on material transactions, including appointment and determination of remuneration and terms and conditions of employment of the CEO, other executive and non-executive directors, have been taken by the Board.
8. All the meetings of the Board were presided over by the Chairman and the board met at least once in every quarter. Written notices of the board meetings, along with agenda and working papers, were circulated at least seven days before the meetings. The minutes of the meetings were appropriately recorded and circulated.
9. There were no new appointments of CFO, Company Secretary or Head of Internal Audit during the year.
10. During the year under review, one director of the Company namely Prof. Dr. Shoab Ahmed Khan, has successfully completed the directors' training program that meets the criteria specified by the SECP.

11. The directors' report for this year has been prepared in compliance with the requirements of the CCG and fully describes the salient matters required to be disclosed.
12. The financial statements of the Company were duly endorsed by CEO and CFO before approval of the board.
13. The directors, CEO and executives do not hold any interest in the shares of the Company other than that disclosed in the pattern of shareholding.
14. The Company has complied with all the corporate and financial reporting requirements of the CCG.
15. The Board has formed an Audit Committee which is comprised of four members, and all of them are non-executive directors. The chairman of the committee is an independent director.
16. The meetings of the audit committee were held at least once every quarter prior to the approval of interim and final results of the Company and as required by the CCG. The terms of reference of the committee have been formed and advised to the committee for compliance.
17. The Board has formed a Human Resource and Remuneration Committee which is comprised of three members, of whom two are non-executive director. The chairman of the committee is a non-executive director.
18. The board has set up an effective internal audit function.
19. The statutory auditors of the Company have confirmed that they have been given a satisfactory rating under the quality control review program of the ICAP, that they or any of the partners of the firm, their spouses and minor children do not hold shares of the Company and that the firm and all its partners are in compliance with International Federation of Accountants (IFAC) guidelines on code of ethics as adopted by ICAP.
20. The statutory auditors or the persons associated with them have not been appointed to provide other services except in accordance with the listing regulations and the auditors have confirmed that they observed IFAC guidelines in this regard.
21. The 'closed period' prior to the announcement of interim/final results, and business decisions, which may materially affect the market price of Company's securities, was determined and intimated to directors, employees and stock exchange.
22. Material/price sensitive information has been disseminated among all market participants at once through stock exchange.
23. The Company has complied with the requirements relating to maintenance of register of persons having access to inside information by designated senior management officer in a timely manner and maintained proper record including basis for inclusion or exclusion of names of persons from the said list.
24. We confirm that all other material principles enshrined in the CCG have been complied with.

ISLAMABAD
September 11, 2017


DR. MANZOOR H. QAZI
Chief Executive Officer

Review Report to the Members

On Statement of Compliance with the Code of Corporate Governance


We have reviewed the enclosed Statement of Compliance with the best practices contained in the Code of Corporate Governance (the Code) prepared by the Board of Directors (the Board) of Shifa International Hospitals Limited, (the Company) for the year ended June 30, 2017, to comply with the requirements of, Rule Book of Pakistan Stock Exchange Limited Chapter 5, Clause 5.19.24(b) of the Code of Corporate Governance, where the Company is listed.

The responsibility for compliance with the Code is that of the Board of the Company. Our responsibility is to review, to the extent where such compliance can be objectively verified, whether the Statement of Compliance reflects the status of the Company's compliance with the provisions of the Code and report if it does not and to highlight any non-compliance with the requirements of the Code. A review is limited primarily to inquiries of the Company's personnel and review of various documents prepared by the Company to comply with the Code.

As part of our audit of financial statements, we are required to obtain an understanding of the accounting and internal control systems sufficient to plan the audit and develop an effective audit approach. We are not required to consider whether the Board's statement on internal control covers all risks and controls or to form an opinion on the effectiveness of such internal controls, the Company's corporate governance procedures and risks.

The Code requires the Company to place before the Audit Committee, and upon recommendation of the Audit Committee, place before the Board for their review and approval its related party transactions distinguishing between transactions carried out on terms equivalent to those that prevail in arm's length transactions and transactions which are not executed at arm's length price and recording proper justification for using such alternative pricing mechanism. We are only required and have ensured compliance of this requirement to the extent of the approval of the related party transactions by the Board upon recommendation of the Audit Committee. We have not carried out any procedure to determine whether the related party transactions were undertaken at arm's length price or not.

Based on our review, nothing has come to our attention which causes us to believe that the Statement of Compliance does not appropriately reflect the Company's compliance, in all material respects, with the best practices contained in the Code as applicable to the Company for the year ended June 30, 2017.



GRANT THORNTON ANJUM RAHMAN

Chartered Accountants

Engagement Partner: Khaliq ur Rahman

Islamabad

Date: September 11, 2017


Auditors' Report to the Members

We have audited the annexed balance sheet of Shifa International Hospitals Limited (the Company) as at 30 June 2017 and the related profit and loss account, statement of comprehensive income, cash flow statement and statement of changes in equity together with the notes forming part thereof, for the year then ended and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of our audit.

It is the responsibility of the Company's management to establish and maintain a system of internal control, and prepare and present the above said statements in conformity with the approved accounting standards and the requirements of the repealed Companies Ordinance, 1984 (as directed by Securities and Exchange Commission of Pakistan (SECP) vide circular no. 17 dated July 20, 2017). Our responsibility is to express an opinion on these statements based on our audit.

We conducted our audit in accordance with the auditing standards as applicable in Pakistan. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the above said statements are free of any material misstatement. An audit includes examining on test basis, evidence supporting the amounts and disclosures in the above said statements. An audit also includes assessing the accounting policies and significant estimates made by management, as well as, evaluating the overall presentation of the above said statements. We believe that our audit provides a reasonable basis for our opinion and, after due verification, we report that:-

- a. in our opinion, proper books of accounts have been kept by the Company as required by the repealed Companies Ordinance, 1984;
- b. in our opinion:-
 - i. the balance sheet and profit and loss account together with the notes thereon, have been drawn up in conformity with the repealed Companies Ordinance, 1984, and are in agreement with the books of account and are further in accordance with accounting policies consistently applied;
 - ii. the expenditure incurred during the year was for the purpose of the Company's business; and
 - iii. the business conducted, investments made and the expenditure incurred during the year were in accordance with the objects of the Company.
- c. in our opinion and to the best of our information and according to the explanations given to us, the balance sheet, profit and loss account, statement of comprehensive income, cash flow statement and statement of changes in equity together with the notes forming part thereof conform with approved accounting standards as applicable in Pakistan, and give the information required by the repealed Companies Ordinance, 1984, in the manner so required and respectively give a true and fair view of the state of the Company's affairs as at 30 June 2017 and of the profit, its comprehensive income, cash flows and changes in equity for the year then ended; and
- d. in our opinion, Zakat deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980), was deducted by the Company and deposited in the Central Zakat Fund established under section 7 of that Ordinance.



GRANT THORNTON ANJUM RAHMAN
Chartered Accountants
Audit Engagement Partner: Khaliq ur Rahman

Islamabad
Date: September 11, 2017

Balance Sheet

As at June 30, 2017

	Note	2017	2016	2015
			(Rupees in '000')	
SHARE CAPITAL AND RESERVES				
Share capital	4	545,379	545,379	505,138
Capital reserve	5	1,046,025	1,046,025	40,000
Unappropriated profit		2,553,295	2,090,865	1,709,813
		4,144,699	3,682,269	2,254,951
SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT				
	6	726,760	742,191	751,182
NON-CURRENT LIABILITIES				
Long term financing - secured	7	168,228	503,991	833,333
Deferred taxation	8	413,646	423,606	457,400
		581,874	927,597	1,290,733
CURRENT LIABILITIES				
Trade and other payables	9	1,958,990	1,506,485	1,488,297
Markup accrued	10	398	483	793
Current portion of long term financing	7	335,764	335,674	333,333
		2,295,152	1,842,642	1,822,423
		7,748,485	7,194,699	6,119,289
CONTINGENCIES AND COMMITMENTS				
	11			

The annexed notes 1 to 42 form an integral part of these financial statements.


CHAIRMAN


CHIEF EXECUTIVE

	Note	2017	2016	2015
			(Rupees in '000')	
NON-CURRENT ASSETS				
Property, plant and equipment	12	5,457,545	4,606,615	4,485,977
Intangible	13	10,585	-	-
Long term investment - at cost	14	18,120	18,000	18,000
Long term deposits	15	45,273	39,677	38,129
		5,531,523	4,664,292	4,542,106
CURRENT ASSETS				
Stores, spare parts and loose tools	16	81,195	64,593	66,809
Stock-in-trade	17	380,052	337,389	321,939
Trade debts - considered good	18	447,770	338,745	334,242
Loans and advances - considered good	19	339,614	159,157	125,594
Trade deposits, short term prepayments and other receivables	20	38,498	21,352	24,926
Markup accrued		1,165	1,501	1,908
Other financial assets	21	189,451	1,096,241	125,305
Tax refunds due from the government (net of provision)	22	97,474	24,980	52,063
Cash and bank balances	23	641,743	486,449	524,397
		2,216,962	2,530,407	1,577,183
		7,748,485	7,194,699	6,119,289

Muneer Babbar
CHIEF FINANCIAL OFFICER

Profit and Loss Account

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
Net revenue	24	9,257,009	8,730,803
Other income	25	136,579	86,760
Operating costs	26	(8,464,606)	(7,668,538)
Finance costs	27	(66,389)	(108,997)
Profit before taxation		862,593	1,040,028
Provision for taxation	28	(256,166)	(279,930)
Profit after taxation		606,427	760,098
----- (Rupees) -----			
Earnings per share - basic and diluted	29	11.12	14.68

The annexed notes 1 to 42 form an integral part of these financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Statement of Comprehensive Income

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
Profit after taxation	606,427	760,098
Other comprehensive income		
Income/(loss) on remeasurement of staff gratuity fund benefit plan	5,980	(74,854)
Deferred tax relating to remeasurement of staff gratuity fund benefit plan	(1,794)	23,205
Income/(loss) on remeasurement of staff gratuity fund benefit plan (net of tax)	4,186	(51,649)
Total comprehensive income for the year	610,613	708,449

The annexed notes 1 to 42 form an integral part of these financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Cash Flow Statement

For the year ended June 30, 2017

	2017	2016
	Note	(Rupees in '000')
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before taxation	862,593	1,040,028
Adjustments for:		
Depreciation/amortization of property, plant and equipment	463,197	415,241
Amortization of intangible	225	-
Provision for doubtful debts	36,649	19,179
Property, plant and equipment written off	13,189	1,414
Gain on disposal of property, plant and equipment	(11,395)	(2,956)
Provision for compensated absences	34,565	44,902
Provision for gratuity	82,192	41,578
Provision for slow moving stores	(4,550)	4,399
Liabilities written back	(7,362)	(2,301)
Profit on investments and bank deposits	(58,130)	(37,314)
Loss on foreign currency translation	419	493
Finance cost	65,970	108,504
Operating cash flows before changes in working capital	1,477,562	1,633,167
Changes in working capital:		
(Increase) / decrease in current assets:		
Stores, spare parts and loose tools	(12,080)	(1,733)
Stock-in-trade	(42,663)	(15,450)
Trade debts	(145,674)	(23,682)
Loans and advances	(180,457)	(33,563)
Trade deposits and short term prepayments	(17,146)	3,574
Increase / (decrease) in current liabilities:		
Trade and other payables	469,891	(17,124)
Cash generated from operations	1,549,433	1,545,189
Finance cost paid	(66,055)	(108,814)
Income tax paid	(340,414)	(263,437)
Payment to SIHL Employees' Gratuity Fund	(76,017)	(113,347)
Compensated absences paid	(29,112)	(26,409)
Net cash from operating activities	1,037,835	1,033,182
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(1,349,851)	(539,970)
Purchase of intangible	(10,810)	-
Proceeds from disposal of property, plant and equipment	33,958	5,184
Investment in TDRs	(50,000)	-
Markup received	58,466	37,721
Investment in subsidiary	(120)	-
Increase in long term deposits	(5,596)	(1,548)
Net cash used in investing activities	(1,323,953)	(498,613)
CASH FLOWS FROM FINANCING ACTIVITIES		
Long term financing - repayments	(335,673)	(327,001)
Proceeds from issue of right shares	-	1,046,266
Dividend paid	(179,286)	(320,353)
Net cash (used in) / generated from financing activities	(514,959)	398,912
Net (decrease) / increase in cash and cash equivalents	(801,077)	933,481
Cash and cash equivalents at beginning of year	1,582,690	649,702
Effect of exchange rate changes on cash and cash equivalents	(419)	(493)
Cash and cash equivalents at end of year	781,194	1,582,690

35

The annexed notes 1 to 42 form an integral part of these financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Statement of Changes in Equity

For the year ended June 30, 2017

	Share capital	Capital reserve	Un-appropriated profit	Surplus on revaluation of property, plant and equipment	Total
----- (Rupees in '000') -----					
Balance at July 01, 2015	505,138	40,000	1,709,813	751,182	3,006,133
Issue of further share capital - right issue	40,241	-	-	-	40,241
Share premium on issue of right shares	-	1,006,025	-	-	1,006,025
Total comprehensive income for the year					
Profit for the year	-	-	760,098	-	760,098
Other comprehensive income - net of tax	-	-	(51,649)	-	(51,649)
	-	-	708,449	-	708,449
Transfer of depreciation/amortization on incremental value arising on revaluation of property, plant and equipment attributed to current year	-	-	8,991	(8,991)	-
Distribution to owners					
Final dividend 2014-15: Rs. 4.5 per share	-	-	(227,312)	-	(227,312)
Interim dividend 2015-16: Rs. 2 per share	-	-	(109,076)	-	(109,076)
Balance at June 30, 2016	545,379	1,046,025	2,090,865	742,191	4,424,460
Balance at July 01, 2016	545,379	1,046,025	2,090,865	742,191	4,424,460
Total comprehensive income for the year					
Profit for the year	-	-	606,427	-	606,427
Other comprehensive income - net of tax	-	-	4,186	-	4,186
	-	-	610,613	-	610,613
Transfer of depreciation/amortization on incremental value arising on revaluation of property, plant and equipment attributed to current year	-	-	8,990	(8,990)	-
Realization of revaluation surplus on disposal of assets	-	-	6,441	(6,441)	-
Distribution to owners					
Final dividend 2015-16: Rs. 3 per share	-	-	(163,614)	-	(163,614)
Balance at June 30, 2017	545,379	1,046,025	2,553,295	726,760	4,871,459

The annexed notes 1 to 42 form an integral part of these financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Notes to the Financial Statements

For the year ended June 30, 2017

1 STATUS AND NATURE OF BUSINESS

- 1.1** Shifa International Hospitals Limited (“the Company”) was incorporated in Pakistan on September 29, 1987 as a private limited company under the repealed Companies Ordinance, 1984 and converted into a public limited company on October 12, 1989. The shares of the Company are quoted on Pakistan Stock Exchange Limited. The registered office of the Company is situated at Sector H-8/4, Islamabad.
- 1.2** The principal activity of the Company is to establish and run medical centers and hospitals in Pakistan. The Company has established its first hospital in 1993 in H-8/4 Islamabad, second hospital in 2011 in Faisalabad and another in 2014 in G-10/4 Islamabad. The Company is also running medical center, pharmacies in Islamabad and franchise pharmacies and Lab collection points in different cities of Pakistan.
- 1.3** These financial statements are separate financial statements of the Company whereas investment in subsidiary is recognized on the basis of direct equity interest rather than on the basis of reporting results of the subsidiary. Consolidated financial statements are prepared separately.

2 BASIS OF PREPARATION

2.1 Statement of compliance

During the year, the Companies Act 2017 (the Act) has been promulgated, however, Securities and Exchange Commission of Pakistan (SECP) vide its circular no. 17 of 2017 dated July 20, 2017 communicated Commission’s decision that the companies whose financial year closes on or before June 30, 2017 shall prepare their financial statements in accordance with the provisions of the repealed Companies Ordinance, 1984. Accordingly, these financial statements have been prepared in accordance with approved accounting standards as applicable in Pakistan. Approved accounting standards comprise of such International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan (ICAP) as are notified under the repealed Companies Ordinance, 1984, provisions of and directives issued under the repealed Companies Ordinance, 1984. In case requirements differ, the provisions or directives of the repealed Companies Ordinance, 1984 shall prevail.

2.2 Basis of measurement

These financial statements have been prepared under the historical cost convention, modified by:-

- revaluation of certain items of property, plant and equipment; and
- recognition of certain employee benefits at present value.

2.3 Functional and presentation currency

These financial statements are presented in Pak Rupees, which is the Company’s functional and presentation currency.

2.4 Use of estimates and judgments

The preparation of financial statements in conformity with approved accounting standards requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgment about carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which estimates are revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Notes to the Financial Statements

For the year ended June 30, 2017

Judgments made by management in the application of the approved accounting standards that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in the ensuing paragraphs.

2.4.1 Property, plant and equipment

The Company reviews the useful lives of property, plant and equipment on a regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of property, plant and equipment with a corresponding effect on the depreciation / amortization charge and impairment.

2.4.2 Intangibles

The Company reviews the useful lives of intangibles on regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of intangibles with the corresponding effect on the amortization charge and impairment.

2.4.3 Provision for doubtful debts

The Company estimates the recoverability of the trade debts and provides for doubtful debts based on its prior experience. The carrying amounts of trade debts and provision for doubtful debts are disclosed in note 18 to these financial statements.

2.4.4 Stock in trade, stores, spares and loose tools

The Company reviews the net realizable value of stock in trade, stores, spares and loose tools to assess any diminution in the respective carrying values. Net realizable value is determined with reference to estimated selling price less estimated expenditures to make the sale.

2.4.5 Employee benefits

The Company operates approved funded gratuity scheme covering all its employees who have completed the minimum qualifying period of service as defined under the scheme. The gratuity scheme is managed by trustees. The calculation of the benefit requires assumptions to be made of future outcomes, the principal ones being in respect of increase in remuneration and the discount rate used to convert future cash flows to current values. The assumptions used for the plan are determined by independent actuary on annual basis.

The amount of the expected return on plan assets is calculated using the expected rate of return for the year and the market-related value at the beginning of the year. Gratuity cost primarily represents the increase in actuarial present value of the obligation for benefits earned on employee service during the year and the interest on the obligation in respect of employee service in previous years, net of the expected return on plan assets. Calculations are sensitive to changes in the underlying assumptions.

2.4.6 Compensated absences

The Company provides provision for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. The Company provides for its estimated liability towards leaves accumulated by employees on an accrual basis using current salary levels.

2.4.7 Taxation

The Company takes into account the current income tax law and decisions taken by appellate authorities. Instances where the Company's view differs from the view taken by the income tax department at the assessment stage and where the Company considers that its view on items of material nature is in accordance with law, the amounts are shown as contingent liabilities.

Notes to the Financial Statements

For the year ended June 30, 2017

2.4.8 Contingencies

The Company has disclosed significant contingent liabilities for the pending litigations and claims against the Company based on its judgment and the advice of the legal advisors for the estimated financial outcome. The actual outcome of these litigations and claims can have an effect on the carrying amounts of the liabilities recognized at the balance sheet date. However, based on the best judgment of the Company and its legal advisors, the likely outcome of these litigations and claims is remote and there is no need to recognize any liability at the balance sheet date.

2.5 New accounting standards, interpretations and amendments

During the year certain amendments to standards or new interpretations became effective, however, the amendments or interpretations did not have any material effect on these financial statements.

The following revised standards and amendments and interpretations to the approved accounting standards, as applicable in Pakistan, would be effective from the dates mentioned below against the respective standard.

		Effective date (annual periods beginning on or after)
IAS 7	Statement of Cash flows	January 1, 2017
IAS 12	Income taxes - Recognition of deferred tax assets for unrealized losses - (Amendment)	January 1, 2017
IAS 40	Investment Property: Transfers of Investment Property (Amendments)	January 1, 2018
IFRS 2	Share based payments - Classification and measurement of share based payments transaction (Amendment)	January 1, 2018
IFRS 4	Insurance Contracts: Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts - (Amendments)	January 1, 2018
IFRS 7	Financial Instruments: Disclosures - Disclosure initiative (Amendments)	January 1, 2017
IFRS 10 & IAS 28	Sale or Contribution of assets between an investor and its associate or joint venture (Amendment)	Not yet Finalized
IFRIC 22	Foreign Currency Transactions and Advance Consideration	January 1, 2018
IFRIC 23	Uncertainty over Income Tax Treatments	January 1, 2019

The management anticipates that the adoption of the above standards, amendments and interpretations in future periods, will have no material impact on the financial statements other than the impact on presentation/disclosures. The Company is yet to assess the full impact of the amendments.

The Company has adopted the following applicable accounting standards, amendments and interpretations of IFRSs which became effective for the current year:

IFRS 10	Consolidated Financial Statements, IFRS 12 Disclosure of interests in Other Entities and IAS 27 Separate Financials Statements: Investment Entities: Applying the consolidation Exception (Amendment)
IFRS 11	Joint Arrangements: Accounting for Acquisition of Interest in Joint Operation (Amendment)

Notes to the Financial Statements

For the year ended June 30, 2017

IAS 1	Presentation of Financial Statements - Disclosure Initiative (Amendments)
IAS 16	Property, Plant and Equipment and IAS 38 Intangible Assets - Clarification of acceptable method of depreciation and amortization (Amendments)
IAS-16	Property, Plant and Equipment and IAS 41 Agriculture - Agriculture: Bearer Plants (Amendment)
IAS-27	Separate Financial Statements - Equity method in separate financial statements (Amendments)

The adoption of above accounting standards did not have any effect on the financial statements.

Annual Improvements

IFRS 5	Non-current Assets Held for Sale and Discontinued Operations - Changes in method of disposal
IFRS 7	Financial Instruments: Disclosure - Serving contracts
IFRS 7	Financial Instruments: Disclosure - Applicability of the offsetting disclosures to condensed interim financial statements
IAS 19	Employees Benefits - Discount rate: regional market issue
IAS 34	Interim Financial Reporting - Disclosure of information 'elsewhere in the interim financial report'

The adoption of the above amendments, improvements to accounting standards and interpretations does not have any material effect on the financial statements.

Further, the following new standards and interpretations have been issued by the International Accounting Standards Board (IASB), which are yet to be notified by the Securities and Exchange Commission of Pakistan (SECP), for the purpose of their applicability in Pakistan:

IFRS 1	First-time adoption of International Financial Reporting standards
IFRS 9	Financial instruments
IFRS 14	Regulatory Deferral Accounts
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases
IFRS 17	Insurance Contracts

3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these financial statements.

3.1 Property, plant and equipment

Property, plant and equipment except freehold, leasehold land and capital work-in-progress are stated at cost less accumulated depreciation/ amortization and impairment in value, if any. Leasehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent accumulated depreciation and impairment losses while freehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent impairment losses, if any. Any revaluation increase arising

Notes to the Financial Statements

For the year ended June 30, 2017

on the revaluation of such assets is credited in 'Surplus on Revaluation of Property, Plant and Equipment'. A decrease in the carrying amount arising on revaluation is charged to profit or loss to the extent that it exceeds the balance, if any, held in the surplus on revaluation account relating to a previous revaluation of that asset. Leasehold land is amortized over the lease period extendable up to 99 years.

The surplus on revaluation of property, plant and equipment to the extent of incremental depreciation/amortization charged on the related asset is transferred to unappropriated profit.

Capital work-in-progress and stores held for capital expenditure are stated at cost less impairment loss recognized, if any. All expenditure connected with specific assets incurred during installation and construction period are carried under capital work-in-progress. These are transferred to specific items of property, plant and equipment when available for intended use.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repairs and maintenance costs that do not meet the recognition criteria are charged to profit and loss account as and when incurred.

Depreciation/amortization is charged to profit and loss account commencing when the asset is ready for its intended use, applying the straight-line method over the estimated useful life.

In respect of additions and disposals during the year, depreciation/amortization is charged when the asset is available for use and up to the month preceding the asset's classification as held for sale or derecognized, whichever is earlier.

Assets are derecognized when disposed off or when no future economic benefits are expected to flow from its use. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized on net basis within "other income" in profit and loss account.

3.2 Intangible

Intangible assets are stated at cost less accumulated amortization and impairment losses, if any. Subsequent cost on intangible assets is capitalized only when it increases the future economic benefits embodied in the specific assets to which it relates. All other expenditure is expensed as incurred.

Amortization is charged to the profit and loss account on a straight line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Amortization on additions to intangible assets is charged from the month in which an item is acquired or capitalized while no amortization is charged for the month in which the item is disposed off.

All intangible assets with an indefinite useful life are systematically tested for impairment at each reporting date. Where the carrying amount of an asset exceeds its estimated recoverable amount it is written down immediately to its recoverable amount. The carrying amount of other intangible assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists then the assets recoverable amount is estimated. The recoverable amount is the greater of its value and fair value less cost to sell. An impairment is recognized if the carrying amount exceeds its estimated recoverable amount.

3.3 Leases

Leases are classified as finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the Company. All other leases are classified as operating leases.

Finance leases as lessee

The Company recognizes finance leases as assets and liabilities in the balance sheet at amounts equal, at the inception of the lease, to the fair value of the asset or, if lower, at the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting

Notes to the Financial Statements

For the year ended June 30, 2017

policy applicable to similar owned assets. In calculating the present value of the minimum lease payments the discount factor used is the interest rate implicit in the lease. Initial direct costs incurred are included as part of the amount recognized as an asset. The liabilities are classified as current and long term depending upon the timing of payment. Lease payments are apportioned between the finance charge and the reduction of outstanding liability. The finance charge is allocated to periods during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Finance charges are charged directly to profit and loss account.

Operating leases / Ijarah

As lessor

Rental income from operating leases is recognized on straight-line basis over the term of the relevant lease.

As lessee

Rentals payable under operating leases/Ijarah are charged to profit and loss account on straight-line basis over the term of relevant lease/Ijarah.

3.4 Impairment

Non - Financial assets

The Company assesses at each balance sheet date whether there is any indication that assets except deferred tax assets and inventory may be impaired. If such indication exists, the carrying amounts of such assets are reviewed to assess whether they are recorded in excess of their recoverable amounts. Where carrying values exceed the respective recoverable amounts, assets are written down to their recoverable amounts and the resulting impairment loss is recognized in profit and loss account except for the impairment loss on revalued assets, which is adjusted against the related revaluation surplus to the extent that the impairment loss does not exceed the surplus on revaluation of that asset. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use.

Where impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised recoverable amount but limited to the extent of the carrying amount that would have been determined (net of depreciation/amortization) had no impairment loss been recognized for the asset in prior years. Reversal of impairment loss is recognized in profit and loss account.

Financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired may include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy.

3.5 Investments

All purchases and sales of investments are recognized using settlement date accounting. Settlement date is the date on which those investments are delivered to or by the Company. All investments are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

3.5.1 Investment in subsidiary

These investments are carried at cost less impairment losses. The profits and losses of the subsidiary are carried forward in the financial statements of the subsidiary and are not dealt with in or for the purpose of these financial statements except to the extent of dividend declared by the subsidiary company. Gain and loss on disposal of investment is included in income.

Notes to the Financial Statements

For the year ended June 30, 2017

3.5.2 Investments held to maturity

Investments with fixed or determinable payments and fixed maturity that the Company has the positive intent and ability to hold till maturity are classified as investment held to maturity. These are initially recognized at cost inclusive of transaction cost and are subsequently carried at amortized cost using the effective interest rate method less impairment loss, if any. This method uses an effective interest rate that exactly discounts estimated future cash receipts through the expected life of the investment to its net carrying amount.

3.5.3 Loans and receivables

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the balance sheet date, those are classified as non-current assets. The Company's loans and receivables comprise 'Advances, deposits and other receivables'.

3.6 Stores, spare parts and loose tools

These are valued at cost, determined on moving average cost basis or net realizable value, whichever is lower, less allowance for obsolete and slow moving items. For items which are slow moving or identified as surplus to the Company's requirement, a provision is made for excess of book value over estimated net realizable value. The Company reviews the carrying amount of stores, spare parts and loose tools on a regular basis and provision is made for obsolescence, if there is any change in usage pattern and physical form of related stores, spare parts and loose tools.

3.7 Stock-in-trade

Stock-in-trade is valued at lower of cost, determined on moving average basis or net realizable value. The cost includes expenditure incurred in acquiring the stock items and other cost incurred in bringing them to their present location and condition.

3.8 Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, cheques in hand, balances with banks and highly liquid short term investments that are readily convertible to known amounts of cash and which are subject to insignificant risk of change in value with maturity of three months or less from the date of acquisition and short term borrowings.

3.9 Financial instruments

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. These are derecognized when the Company loses control of contracted rights that comprise the financial assets and in the case of financial liabilities when the obligation specified in the contract is discharged, cancelled or expired. Any gain or loss on derecognition of financial assets and financial liabilities is included in profit and loss account.

The particular recognition methods adopted by the Company are disclosed in the individual policy statements associated with each item of the financial instruments.

3.9.1 Trade debts and other receivables

Trade debts and other receivables are carried at original bill amount less an estimate made for doubtful receivables based on review of outstanding amounts at the year end. Balances considered bad and irrecoverable are written off against provision.

3.9.2 Trade and other payables

Liabilities for trade and other payables are measured at cost which is the fair value of the consideration to be paid in the future for goods and services received.

Notes to the Financial Statements

For the year ended June 30, 2017

3.9.3 Offsetting

A financial asset and a financial liability is offset and the net amount is reported in the balance sheet, if the Company has a legal enforceable right to set-off the recognized amounts and intends either to settle on net basis or to realize the asset and settle the liability simultaneously.

3.10 Employee benefits

Defined benefit plan

The Company operates approved funded gratuity scheme for all its employees who have completed the minimum qualifying period of service as defined under the respective scheme. Provision is made annually to cover obligations under the scheme on the basis of actuarial valuation and is charged to income. The most recent valuation was carried out as at June 30, 2017 using the "Projected Unit Credit Method". The actuarial gains or losses at each evaluation date are charged to other comprehensive income. The results of actuarial valuation are summarized in note 9.4 of these financial statements.

The amount recognized in the balance sheet represents the present value of defined benefit obligations as reduced by the fair value of plan assets.

Calculation of gratuity requires assumptions to be made of future outcomes which mainly include increase in remuneration, expected long term return on plan assets and the discount rate used to convert future cash flows to current values. Calculations are sensitive to changes in the underlying assumptions.

Compensated absences

The Company provides for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. Accrual to cover the obligations is made using the current salary levels of the employees.

3.11 Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount can be made. However, provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

3.12 Taxation

Taxation for the year comprises current and deferred tax. Taxation is recognized in the profit and loss account except to the extent that it relates to items recognized directly in equity or in other comprehensive income.

Current

Provision for current taxation is based on taxable income at the current rates of tax after taking into account applicable tax credits, rebates, losses and exemptions available, if any.

Deferred

Deferred tax is accounted for using the balance sheet liability method in respect of all taxable temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are recognized for all taxable temporary differences and deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which the deductible temporary differences, unused tax losses and tax credits can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that is no longer probable that the related tax benefit will be realized.

Notes to the Financial Statements

For the year ended June 30, 2017

Deferred tax is calculated at the rates that are expected to apply to the period when the differences reverse, based on tax rates that have been enacted. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets and they relate to income taxes levied by the same tax authority on the same taxable entity or on different tax entities but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

3.13 Foreign currencies

Transactions in currencies other than Pak Rupees are recorded at the rates of exchange prevailing on the dates of transactions. At each balance sheet date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the balance sheet date. Gains and losses arising on retranslation are included in profit and loss for the year.

3.14 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts received or receivable for goods and services provided in the normal course of business. Revenue is recognized in the accounting period in which the services are rendered and goods are delivered and it is probable that the economic benefits associated with the transactions will flow to the Company and the amount of the revenue can be measured reliably.

Interest income is accrued on time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount.

Rental income is recognized on a straight line basis over the term of the rent agreement.

Scrap sales and miscellaneous receipts are recognized on realized amounts.

3.15 Borrowings

Borrowings are recognized initially at fair value net off transaction cost incurred and are subsequently measured at amortized cost using the effective interest rate method. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of liability for at least twelve months after the balance sheet date.

3.16 Borrowing costs

Borrowing costs which are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of that asset. All other borrowing costs are charged to profit and loss.

3.17 Earnings per share

The Company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholder and weighted average number of ordinary shares outstanding for the effects of all potential ordinary shares.

3.18 Dividend

Dividend is recognized as a liability in the period in which it is declared.

Notes to the Financial Statements

For the year ended June 30, 2017

3.19 Non-current assets held for sale

Non-current assets are classified as held for sale when their carrying amounts are expected to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount immediately prior to their classification as held for sale and fair value less cost to sell. Once classified as held for sale, the assets are not subject to depreciation or amortization. In case where classification criteria of non current asset held for sale is no longer met such asset is classified on its carrying amount before the asset was classified as held for sale, adjusted for depreciation/revaluation that would have been recognized had the asset not been classified as held for sale. The required adjustment to the carrying amount of a non-current asset that ceases to be classified as held for sale is charged in profit and loss account.

4 SHARE CAPITAL

Authorized capital

This represents 54,537,900 (2016: 54,537,900) ordinary shares of Rs. 10 each amounting to Rs. 545,379 thousand (2016: Rs. 545,379 thousand).

Issued, subscribed and paid up capital

2017	2016		2017	2016
Number			(Rupees in '000')	
54,537,900	50,513,800	Opening balance: Ordinary shares of Rs. 10 each	545,379	505,138
-	4,024,100	Addition: Right issue of ordinary shares of Rs. 10 each	-	40,241
<u>54,537,900</u>	<u>54,537,900</u>	Closing balance: Ordinary shares of Rs. 10 each fully paid in cash	<u>545,379</u>	<u>545,379</u>

4.1 The Company has only one class of ordinary shares which carries no right to fixed income. The shareholders are entitled to receive dividend as declared from time to time and are entitled to one vote per share at meetings of the Company. All shares rank equally with regard to the Company's residual assets.

4.2 The Company has no reserved shares for issuance under options and sales contracts.

5 CAPITAL RESERVE

This represents premium of Rs. 5 and Rs. 250 per share received on public issue of 8,000,000 and 4,024,100 ordinary shares of Rs.10 each in 1994 and 2016 respectively. This reserve cannot be utilized except for the purposes mentioned under section 81 of the Companies Act, 2017.

6 SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT

	2017	2016
	(Rupees in '000')	
Balance at beginning of year	742,191	751,182
Realization of revaluation surplus on disposal of assets	(6,441)	-
Transferred to unappropriated profits in respect of incremental depreciation charged during the year	(8,990)	(8,991)
Balance at end of year	<u>726,760</u>	<u>742,191</u>

Notes to the Financial Statements

For the year ended June 30, 2017

- 6.1** Surplus on revaluation of fixed assets in respect of leasehold and freehold land, which were revalued in 1999, 2004, 2009 and 2014 as disclosed in note 12.1, cannot be utilized directly or indirectly by way of dividend or bonus. As the surplus on revaluation is on leasehold and freehold land, the incidence of related deferred tax does not arise.

7	LONG TERM FINANCING - SECURED	Note	2017 (Rupees in '000')	2016
From banking companies:				
	Syndicated Islamic Finance Facility	7.2	500,000	833,333
	Diminishing Musharakah Facility	7.3	3,992	6,332
			<u>503,992</u>	<u>839,665</u>
	Less: Current portion		<u>335,764</u>	<u>335,674</u>
			<u>168,228</u>	<u>503,991</u>

- 7.1** The Company has fully availed all the above facilities.

- 7.2** This represents Syndicated Islamic Finance Facility, arranged and lead by Meezan Bank Limited, obtained on mark-up basis at 3 months KIBOR plus 1% (2016: 3 months KIBOR plus 1%) per annum, repayable in 18 equal quarterly installments. The sanction limit of this facility was Rs. 1,500 million (2016: Rs. 1,500 million) repayable by December 28, 2018. The financing is secured by ranking charge upgraded into first pari passu charge on all present and future fixed assets of the Company (excluding plot No.5, F-11 Markaz, Islamabad) amounting to Rs. 2,000 million. Meezan Bank Limited has the custody of original ownership documents of the Company's land located at sector H-8/4 Islamabad.

- 7.3** This represents a long term Islamic finance facility obtained under the Diminishing Musharakah basis from Al Baraka Bank (Pakistan) Limited to finance purchase of brand new vehicles. Principal amount is repayable in 36 equal monthly installments carrying markup at 3 months KIBOR plus 1.25 % (2016: 3 months KIBOR plus 1.25%).

8	DEFERRED TAXATION	Note	2017 (Rupees in '000')	2016
	Deferred tax liability	8.1	471,862	480,334
	Deferred tax asset	8.2	(58,216)	(56,728)
	Net deferred tax liability		<u>413,646</u>	<u>423,606</u>
8.1	Deferred tax liability on taxable temporary differences:			
	Accelerated depreciation/amortization allowance		470,068	480,334
	Retirement benefit obligation		1,794	-
			<u>471,862</u>	<u>480,334</u>
8.2	Deferred tax asset on deductible temporary differences:			
	Specific provisions		(27,116)	(25,628)
	Retirement benefit obligation		(31,100)	(31,100)
			<u>(58,216)</u>	<u>(56,728)</u>

Notes to the Financial Statements

For the year ended June 30, 2017

	As at July 1, 2016	Profit and Loss	Other Comprehensive Income	As at June 30, 2017
----- (Rupees in '000') -----				
8.3 Movement in deferred taxation				
Deferred tax liabilities/(assets)				
The balance of deferred tax is in respect of the following temporary differences:				
Effect of taxable temporary differences				
Accelerated depreciation/amortization allowance	480,334	(10,266)	-	470,068
Retirement benefit obligation	-	-	1,794	1,794
Effect of deductible temporary differences				
Provision for doubtful debts	(25,628)	(1,488)	-	(27,116)
Retirement benefit obligation	(31,100)	-	-	(31,100)
	<u>423,606</u>	<u>(11,754)</u>	<u>1,794</u>	<u>413,646</u>
	As at July 1, 2015	Profit and Loss	Other Comprehensive Income	As at June 30, 2016
----- (Rupees in '000') -----				
Deferred tax liabilities/(assets)				
The balance of deferred tax is in respect of the following temporary differences:				
Effect of taxable temporary differences				
Accelerated depreciation allowance	497,566	(17,232)	-	480,334
Effect of deductible temporary differences				
Provision for doubtful debts	(9,082)	(16,546)	-	(25,628)
Retirement benefit obligation	(31,084)	23,189	(23,205)	(31,100)
	<u>457,400</u>	<u>(10,589)</u>	<u>(23,205)</u>	<u>423,606</u>

9 TRADE AND OTHER PAYABLES	Note	2017	2016
		(Rupees in '000')	
Creditors		740,612	566,898
Accrued liabilities		340,766	258,284
Advances from customers		199,926	85,111
Medical consultants' charges		376,156	329,544
Payable to related parties - unsecured	9.1	29,170	6,289
Security deposits	9.2	109,332	85,875
Compensated absences	9.3	90,189	84,736
Unclaimed dividend		27,052	42,724
Retention money		10,479	11,911
Payable to Shifa International Hospitals Limited (SIHL) Employees' Gratuity Fund	9.4	35,308	35,113
		<u>1,958,990</u>	<u>1,506,485</u>

9.1 This represents payable to Tameer-e-Millat Foundation, Shifa Foundation and Shifa Tameer-e-Millat University having common directorship with the Company and Shifa Consulting Services (Private) Limited being the wholly owned subsidiary of the Company. Maximum amount due at the end of any month during the year was Rs. 6,076 thousand (2016: 4,138 thousand), Rs. Nil (2016: 4,042 thousand), Rs. 22,949 thousand (2016: 6,053 thousand) and Rs. 885 thousand (2016: Rs. Nil) respectively. Detail of balances of each related party is as under:

Notes to the Financial Statements

For the year ended June 30, 2017

		2017	2016
		(Rupees in '000')	
Tameer-e-Millat Foundation		5,336	3,923
Shifa Foundation		-	709
Shifa Tameer-e-Millat University		22,949	1,657
Shifa Consulting Services (Private) Limited		885	-
		29,170	6,289
9.2	This represents customers' and employees' security deposits that are repayable on termination of respective agreements.		
		2017	2016
		(Rupees in '000')	
9.3	Compensated absences		
	Note		
Balance at beginning of the year		84,736	66,243
Provision made for the year		34,565	44,902
		119,301	111,145
Payment made during the year		(29,112)	(26,409)
Closing balance as at year end		90,189	84,736
9.4	The amounts recognized in the balance sheet are as follows:		
Present value of defined benefit obligations	9.4.1	424,984	373,317
Fair value of plan assets	9.4.2	(389,676)	(338,204)
		35,308	35,113
9.4.1	Movement in the present value of funded obligation is as follows:		
Present value of defined benefit obligation at beginning		373,317	298,538
Interest cost		25,324	26,627
Current service cost		82,427	62,265
Past service cost		-	(18,192)
Benefits paid		(47,343)	(48,995)
Benefits payable		(710)	(1,882)
Non refundable loan to employees adjustable against gratuity		(2,540)	(1,399)
Remeasurement (gain)/loss on defined benefit obligation		(5,491)	56,355
Present value of defined benefit obligation at year end		424,984	373,317
9.4.2	Movement in the fair value of plan assets is as follows:		
Fair value of plan assets at beginning		338,204	266,510
Expected return on plan assets		25,559	29,122
Contributions		76,017	113,347
Benefits paid		(47,343)	(48,995)
Benefits payable		(710)	(1,882)
Non refundable loan to employees adjustable against gratuity		(2,540)	(1,399)
Remeasurement gain/(loss) on plan assets		489	(18,499)
Fair value of plan assets at year end		389,676	338,204
9.4.3	Charge for the year is as follows:		
Current service cost		82,427	62,265
Past service cost		-	(18,192)
Interest cost		25,324	26,627
Expected return on plan assets		(25,559)	(29,122)
		82,192	41,578

Notes to the Financial Statements

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
9.4.4 Remeasurements recognized in other comprehensive income (OCI) during the year		
Remeasurement (income)/loss on obligation	(5,491)	56,355
Remeasurement (income)/loss on plan assets	(489)	18,499
Remeasurement (income)/loss recognized in OCI	(5,980)	74,854
9.4.5 Movement in liability recognized in balance sheet:		
Balance at beginning of year	35,113	32,304
Cost for the year	82,192	41,578
Total amount of remeasurement recognized in OCI during the year	(5,980)	74,854
Contributions during the year	(76,017)	(113,347)
Other adjustment	-	(276)
Balance at end of year	35,308	35,113
9.4.6 Plan assets comprise of:		
Accrued mark up	2,947	1,997
Term deposit receipts	231,000	231,000
Cash and bank balances	158,321	107,089
Payable to outgoing members	(2,592)	(1,882)
	389,676	338,204
9.4.7 The principal actuarial assumptions used in the actuarial valuation are as follows:		
	2017	2016
Discount rate used for interest cost in profit and loss	7.25%	9.75%
Discount rate used for year end obligation	7.75%	7.25%
Expected rate of salary growth		
Salary increase FY 2017	N/A	6.25%
Salary increase FY 2018 onward	6.75%	6.25%
Mortality rate	SLIC 2001-2005 set back 1 year	SLIC 2001-2005 set back 1 year
Withdrawal rates	age based	age based
Retirement assumption	Age 60	Age 60
9.4.8 Sensitivity analysis		

The calculation of the defined benefit obligation is sensitive to assumptions set out above. The following table summarizes how the impact on the defined benefit obligation at the end of the reporting period would have increased/decreased as a result of a change in respective assumptions by one percent.

Notes to the Financial Statements

For the year ended June 30, 2017

	Defined benefit obligation	
	Effect of 1% increase	Effect of 1% decrease
Discount rate	395,473	459,282
Future salary increase	459,951	394,338

(Rupees in '000')

9.4.9 The average duration of the defined benefit obligation as at June 30, 2017 is 8 years (2016: 7 years).

10 MARKUP ACCRUED

This represents mark up accrued on long term financing.

11 CONTINGENCIES AND COMMITMENTS

	2017	2016
Note	(Rupees in '000')	

11.1 Contingencies

Claims against the Company not acknowledged as debts:

Patients	11.1.1	111,000	111,000
Others	11.1.2	20,000	20,000
Letter of guarantee	11.1.3	34,600	34,600

11.1.1 This represents claims lodged by patients and their heirs against the Company for alleged negligence on part of the consultants/doctors. The management is contesting the claims which are pending in courts and believes that the contention of the claimants will not be successful and no material liability is likely to arise.

11.1.2 This represents the penalty imposed by Competition Commission of Pakistan to each Gulf Cooperation Council's (GCC) Approved Medical Centers (GAMCs) including SIHL on account of alleged non competitive practice/B363 arrangement of territorial division and equal allocation of GAMCs customers. Management of the Company and other GAMCs are jointly contesting the matter and firmly believe that the case will be decided in favor of the GAMCs including SIHL.

11.1.3 This represents letters of guarantees issued by bank in favor of Sui Northern Gas Pipelines Limited (SNGPL) and Ministry of Economy U.A.E. in ordinary course of Company's business.

11.1.4 The Assistant Commissioner inland Revenue under section 221 of the Income Tax Ordinance, 2001 has amended the Company's assessment for a tax year 2014 which resulted a tax demand of Rs. 11.77 million. Being aggrieved, the Company has filed an appeal before the Commissioner Inland Revenue which is pending adjudication. The Company is confident for a favorable outcome and therefore, no provision in respect of this matter has been recorded in these financial statements.

	2017	2016
	(Rupees in '000')	

11.2 Commitments

11.2.1 Capital expenditure contracted	96,548	282,614
11.2.2 Letters of credit	59,055	22,333

Notes to the Financial Statements

For the year ended June 30, 2017

12. PROPERTY, PLANT AND EQUIPMENT

Particulars	Owned assets											Capital work-in-progress (note 12.6)	Total
	Freehold land	Leasehold land	Building on leasehold land	Leasehold improvements	Biomedical equipment	Air conditioning equipment and machinery	Electrical and other equipment	Furniture and fittings	Construction equipment	Computer installations	Vehicles		
Cost/Revalued amount	(Rupees in 000)												
Balance as at July 01, 2015	257,350	960,959	1,930,894	-	2,269,693	186,098	372,352	122,258	8,671	215,856	100,023	54,515	6,478,669
Additions	66,402	-	-	-	290,421	40,796	40,192	17,008	-	37,413	17,320	29,975	539,527
Disposals	-	-	-	-	(13,860)	-	(3,024)	-	-	(263)	(4,234)	-	(21,381)
Write offs	-	-	(221)	-	(5,130)	-	(49)	(214)	-	(789)	-	-	(6,403)
Transfer	-	-	29,245	-	-	-	-	-	-	-	-	(29,245)	-
Balance as at June 30, 2016	323,752	960,959	1,959,918	-	2,541,124	226,894	409,471	139,052	8,671	252,217	113,109	55,245	6,990,412
Balance as at July 01, 2016	323,752	960,959	1,959,918	-	2,541,124	226,894	409,471	139,052	8,671	252,217	113,109	55,245	6,990,412
Additions	565,777	-	-	-	387,034	20,945	34,015	25,353	830	62,097	7,283	246,552	1,349,886
Disposals	(22,010)	-	-	-	(81)	-	-	-	(7,614)	(142)	(5,298)	-	(35,145)
Write offs	-	-	(29,479)	-	(2,377)	-	-	(185)	-	(436)	-	-	(32,477)
Transfers	-	-	102,941	35,295	-	-	-	-	-	-	-	(138,236)	-
Balance at June 30, 2017	867,519	960,959	2,033,380	35,295	2,925,700	247,839	443,486	164,220	1,887	313,736	115,094	163,561	8,272,676
Depreciation/amortization													
Balance as at July 01, 2015	-	12,987	401,385	-	1,003,487	114,500	208,647	54,453	8,639	120,614	67,980	-	1,992,691
Charge for the year	-	18,671	61,272	-	208,606	15,376	41,895	10,909	9	45,003	13,506	-	415,247
On disposals	-	-	-	-	(13,860)	-	(3,024)	-	-	(174)	(2,095)	-	(19,152)
On write offs	-	-	(221)	-	(3,800)	-	(42)	(160)	-	(766)	-	-	(4,989)
Balance as at June 30, 2016	-	31,658	462,436	-	1,194,433	129,876	247,476	65,202	8,648	164,677	79,391	-	2,383,797
Balance as at July 01, 2016	-	31,658	462,436	-	1,194,433	129,876	247,476	65,202	8,648	164,677	79,391	-	2,383,797
Charge for the year	-	18,671	59,180	3,951	240,925	18,553	44,367	12,892	23	53,241	11,401	-	463,204
On disposals	-	-	-	-	(53)	-	-	-	(7,614)	(79)	(4,836)	-	(12,582)
On write offs	-	-	(17,736)	-	(978)	-	-	(138)	-	(436)	-	-	(19,288)
Balance at June 30, 2017	-	50,329	503,880	3,951	1,434,327	148,429	291,843	77,956	1,057	217,403	85,956	-	2,815,131
Carrying value as at June 30, 2016	323,752	929,301	1,497,482	-	1,346,691	97,018	161,995	73,850	23	87,540	33,718	55,245	4,606,615
Carrying value as at June 30, 2017	867,519	910,630	1,529,500	31,344	1,491,373	99,410	151,643	86,264	830	96,333	29,138	163,561	5,457,545
Annual rate of depreciation %	-	1.34-3.03	2.5-10	20	10	10-15	10-15	10	10-20	25	20	-	-

Notes to the Financial Statements

For the year ended June 30, 2017

- 12.1** The Company had its leasehold land revalued in 1999, 2004, 2009 and 2014 and freehold land in 2009 and 2014 by independent valuers, using fair market value. These revaluations resulted in net surplus of Rs. 180,873 thousand, Rs. 63,891 thousand, Rs. 392,360 thousand and Rs. 184,284 thousand respectively. The revaluation surplus amounting to Rs. 821,408 thousand has been included in the carrying value of the respective assets. Out of the revaluation surplus, an amount of Rs. 726,760 thousand (2016: Rs. 742,191 thousand) remains undepreciated as at June 30, 2017.

Had there been no revaluation the carrying value would have been as under:

	Cost at June 30	Accumulated amortization at June 30	Carrying value at June 30
	(Rupees in '000')		
Leasehold land			
2017	325,065	52,755	272,310
2016	325,065	43,074	281,991
Freehold land			
2017	779,078	-	779,078
2016	228,870	-	228,870

- 12.2** Property, plant and equipment include items with aggregate cost of Rs. 843,756 thousand (2016: Rs. 639,721 thousand) representing fully depreciated assets that are still in use of the Company.

- 12.3** Property, plant and equipment of the Company are encumbered under an aggregate charge of Rs. 3,014.67 million (2016: Rs. 3,064.67 million) in favor of banking companies under various financing arrangements as disclosed in notes 7, 11.2.2 and 31.

- 12.4** The depreciation/amortization charge for the year has been allocated as follows:

	Note	2017 (Rupees in '000')	2016
Operating costs	26	463,197	415,241
Capital work-in-progress		7	6
		463,204	415,247

- 12.5** Detail of property, plant and equipment disposed off during the year, having carrying value of more than fifty thousand rupees:

Sr. No.	Asset Particulars	Cost	Carrying Value	Sale Proceed	Purchaser	Mode of Disposal
(Rupees in '000')						
1	Freehold land	11,005	11,005	13,800	Dr. Saeed Zameer	Negotiation
2	Freehold land	11,005	11,005	13,800	Mr. Abdul Wahid	Negotiation
3	Honda City	276	161	276	Mr. Afzaal Ahmed	As per Company policy
4	Honda City	252	75	254	Mr. Wazir Muhammad	As per Company policy
5	Honda City	271	140	270	Mr. Malik M. Uzair	As per Company policy
6	Laptop	84	63	65	Mr. Wazir Muhammad	As per Company policy
		22,893	22,449	28,465		
	Other assets having carrying value less than 50,000 rupees	12,252	114	5,493		
2017		35,145	22,563	33,958		
2016		21,381	2,228	5,184		

Notes to the Financial Statements

For the year ended June 30, 2017

12.6 Capital work-in-progress

	Note	2017 (Rupees in '000')	2016
Construction work-in-progress - at cost	12.6.1	68,932	-
Stores held for capital expenditure	12.6.2	47,286	49,998
Installation of equipment in progress	12.6.3	47,343	5,247
		<u>163,561</u>	<u>55,245</u>

12.6.1 Construction work-in-progress - at cost

This was cost of civil works mainly comprising of cost of materials, payments to contractors, salaries and benefits pertaining to different blocks of hospital building in H-8/4 and F-11 Hospital. Given below was the break-up of civil works:

	Note	2017 (Rupees in '000')	2016
Block "C"		21,939	-
F-11 Hospital		35,334	-
Other constructions		11,659	-
		<u>68,932</u>	<u>-</u>

12.6.2 Stores held for capital expenditure

Stores held for capital expenditure		50,365	53,105
Less: provision for slow moving items	12.6.2.1	3,079	3,107
		<u>47,286</u>	<u>49,998</u>
12.6.2.1 Balance at beginning of the year		3,107	2,657
Charged/(reversed) during the year		(28)	450
Balance at the end of the year		<u>3,079</u>	<u>3,107</u>

12.6.3 Installation of equipment in progress

Mobile C-Arm		-	5,247
Steam Sterilizer		7,000	-
Auto Washer Disinfector		6,116	-
Plasma Sterilizer		10,853	-
Fire Doors		23,374	-
		<u>47,343</u>	<u>5,247</u>

13 INTANGIBLE

This represents the cost of Oracle financials software being capitalized during the current year. Amortization of intangible for the year has been charged to operating costs at a rate of 25% (2016: Nil).

14 LONG TERM INVESTMENT - AT COST

This represents investment in 100% fully paid ordinary shares of Shifa Consulting Services (Private) Limited, a wholly owned subsidiary company having principal place of business in Islamabad. Fair value of this investment is not given as no reliable measures are available. The breakup value of this investment based on net assets of the investee company is Rs. 1.64 (2016: Rs. 1.54) per share.

15 LONG TERM DEPOSITS

	Note	2017 (Rupees in '000')	2016
Ijarah key money deposits	15.1	6,844	4,009
Less: current portion of Ijarah key money deposits	20	3,300	304
		<u>3,544</u>	<u>3,705</u>
Security deposits	15.2	41,729	35,972
		<u>45,273</u>	<u>39,677</u>

Notes to the Financial Statements

For the year ended June 30, 2017

15.1 This represents Ijarah key money deposits adjustable on expiry of respective Ijarah financing arrangements against transfer of titles of relevant assets.

15.2 This represents security deposits given to various institutions / persons and are generally refundable on termination of relevant services / arrangements.

16 STORES, SPARE PARTS AND LOOSE TOOLS	Note	2017	2016
		(Rupees in '000')	
Stores		76,107	64,234
Spare parts		20,391	19,748
Loose tools		202	638
		96,700	84,620
Less: provision for slow moving items	16.1	15,505	20,027
		81,195	64,593
16.1 Balance at beginning of year		20,027	16,078
(Reversed) / charged for the year		(4,522)	3,949
Balance at the end of year		15,505	20,027

17 STOCK-IN-TRADE

This represents medicines being carried at moving average cost.

18 TRADE DEBTS - CONSIDERED GOOD

Considered good			
Related party - Shifa Foundation	18.1	12,979	9,020
Others		434,791	329,725
Considered doubtful			
Others		55,078	47,559
Considered bad			
Others		29,130	-
		531,978	386,304
Less: provision for doubtful debts	18.2 & 36.1.3	55,078	47,559
Bad debts written off	36.1.3	29,130	-
		447,770	338,745

18.1 Maximum amount due from Shifa Foundation at the end of any month during the year was Rs. 29,327 thousand (2016: Rs. 24,406 thousand).

18.2 Trade debts are provided on estimated irrecoverable amounts, on the basis of past experience of the management of the Company.

19 LOANS AND ADVANCES - CONSIDERED GOOD	Note	2017	2016
		(Rupees in '000')	
Considered good - unsecured			
Executives	19.1	10,709	10,473
Other employees		27,020	27,550
		37,729	38,023
Consultants		9,911	13,836
Suppliers	19.2	291,974	107,298
		339,614	159,157

Notes to the Financial Statements

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
19.1 Reconciliation of carrying amount of advances given to executives:		
Balance at beginning of year	10,473	4,459
Disbursements during the year	41,311	38,871
	51,784	43,330
Less: Repayments during the year	41,075	32,857
Balance at end of year	10,709	10,473

The above advances were given in accordance with the Company's service rules. The maximum amount due from executives at the end of any month during the year was Rs. 12,945 thousand (2016: Rs. 10,473 thousand).

- 19.2** The corresponding figure included an advance amounting to Rs. 3,000 thousand given to Shifa Consulting Services (Private) Limited for consultancy services.

20 TRADE DEPOSITS, SHORT TERM PREPAYMENTS AND OTHER RECEIVABLES

		2017	2016
	Note	(Rupees in '000')	
Current portion of Ijarah key money deposits	15	3,300	304
Other deposits		2,560	2,560
Short term prepayments		14,011	16,467
Other receivables	20.1	18,627	2,021
		38,498	21,352

- 20.1** The corresponding figures represented receivable from Shifa Consulting Services (Private) Limited.

		2017	2016
	Note	(Rupees in '000')	
21 OTHER FINANCIAL ASSETS (Held to Maturity Investment)			
Meezan Bank Limited	21.1	-	75,222
Faysal Bank Limited	21.2	89,022	89,068
Al Baraka Bank (Pakistan) Limited	21.3	-	780,006
JS Bank Limited	21.4	-	101,460
Dubai Islamic Bank Limited	21.5	50,238	50,485
MCB Islamic Bank	21.6	50,191	-
		189,451	1,096,241

- 21.1** This represented term deposit receipt (TDR) having face value of Rs. 75 million with three month maturity, encashed on March 08, 2017. TDR carried an effective interest rate of 4.69% per annum.

- 21.2** This represents three TDRs having face value of Rs. 50 million, Rs. 25 million and Rs. 13 million with three month maturity (2016: three TDRs having face value of Rs. 50 million, Rs. 25 million and Rs. 13 million) due on July 10, 2017, August 02, 2017 and August 02, 2017 respectively. These TDRs carry an effective interest rate ranging from 5.4% to 6.1% per annum respectively (2016: 5.5% and 6.15 % per annum).

- 21.3** This represented five TDRs having face value of Rs. 200 million, Rs. 200 million, Rs. 200 million, Rs. 102 million and Rs. 75 million respectively with three month maturity. These TDRs were encashed during the year. These TDRs carried effective profit rate ranging from 4.7% to 6.4% per annum (2016: 5% to 6.4% per annum).

Notes to the Financial Statements

For the year ended June 30, 2017

- 21.4** This represented TDR having face value of Rs. 100 million with three month maturity, encashed on July 08, 2016 with effective interest rate of 6.5% per annum (2016: 6.5% per annum).
- 21.5** This represents TDR having face value of Rs. 50 million (2016: Rs. 50.32 million) with three month maturity, due on August 30, 2017 carrying effective interest rate of 5.5% (2016: 5.35%) per annum.
- 21.6** This represents TDR having face value of Rs. 50 million (2016: Nil) with six month maturity, due on November 30, 2017 carrying effective interest rate of 5.06% (2016: Nil) per annum.

22 TAX REFUNDS DUE FROM THE GOVERNMENT (NET OF PROVISION)

	Note	2017 (Rupees in '000')	2016
Balance at beginning of year		24,980	52,063
Income tax paid/deducted at source during the year		340,414	263,437
		365,394	315,500
Provision for taxation for the year	28	(267,920)	(290,520)
Balance at end of year		97,474	24,980

23 CASH AND BANK BALANCES

Cash at banks in:			
Current accounts			
Local currency		62,156	71,358
Foreign currency		4,333	3,466
		66,489	74,824
Saving accounts:			
Local currency		565,546	400,400
Foreign currency		587	47
	23.1	566,133	400,447
	23.2	632,622	475,271
Cash in hand		9,121	11,178
		641,743	486,449

23.1 These carry effective profit rates ranging from 1.79% - 4.9% and 0.1% (2016: 2.4% - 6% and 0.1%) per annum in respect of local and foreign currency accounts respectively.

23.2 Balances with banks includes Rs. 109,332 thousand (2016: Rs. 85,875 thousand) in respect of security deposits (note 9.2).

24 NET REVENUE

	Note	2017 (Rupees in '000')	2016
Inpatients		3,899,292	3,677,215
Outpatients		2,077,577	2,154,542
Pharmacy	24.1	3,025,970	2,657,462
Cafeteria		312,703	261,084
Rent of building	24.2	19,655	31,593
Other services		2,910	32,116
		9,338,107	8,814,012
Less: discount		81,098	83,209
Net revenue		9,257,009	8,730,803

24.1 This includes revenue of Rs. 315,066 thousand (2016: Rs. 124,822 thousand) from external pharmacy outlets.

24.2 This mainly includes rental income on operating leases to related parties.

Notes to the Financial Statements

For the year ended June 30, 2017

25 OTHER INCOME	Note	2017 (Rupees in '000')	2016
Income from financial assets:			
Profit on investments and bank deposits		58,130	37,314
Income from other than financial assets:			
Gain on disposal of property, plant and equipment		11,395	2,956
Liabilities written back		7,362	2,301
Sale of scrap		10,399	7,316
Miscellaneous	25.1	49,293	36,873
		136,579	86,760

25.1 This mainly includes sale of Shifa News (magazine of Shifa Publications), related advertisement income from Shifa News and other miscellaneous income.

26 OPERATING COSTS	Note	2017 (Rupees in '000')	2016
Salaries, wages and benefits	26.1	3,386,716	3,053,772
Utilities		294,184	292,715
Supplies consumed		1,161,211	1,018,454
Medicines		2,225,568	1,970,891
Communication		26,494	22,900
Travelling and conveyance		19,803	21,480
Printing and stationery		70,049	57,562
Repairs and maintenance		349,192	373,683
Auditors' remuneration	26.2	2,350	2,347
Legal and professional		32,539	14,539
Rent		131,710	97,677
Rates and taxes		6,316	59,851
Advertising and sales promotion		39,338	35,445
Fee, subscription and membership		15,329	38,063
Vehicle and equipment rentals	26.3	7,775	7,612
Cleaning and washing		77,538	62,387
Insurance		12,360	11,451
Property, plant and equipment written off	26.4	13,189	1,414
Provision for doubtful debts		36,649	19,179
Provision for slow moving stores		(4,550)	4,399
Depreciation/amortization	12.4	463,197	415,241
Amortization intangible	13	225	-
Donation	26.5	52,400	50,000
Other expenses		45,024	37,476
		8,464,606	7,668,538

26.1 This includes employee retirement benefits (gratuity) of Rs. 82,192 thousand (2016: Rs. 41,578 thousand), expense for compensated absences of Rs. 34,565 thousand (2016: Rs. 44,902 thousand) and provision for bonus to employees of Rs. 173,215 thousand (2016: Rs. 140,856 thousand).

Notes to the Financial Statements

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
26.2 Auditors' remuneration		
Annual audit fee	1,417	1,415
Half yearly review fee	583	585
Other certifications	350	201
Out of pocket expenses	-	146
	2,350	2,347

26.3 This includes ujarah payments under an Ijarah. As required under Islamic Financial Accounting Standard (IFAS 2) "Ijarah" (notified through SRO 431 (I)/2007 by Securities & Exchange Commission of Pakistan) ujarah payments under an Ijarah are recognized as an expense in the profit and loss account on straight line basis over the Ijarah term.

The amounts of future ujarah payments and the periods in which these will be due are as follows:

	2017	2016
	(Rupees in '000')	
Within one year	6,987	5,986
After one year but not more than five years	7,412	3,134
Total ujarah payments	14,399	9,120

26.4 This mainly includes the written down value of store building, which has been demolished during the current year. While the balance represents assets written off that were determined to be irreparable after carrying out detailed physical verification exercise by the management.

	2017	2016
	(Rupees in '000')	
26.5 Donation		
Shifa Foundation	2,400	-
Shifa Tameer-e-Millat University (STMU)	50,000	50,000
	52,400	50,000

Shifa Foundation and Shifa Tameer-e-Millat University (STMU) are related parties due to common directorship and related information is as under:

Name of common directors	Interest in donee	Name & address of the donee
Dr. Manzoor H. Qazi	Director	Shifa Foundation and STMU, H-8/4, Islamabad
Dr. Habib ur Rahman	Director	Shifa Foundation and STMU, H-8/4, Islamabad
Dr. Mohammad Salim Khan	Director	Shifa Foundation, H-8/4, Islamabad
Mr. Muhammad Zahid	Director	Shifa Foundation, H-8/4, Islamabad
Dr. Samea Kauser Ahmad	Director	STMU, H-8/4, Islamabad

Notes to the Financial Statements

For the year ended June 30, 2017

27	FINANCE COSTS	Note	2017	2016
			(Rupees in '000')	
	Markup on:			
	Long term loans		50,418	82,235
	Running finance and murabaha facilities		267	158
	Credit card payment collection charges		14,594	12,340
	Loss on foreign currency translation		419	493
	Bank charges and commission		691	13,771
			66,389	108,997
28	PROVISION FOR TAXATION			
	Current			
	for the year		258,010	313,709
	Prior year		9,910	(23,189)
	Deferred	22	267,920	290,520
			(11,754)	(10,590)
			256,166	279,930
28.1	Reconciliation of tax charge for the year			
	Profit before taxation		862,593	1,040,028
	Applicable tax rate		31%	32%
	Additional tax		3%	3%
	Total		34%	35%
	Add: Tax effect of amounts taxed at lower rates/others		19%	10%
	Less: Net tax effect of amounts that are deductible for tax purposes		24%	18%
	Average effective tax rate charged on income		29%	27%
29	EARNINGS PER SHARE - BASIC AND DILUTED			
	Profit after taxation for the year		606,427	760,098
			(Number of shares in '000')	
	Weighted average number of ordinary shares in issue during the year	4	54,538	51,781
			(Rupees)	
	Earnings per share - basic and diluted		11.12	14.68

29.1 There is no dilutive effect on the basic earnings per share.

29.2 The corresponding weighted average number of ordinary shares were adjusted for a right issue fully subscribed and allotted during the last quarter of the previous financial year.

30 CAPACITY UTILIZATION

The actual inpatient available bed days, occupied bed days and room occupancy ratio of Shifa International Hospitals Limited (SIHL) are given below:

Notes to the Financial Statements

For the year ended June 30, 2017

	2017	2016	2017	2016	2017	2016
	Available bed days		Occupied bed days		Occupancy Ratio	
SIHL H-8/4 Islamabad	162,356	166,579	113,927	118,698	70.17%	71.26%
SIHL G-10/4 Islamabad	8,110	8,110	3,050	2,795	37.61%	34.46%
SIHL Faisalabad	16,514	15,330	5,095	4,596	30.85%	29.98%

30.1 The under utilization reflects the pattern of patient turnover which is beyond the management's control.

31 UNAVAILED CREDIT FACILITIES

	2017	2016
	(Rupees in '000')	
Unavailed credit facilities at year end are as under:		
Running/Murabaha financing	124,055	136,900
Letter of credit	50,000	84,709
Ijarah financing	1,935	10,000
	175,990	231,609

32 NUMBER OF EMPLOYEES

The Company had 4,584 employees (2016: 4,459) at the year end and average number of employees during the year were 4,520 (2016: 4,315).

33 RELATED PARTIES TRANSACTIONS

The related parties comprise of subsidiary, directors, major shareholders, key management personnel, SIHL Employees' Gratuity Fund and the entities over which directors are able to exercise influence. The amounts due from and due to these undertakings are shown under trade debts, loans and advances and trade and other payables. Other transactions with the related parties are given below:

	Note	2017	2016
		(Rupees in '000')	
Shifa Foundation: (Related party by virtue of common directorship)			
Revenue from services earned by the Company	33.1	113,702	66,353
Revenue from rent earned by the Company		44	44
Expenses paid by and reimbursed to the Company		3,508	-
Other services provided to the Company	33.2	15,840	15,840
Donation given by the Company		2,400	-
Tameer-e-Millat Foundation: (Related party by virtue of common directorship)			
Revenue from services earned by the Company	33.1	-	19
Revenue from rent earned by the Company		311	177
Other supplies provided to the Company		21,301	16,631
Other services provided to the Company	33.2	5,515	6,121
Expenses paid by and reimbursed to the Company		169	-
Rent paid by the Company		5,060	2,192

Notes to the Financial Statements

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
SIHL Employees' Gratuity Fund			
Payments made by the Company during the year		76,017	113,347
Shifa Tameer-e-Millat University: (Related party by virtue of common directorship)			
Revenue from services earned by the Company	33.1	26,865	27,928
Revenue from rent earned by the Company		13,613	24,494
Other services provided to the Company	33.2	24,066	17,209
Expenses paid by and reimbursed to the Company		14,291	25,537
Other supplies provided to the Company		-	1,300
Donation given by the Company		50,000	50,000
Shifa Consulting Services (Private) Limited (subsidiary company)			
Revenue from services earned by the Company	33.1	38	-
Expenses paid by and reimbursed to the Company		508	-
Other supplies provided to the company		360	-
Sale of vehicle by the company		-	2,021
Advance given for consultancy services by the Company	19.2	-	3,000
Other services provided to the Company	33.2	18,000	-
Further investment made by the Company		120	-
Remuneration including benefits and perquisites of key management personnel			
	33.3	275,619	228,486

33.1 Revenue earned from related parties includes medical, surgical, clinical and lab services rendered to referred inpatients and outpatients, sale of medicines and provision of cafeteria services. These transactions are based on commercial terms which are approved by the Board of Directors of the Company.

33.2 Other services are received by the Company for nursing education/training, employees' children education and consultancy services. These transactions are based on commercial terms which are approved by the Board of Directors of the Company.

33.3 Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, including directors of the Company. There were no transactions with the key management personnel during the year other than their terms of employment / entitlements.

34 REMUNERATION OF CHIEF EXECUTIVE, DIRECTORS AND EXECUTIVES

The aggregate amount charged in these financial statements in respect of remuneration and allowances, including all benefits, to chief executive, directors and executives of the Company are given below:

	Chief Executive		Executive Directors		Non-Executive Directors		Executives	
	2017	2016	2017	2016	2017	2016	2017	2016
..... (Rupees in '000')								
Managerial remuneration	42,772	28,670	34,115	26,252	7,177	8,400	227,519	192,197
Rent and utilities	8,872	7,187	2,958	2,957	1,407	1,407	48,505	40,282
Bonus and incentives	2,657	2,196	2,880	-	430	430	21,467	19,328
Gratuity	-	-	-	-	-	-	12,071	10,863
Medical insurance	-	-	323	157	54	79	5,944	5,167
Leave encashment	-	-	-	-	-	-	6,039	5,585
	54,301	38,053	40,276	29,366	9,068	10,316	321,545	273,422
Number of persons	1	1	2	2	6	6	100	87

Notes to the Financial Statements

For the year ended June 30, 2017

- 34.1** The chief executive is provided with a Company maintained car, while two other directors and forty executives availed car facility.
- 34.2** Managerial remuneration includes Rs. 2,571 thousand (2016: 3,509 thousand) paid to directors in respect of meeting attending fee.
- 34.3** Travelling expenses of directors for official purposes are reimbursed by the Company.

35 CASH AND CASH EQUIVALENTS	Note	2017 (Rupees in '000')	2016
Cash and bank balances	23	641,743	486,449
Other financial assets (excluding TDR having maturity more than three months)	21	139,451	1,096,241
		781,194	1,582,690

36 FINANCIAL RISK MANAGEMENT

The Company has exposure to the following risks from its use of financial instruments:

Credit risk
Liquidity risk
Market risk

This note presents information about the Company's exposure to each of the above risks, the Company's objectives, policies and processes for measuring and managing risk and the Company's management of capital. Further quantitative disclosures are included throughout these financial statements.

The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework and policies.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company through its training and management standards and procedures aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Audit Committee oversees how management monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee.

36.1 Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Company has credit policy in place to ensure that services are rendered to customers with an appropriate credit history.

The Company is also exposed to credit risk from its operating and short term investing activities. The Company's credit risk exposures are categorized under the following headings:

Notes to the Financial Statements

For the year ended June 30, 2017

36.1.1 Counterparties

The Company conducts transactions with the following major types of counterparties:

Trade debts

Trade debts are essentially due from government companies/institutions, private companies (panel companies) and individuals to whom the Company is providing medical services. Normally the services are rendered to the panel companies on agreed rates and limits from whom the Company does not expect any inability to meet their obligations. The Company manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Company has credit policy in place to ensure that services are rendered to customers with an appropriate credit history.

The Company establishes an allowance for impairment that represents its estimate of incurred losses in respect of trade debts. This allowance is based on the management's assessment of a specific loss component that relates to individually significant exposures.

Cash and investments

The Company limits its exposure to credit risk by investing in liquid securities and maintaining bank accounts only with counterparties that have a credit rating of at least A-2 and A-. Given these credit ratings, management does not expect any counterparty to fail to meet its obligations.

36.1.2 Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	2017	2016
	(Rupees in '000')	
Long term deposits	41,729	35,972
Trade debts - considered good	447,770	338,745
Loans and advances - considered good	47,640	51,859
Trade deposits and other receivables	21,187	2,560
Markup accrued	1,165	1,501
Other financial assets	189,451	1,096,241
Bank balances	632,622	475,271
	1,381,564	2,002,149

The maximum exposure to credit risk for trade debts at the reporting date by type of customer was:

	2017	2016
	(Rupees in '000')	
Government companies	247,581	136,105
Private companies	125,693	127,662
Individuals	47,999	63,904
Related parties	12,979	9,020
Others	13,518	2,054
	447,770	338,745

Notes to the Financial Statements

For the year ended June 30, 2017

36.1.3 Impairment losses

The aging of trade debts at the reporting date was:

	2017		2016	
	Gross debts	Impaired	Gross debts	Impaired
	(Rupees in '000')		(Rupees in '000')	
Not past due	203,901	-	198,836	-
1 - 4 months	193,600	-	75,836	-
5 - 7 months	8,868	443	1,846	92
8 - 12 months	34,427	143	61,902	1,302
13 - 18 months	43,866	36,306	28,434	26,715
19 - 23 months	18,186	18,186	19,450	19,450
	502,848	55,078	386,304	47,559

The movement in the allowance for impairment in respect of trade debts during the year was as follows:

	Note	2017	2016
		(Rupees in '000')	
Balance at beginning of year		47,559	28,380
Provision made during the year		36,649	19,179
Less: bad debts written off		29,130	-
Balance at end of year	18	55,078	47,559

The allowance account in respect of trade debts is used to record impairment losses where the Company is satisfied that recovery of the due amount is doubtful, and when the amount considered irrecoverable it is written off against the financial asset.

36.1.4 The Company believes that no impairment allowance is necessary in respect of loan and advances, markup accrued, deposits and other financial assets as the recovery of such amounts is possible.

36.2 Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. For this purpose the Company has credit facilities as mentioned in notes 7 and 31 to the financial statements. Further liquidity position of the Company is monitored by the Board through budgets, cash flow projections and comparison with actual results.

Following is the maturity analysis of financial liabilities:

	Carrying amount	Six months or less	Six to twelve months	One to two years	Two to five years	Above five years
	----- (Rupees in '000') -----					
	2017					
Long term financing	503,992	167,870	167,894	168,228	-	-
Trade and other payables	1,759,064	1,759,064	-	-	-	-
Markup accrued	398	398	-	-	-	-
	2,263,454	1,927,332	167,894	168,228	-	-

Notes to the Financial Statements

For the year ended June 30, 2017

	Carrying amount	Six months or less	Six to twelve months	One to two years	Two to five years	Above five years
2016	----- (Rupees in '000') -----					
Long term financing	839,665	167,826	167,848	335,764	168,227	-
Trade and other payables	1,421,374	1,421,374	-	-	-	-
Markup accrued	483	483	-	-	-	-
	<u>2,261,522</u>	<u>1,589,683</u>	<u>167,848</u>	<u>335,764</u>	<u>168,227</u>	<u>-</u>

36.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, markup rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return on risk. The Company is exposed to currency and markup rate risk.

36.3.1 Foreign currency risk

Exposure to foreign currency risk

Foreign currency risk arises mainly where receivables and payables exist due to transactions with foreign undertakings and cash in foreign currency bank account. The transactions and balances in foreign currency are very nominal therefore the Company's exposure to foreign currency risk is very minimal. The Company's exposure to foreign currency risk is as follows:

	2017 (Amount in '000')			2016 (Amount in '000')		
	GBP	USD	AED	GBP	USD	AED
Bank balances	-	5.61	151.89	-	0.45	121.83
Letter of credit	-	(490)	-	(9.09)	(124.09)	-
	<u>-</u>	<u>(484.40)</u>	<u>151.89</u>	<u>(9.09)</u>	<u>(123.64)</u>	<u>121.83</u>

	2017 (Rupees in '000')			2016 (Rupees in '000')		
	Bank balances	-	587	4,333	-	47
Letter of credit	-	(51,352)	-	(1,276)	(12,992)	-
	<u>-</u>	<u>(50,765)</u>	<u>4,333</u>	<u>(1,276)</u>	<u>(12,945)</u>	<u>3,466</u>

The following significant exchange rates applied during the year:

	Average rate		Closing rate	
	2017	2016	2017	2016
	----- (Rupees) -----			
USD 1	<u>103.76</u>	103.39	<u>104.80</u>	104.70
AED 1	<u>28.24</u>	28.14	<u>28.53</u>	28.45
GBP 1	<u>131.60</u>	154.22	<u>136.42</u>	140.38

Foreign currency sensitivity analysis

A 10 percent variation of the PKR against the USD and AED at June 30 would have effected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular markup rates, remain constant.

Notes to the Financial Statements

For the year ended June 30, 2017

	Change in Foreign Exchange Rates	Effect on Profit	Effect on Equity
	%	(Rupees in '000')	
2017			
Foreign currencies	+10%	(4,643)	(4,643)
Foreign currencies	-10%	4,643	4,643
2016			
Foreign currencies	+10%	(1,076)	(1,076)
Foreign currencies	-10%	1,076	1,076

36.3.2 Markup rate risk

The markup rate risk is the risk that the fair value or future cash flow of a financial instrument will fluctuate due to changes in the market markup rates. Sensitivity to markup rate risk arises from mismatch of financial assets and liabilities that mature in a given period. The Company's exposure to the risk of changes in market markup rates relates primarily to Company's long term debt obligations with floating markup rates.

The Company analyses its markup rate exposure on a dynamic basis. Various scenarios are simulated taking into consideration refinancing, renewal of existing positions, alternative financing. Based on these scenarios, the Company calculates the impact on profit and loss of a defined markup rate shift. For each simulation, the same markup rate shift is used for all currencies. The scenarios are run only for liabilities that represent the major markup-bearing positions.

The Company adopts a policy to ensure that markup rate risk is minimized by investing its surplus funds in fixed rate investments like TDRs.

Profile

At the reporting date the markup rate profile of the Company's markup-bearing financial instruments is:

	Note	2017	2016
		(Rupees in '000')	
Financial assets			
Other financial assets	21	189,451	1,096,241
Bank balances	23	566,133	400,447
		755,584	1,496,688
Financial liabilities			
Long term financing - secured	7	503,992	839,665
		251,592	657,023

The effective markup rates for the financial assets and liabilities are mentioned in respective notes to the financial statements.

Markup rate sensitivity analysis

If markup rates had been 50 basis points higher/lower and all other variables were held constant, the Company's profit for the year ended June 30, 2017 would decrease/increase by Rs. 3,547 thousand (2016: decrease/increase by Rs. 5,209 thousand). This is mainly attributable to the Company's exposure to markup rates on its variable rate borrowings.

Notes to the Financial Statements

For the year ended June 30, 2017

36.4 Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern so that it can continue to provide returns for shareholders and benefits for other stakeholders and to maintain a strong capital base to support the sustained development of its business. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividend to ordinary shareholders. There were no changes to the Company's approach to capital management during the year.

37 FINANCIAL INSTRUMENTS

Fair value of financial instruments

Fair value is the amount that would be received on sale of an asset or paid on transfer of a liability in an orderly transaction between market participants at the measurement date. Consequently, differences can arise between carrying values and fair value estimates. Underlying the definition of fair value is the presumption that the Company is a going concern without any intention or requirement to curtail materially the scale of its operations or to undertake a transaction on adverse terms.

IFRS 13, 'Fair Value Measurements' requires the Company to classify fair value measurements using fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the assets or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

Notes to the Financial Statements

For the year ended June 30, 2017

Financial instruments by category

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy for financial instruments measured at fair value. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

	Carrying Amount			Fair Value					
	Loans and receivables	Available for sale instruments	Fair value through profit or loss	Other financial instruments	Total	Level 1	Level 2	Level 3	Total
(Rupees in '000')									
June 30, 2017									
Financial assets not measured at fair value									
Non-current assets									
Long term deposits					41,729	-	-	-	41,729
Current assets									
Trade debts - considered good	447,770	-	-	-	447,770	-	-	-	447,770
Loans and advances - considered good	47,640	-	-	-	47,640	-	-	-	47,640
Trade deposits and other receivables	21,187	-	-	-	21,187	-	-	-	21,187
Markup accrued	1,165	-	-	-	1,165	-	-	-	1,165
Other financial assets	189,451	-	-	-	189,451	-	-	-	189,451
Bank balances	632,622	-	-	-	632,622	-	-	-	632,622
	1,381,564	-	-	-	1,381,564	-	-	-	1,381,564
Financial liabilities not measured at fair value									
Non-current liabilities									
Long term financing - secured	-	-	-	168,228	168,228	-	-	-	168,228
Current liabilities									
Trade and other payables	-	-	-	1,759,064	1,759,064	-	-	-	1,759,064
Markup accrued	-	-	-	398	398	-	-	-	398
Current portion of long term financing	-	-	-	335,764	335,764	-	-	-	335,764
	-	-	-	2,263,454	2,263,454	-	-	-	2,263,454
June 30, 2016									
Financial assets not measured at fair value									
Non-current assets									
Long term deposits	35,972	-	-	-	35,972	-	-	-	35,972
Current assets									
Trade debts - considered good	338,745	-	-	-	338,745	-	-	-	338,745
Loans and advances - considered good	51,859	-	-	-	51,859	-	-	-	51,859
Trade deposits	4,581	-	-	-	4,581	-	-	-	4,581
Markup accrued	1,501	-	-	-	1,501	-	-	-	1,501
Other financial assets	1,096,241	-	-	-	1,096,241	-	-	-	1,096,241
Bank balances	475,271	-	-	-	475,271	-	-	-	475,271
	2,004,170	-	-	-	2,004,170	-	-	-	2,004,170
Financial liabilities not measured at fair value									
Non-current liabilities									
Long term financing - secured	-	-	-	503,991	503,991	-	-	-	503,991
Current liabilities									
Trade and other payables	-	-	-	1,421,374	1,421,374	-	-	-	1,421,374
Markup accrued	-	-	-	483	483	-	-	-	483
Current portion of long term financing	-	-	-	335,674	335,674	-	-	-	335,674
	-	-	-	2,261,522	2,261,522	-	-	-	2,261,522

Notes to the Financial Statements

For the year ended June 30, 2017

38 OPERATING SEGMENTS

The financial statements have been prepared on the basis of single reportable segment.

38.1 All revenue of the Company is earned from customers located in Pakistan.

38.2 All non-current assets of the Company at June 30, 2017 are located in Pakistan.

38.3 There is no customer with more than 10% of total revenue of the company for the year.

39 RECLASSIFICATION

Following corresponding figures have been reclassified for the purpose of comparison.

		2016 (Rupees in '000')
Balance Sheet		
Reclassification from	Reclassification to	
Current Assets	Current Assets	
Stores, spare parts and loose tools	Stock-in-trade	80,931
		<hr/> <hr/>
Profit and Loss		
Reclassification from	Reclassification to	
Inpatients revenue	Pharmacy revenue	675,968
Supplies consumed	Medicines	402,371
		<hr/> <hr/>
		2015 (Rupees in '000')
Balance Sheet		
Reclassification from	Reclassification to	
Current Assets	Current Assets	
Stores, spare parts and loose tools	Stock-in-trade	119,476
		<hr/> <hr/>

No other major reclassifications were made during the year.

40 GENERAL

Figures have been rounded off to the nearest one thousand Pak Rupees unless otherwise stated.

41 EVENTS AFTER BALANCE SHEET DATE

The Board of Directors in their meeting held on September 11, 2017 have proposed a final dividend of Rs. 5 per share.

42 DATE OF AUTHORIZATION FOR ISSUE

These financial statements have been authorized for issue by the Board of Directors of the Company on September 11, 2017.



CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

CONSOLIDATED FINANCIAL STATEMENTS

For the year ended June 30, 2017



Grant Thornton Anjum Rahman
302 B, 3rd Floor Evacuee
Trust Complex,
Aga Khan Road F-5/1,
Islamabad Pakistan

T: +92 51 2271906, 2274665
F: +92 51 2273874
www.gtpak.com

Auditors' Report to the Members

We have audited the annexed consolidated financial statements comprising consolidated balance sheet of Shifa International Hospitals Limited (the Holding Company) and its subsidiary company, Shifa Consulting Services (Private) Limited as at 30 June, 2017 and the related consolidated profit and loss account, consolidated statement of comprehensive income, consolidated cash flow statement and consolidated statement of changes in equity together with the notes forming part thereof (hereafter referred to as the consolidated financial statement), for the year then ended. We have also expressed separate opinions on the financial statements of the Holding Company and its subsidiary company Shifa Consulting Services (Private) Limited. These consolidated financial statements are the responsibility of the Holding Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.

Our audit was conducted in accordance with the International Standards on Auditing and accordingly included such tests of accounting records and such other auditing procedures as we considered necessary in the circumstances.

In our opinion, the consolidated financial statements present fairly the financial position of the Holding Company and its subsidiary company as at 30 June 2017 and the results of their operations for the year then ended.

GRANT THORNTON ANJUM RAHMAN
Chartered Accountants

Engagement Partner: Khaliq ur Rahman

Islamabad
Date: September 11, 2017

Consolidated Balance Sheet

As at June 30, 2017

	Note	2017	2016	2015
(Rupees in '000')				
SHARE CAPITAL AND RESERVES				
Share capital	4	545,379	545,379	505,138
Capital reserve	5	1,046,025	1,046,025	40,000
Unappropriated profit		2,539,594	2,076,255	1,703,323
		4,130,998	3,667,659	2,248,461
NON-CONTROLLING INTEREST				
		-	2,641	7,675
SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT				
	6	726,760	742,191	751,182
NON-CURRENT LIABILITIES				
Long term financing - secured	7	168,228	503,991	833,333
Deferred taxation	8	413,646	423,606	457,400
		581,874	927,597	1,290,733
CURRENT LIABILITIES				
Trade and other payables	9	1,959,884	1,508,344	1,488,746
Markup accrued	10	398	483	793
Current portion of long term financing	7	335,764	335,674	333,333
		2,296,046	1,844,501	1,822,872
		7,735,678	7,184,589	6,120,923
CONTINGENCIES AND COMMITMENTS				
	11			

The annexed notes 1 to 41 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE

	Note	2017	2016	2015
			(Rupees in '000')	
NON-CURRENT ASSETS				
Property, plant and equipment	12	5,458,261	4,609,949	4,488,219
Intangible	13	10,585	-	-
Long term deposits	14	45,273	39,987	38,439
		5,514,119	4,649,936	4,526,658
CURRENT ASSETS				
Stores, spare parts and loose tools	15	81,195	64,593	66,809
Stock-in-trade	16	380,052	337,389	321,939
Trade debts - considered good	17	450,056	345,495	337,005
Loans and advances - considered good	18	339,628	157,580	126,690
Trade deposits, short term prepayments and other receivables	19	39,334	19,416	25,468
Markup accrued		1,165	1,501	1,908
Other financial assets	20	189,451	1,096,241	125,305
Tax refunds due from the government (net of provision)	21	97,543	25,737	52,154
Cash and bank balances	22	643,135	486,701	536,987
		2,221,559	2,534,653	1,594,265
		7,735,678	7,184,589	6,120,923

Muneer Babbar
CHIEF FINANCIAL OFFICER

Consolidated Profit and Loss Account

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
Net revenue	23	9,262,363	8,744,058
Other income	24	135,851	86,163
Operating costs	25	(8,468,607)	(7,694,192)
Finance costs	26	(66,390)	(108,998)
Profit before taxation		863,217	1,027,031
Provision for taxation	27	(258,402)	(280,087)
Profit after taxation		604,815	746,944
Attributable to:			
Equity holders of Shifa International Hospitals Limited		604,920	751,978
Non-Controlling interest		(105)	(5,034)
		604,815	746,944
		(Rupees)	
Earnings per share - basic and diluted	28	11.09	14.52

The annexed notes 1 to 41 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Consolidated Statement of Comprehensive Income

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
Profit after taxation	604,815	746,944
Other comprehensive income		
Income / (loss) on remeasurement of staff gratuity fund benefit plan	5,980	(74,854)
Deferred tax relating to remeasurement of staff gratuity fund benefit plan	(1,794)	23,205
Income / (loss) on remeasurement of staff gratuity fund benefit plan (net of tax)	4,186	(51,649)
Total comprehensive income for the year	609,001	695,295
Attributable to:		
Equity holders of Shifa International Hospitals Limited	609,106	700,329
Non-Controlling interest	(105)	(5,034)
	609,001	695,295

The annexed notes 1 to 41 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Consolidated Cash Flow Statement

For the year ended June 30, 2017

Note	2017 (Rupees in '000')	2016
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before taxation	863,217	1,027,031
Adjustments for:		
Depreciation/amortization of property, plant and equipment	463,713	415,746
Amortization of intangible	225	-
Provision for doubtful debts	41,149	19,179
Property, plant and equipment written off	13,189	1,414
Gain on disposal of property, plant and equipment	(10,667)	(2,324)
Provision for compensated absences	34,565	44,902
Provision for gratuity	82,192	41,578
Provision for slow moving stores	(4,550)	4,399
Liabilities written back	(7,362)	(2,301)
Profit on investments and bank deposits	(58,130)	(37,314)
Loss on foreign currency translation	419	493
Finance cost	65,971	108,505
Operating cash flows before changes in working capital	1,483,931	1,621,308
Changes in working capital:		
(Increase) / decrease in current assets:		
Stores, spare parts and loose tools	(12,080)	(1,733)
Stock-in-trade	(42,663)	(15,450)
Trade debts	(145,710)	(27,669)
Loans and advances	(182,048)	(30,890)
Trade deposits and short term prepayments	(19,918)	6,052
Increase/(decrease) in current liabilities:		
Trade and other payables	468,926	(15,714)
Cash generated from operations	1,550,438	1,535,904
Finance cost paid	(66,056)	(108,815)
Income tax paid	(341,962)	(264,259)
Payment to SIHL Employees' Gratuity Fund	(76,017)	(113,347)
Compensated absences paid	(29,112)	(26,409)
Net cash from operating activities	1,037,291	1,023,074
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(1,349,912)	(540,178)
Purchase of intangible	(10,810)	-
Proceeds from disposal of property, plant and equipment	35,393	3,162
Investment in TDRs	(50,000)	-
Markup received	58,466	37,721
Investment in subsidiary	(120)	-
Increase in long term deposits	(5,286)	(1,548)
Net cash used in investing activities	(1,322,269)	(500,843)
CASH FLOWS FROM FINANCING ACTIVITIES		
Long term financing - repayments	(335,673)	(327,001)
Proceeds from issue of right shares	-	1,046,266
Dividend paid	(179,286)	(320,353)
Net cash (used in) / generated from financing activities	(514,959)	398,912
Net (decrease) / increase in cash and cash equivalents	(799,937)	921,143
Cash and cash equivalents at beginning of year	1,582,942	662,292
Effect of exchange rate changes on cash and cash equivalents	(419)	(493)
Cash and cash equivalents at end of year	782,586	1,582,942

34

The annexed notes 1 to 41 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Consolidated Statement of Changes in Equity

For the year ended June 30, 2017

	Share capital	Capital reserve	Un-appropriated profit	Surplus on revaluation of property, plant and equipment	Non - controlling interest	Total
Note	(Rupees in '000')					
Balance at July 01, 2015	505,138	40,000	1,703,323	751,182	7,675	3,007,318
Issue of further share capital - right issue	40,241	-	-	-	-	40,241
Share premium on issue of right shares	-	1,006,025	-	-	-	1,006,025
Total comprehensive income for the year						
Profit for the year	-	-	751,978	-	(5,034)	746,944
Other comprehensive income - net of tax	-	-	(51,649)	-	-	(51,649)
	-	-	700,329	-	(5,034)	695,295
Transfer of depreciation / amortization on incremental value arising on revaluation of property, plant and equipment attributed to current year	-	-	8,991	(8,991)	-	-
Distribution to owners						
Final dividend 2014-15: Rs. 4.5 per share	-	-	(227,312)	-	-	(227,312)
Interim dividend 2015-16: Rs. 2 per share	-	-	(109,076)	-	-	(109,076)
Balance at June 30, 2016	545,379	1,046,025	2,076,255	742,191	2,641	4,412,491
Balance at July 01, 2016	545,379	1,046,025	2,076,255	742,191	2,641	4,412,491
Total comprehensive income for the year						
Profit for the year	-	-	604,920	-	(105)	604,815
Other comprehensive income - net of tax	-	-	4,186	-	-	4,186
	-	-	609,106	-	(105)	609,001
Transfer of depreciation / amortization on incremental value arising on revaluation of property, plant and equipment attributed to current year	-	-	8,990	(8,990)	-	-
Realization of revaluation surplus on disposal of assets	-	-	6,441	(6,441)	-	-
Distribution to owners						
Final dividend 2015-16: Rs. 3 per share	-	-	(163,614)	-	-	(163,614)
Changes in ownership interests						
Acquisition of NCI without a change in control 1.3	-	-	2,416	-	(2,536)	(120)
Balance at June 30, 2017	545,379	1,046,025	2,539,594	726,760	-	4,857,758

The annexed notes 1 to 41 form an integral part of these consolidated financial statements.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

1 STATUS AND NATURE OF BUSINESS

1.1 Shifa International Hospitals Limited (“the Group”) comprises of Shifa International Hospitals Limited (SIHL / parent company) and its subsidiary Shifa Consulting Services (Private) Limited. SIHL was incorporated in Pakistan on September 29, 1987 as a private limited company under the repealed Companies Ordinance, 1984 and converted into a public limited company on October 12, 1989. The shares of the Company are quoted on Pakistan Stock Exchange Limited. The registered office of the Company is situated at Sector H-8/4, Islamabad.

1.2 The principal activity of the SIHL is to establish and run medical centers and hospitals in Pakistan. The SIHL has established its first hospital in 1993 in H-8/4 Islamabad, second hospital in 2011 in Faisalabad and another in 2014 in G-10/4 Islamabad. The SIHL is also running medical center, pharmacies in Islamabad and franchise pharmacies and Lab collection points in different cities of Pakistan.

1.3 Shifa Consulting Services (Private) Limited (SCSPL) was incorporated on December 18, 2014. The principal activity of Shifa Consulting Services (Private) Limited is to provide consulting services relating to healthcare facilities, medical staff, availability of human resource and hospital quality.

During the year SIHL acquired remaining 40% shareholding from minority shareholders, previously SIHL held 60% shareholding in SCSPL now SCSPL becomes wholly owned subsidiary of SIHL. The Group recognized a decrease in NCI of Rs. 2,536 thousand and increase in retained earnings of Rs. 2,416 thousand attributable to the owners of the Group for changes in the Company’s ownership interest in Shifa Consulting Services (Private) Limited.

	(Rupees in '000')
Carrying amount of NCI acquired	2,536
Less: Consideration paid	120
	<u>2,416</u>

The auditors of SCSPL have given two emphasis of matters paragraphs on its separate financial statements to note 1.2 and 12 respectively which describe that during the current year ended June 30, 2017 Shifa Consulting Services (Pvt) Limited (SCSPL/the subsidiary) has earned a net profit of Rs. 0.31 million (June 2016: 14.57 million loss) showing a decrease in loss by Rs. 14.88 million and as of that date the cumulative losses have eroded the equity by Rs. 25.08 million (June 2016: 25.38 million) leaving a net equity of Rs. 4.92 million (June 2016: 4.62 million). Due to accumulated losses, the subsidiary is dependent on the financial assistance of its parent company. The Group management is confident that the Company has the potential to gradually develop its business and overcome the financial difficulties and during this phase the subsidiary has available full financial and technical support of its parent company. In view of the above, the going concern assumption is appropriate and has, as such, prepared SCSPL financial statements for the year ended June 30, 2017 on a going concern basis and the legal basis for non-recognition of sales tax recorded.

2 BASIS OF PREPARATION

2.1 Statement of compliance

During the year, the Companies Act 2017 (the Act) has been promulgated, however, Securities and Exchange Commission of Pakistan (SECP) vide its circular no. 17 of 2017 dated July 20, 2017 communicated Commission’s decision that the companies whose financial year closes on or before June 30, 2017 shall prepare their financial statements in accordance with the provisions of the repealed Companies Ordinance, 1984. Accordingly, these consolidated financial statements have been prepared in accordance with approved accounting standards as applicable in Pakistan. Approved accounting standards comprise of such International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and Islamic Financial Accounting Standards (IFAS) issued by the Institute of Chartered Accountants of Pakistan (ICAP) as are notified under the repealed Companies Ordinance, 1984, provisions of and directives issued under the repealed Companies Ordinance, 1984. In case requirements differ, the provisions or directives of the repealed Companies Ordinance, 1984 shall prevail.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

2.2 Basis of measurement

These consolidated financial statements have been prepared under the historical cost convention, modified by:-

- revaluation of certain items of property, plant and equipment; and
- recognition of certain employee benefits at present value.

2.3 Functional and presentation currency

These consolidated financial statements are presented in Pak Rupees, which is the Group's functional and presentation currency.

2.4 Use of estimates and judgments

The preparation of consolidated financial statements in conformity with approved accounting standards requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and underlying assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgment about carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which estimates are revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgments made by the management in the application of the approved accounting standards that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in the ensuing paragraphs.

2.4.1 Property, plant and equipment

The Group reviews the useful lives of property, plant and equipment on a regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of property, plant and equipment with a corresponding effect on the depreciation / amortization charge and impairment.

2.4.2 Intangibles

The Group reviews the useful lives of intangibles on regular basis. Any change in estimates in future years might affect the carrying amounts of the respective items of intangibles with the corresponding effect on the amortization charge and impairment.

2.4.3 Provision for doubtful debts

The Group estimates the recoverability of the trade debts and provides for doubtful debts based on its prior experience. The carrying amounts of trade debts and provision for doubtful debts are disclosed in note 17 to these financial statements.

2.4.4 Stock in trade, stores, spares and loose tools

The Group reviews the net realizable value of stock in trade, stores, spares and loose tools to assess any diminution in the respective carrying values. Net realizable value is determined with reference to estimated selling price less estimated expenditures to make the sale.

2.4.5 Employee benefits

The SIHL operates approved funded gratuity scheme covering all its employees who have completed the

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

minimum qualifying period of service as defined under the scheme. The gratuity scheme is managed by trustees. The calculation of the benefit requires assumptions to be made of future outcomes, the principal ones being in respect of increase in remuneration and the discount rate used to convert future cash flows to current values. The assumptions used for the plan are determined by independent actuary on annual basis.

The amount of the expected return on plan assets is calculated using the expected rate of return for the year and the market-related value at the beginning of the year. Gratuity cost primarily represents the increase in actuarial present value of the obligation for benefits earned on employee service during the year and the interest on the obligation in respect of employee service in previous years, net of the expected return on plan assets. Calculations are sensitive to changes in the underlying assumptions.

2.4.6 Compensated absence

The Group provides provision for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. The Group provides for its estimated liability towards leaves accumulated by employees on an accrual basis using current salary levels.

2.4.7 Taxation

The Group takes into account the current income tax law and decisions taken by appellate authorities. Instances where the Group's view differs from the view taken by the income tax department at the assessment stage and where the Group considers that its view on items of material nature is in accordance with law, the amounts are shown as contingent liabilities.

2.4.8 Contingencies

The Group has disclosed significant contingent liabilities for the pending litigations and claims against the Group based on its judgment and the advice of the legal advisors for the estimated financial outcome. The actual outcome of these litigations and claims can have an effect on the carrying amounts of the liabilities recognized at the balance sheet date. However, based on the best judgment of the Group and its legal advisors, the likely outcome of these litigations and claims is remote and there is no need to recognize any liability at the balance sheet date.

2.5 New accounting standards, interpretations and amendments

During the year certain amendments to standards or new interpretations became effective, however, the amendments or interpretations did not have any material effect on these financial statements.

The following revised standards and amendments and interpretations to the approved accounting standards, as applicable in Pakistan, would be effective from the dates mentioned below against the respective standard.

		Effective date (annual periods beginning on or after)
IAS 7	Statement of Cash flows	January 1, 2017
IAS 12	Income taxes - Recognition of deferred tax assets for unrealized losses - (Amendment)	January 1, 2017
IAS 40	Investment Property: Transfers of Investment Property (Amendments)	January 1, 2018
IFRS 2	Share based payments - Classification and measurement of share based payments transaction (Amendment)	January 1, 2018
IFRS 4	Insurance Contracts: Applying IFRS 9 Financial Instruments with IFRS 4 Insurance Contracts - (Amendments)	January 1, 2018

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

IFRS 7	Financial Instruments: Disclosures - Disclosure initiative (Amendments)	January 1, 2017
IFRS 10 & IAS 28	Sale or Contribution of assets between an investor and its associate or joint venture (Amendment)	Not yet Finalized
IFRIC 22	Foreign Currency Transactions and Advance Consideration	January 1, 2018
IFRIC 23	Uncertainty over Income Tax Treatments	January 1, 2019

The management anticipates that the adoption of the above standards, amendments and interpretations in future periods, will have no material impact on the consolidated financial statements other than the impact on presentation/disclosures. The Group is yet to assess the full impact of the amendments.

The Group has adopted the following applicable accounting standards, amendments and interpretations of IFRSs which became effective for the current year:

IFRS 10	Consolidated Financial Statements, IFRS 12 Disclosure of interests in Other Entities and IAS 27 Separate Financials Statements: Investment Entities: Applying the consolidation Exception (Amendment)
IFRS 11	Joint Arrangements: Accounting for Acquisition of Interest in Joint Operation (Amendment)
IAS 1	Presentation of Financial Statements - Disclosure Initiative (Amendments)
IAS 16	Property, Plant and Equipment and IAS 38 Intangible Assets - Clarification of acceptable method of depreciation and amortization (Amendments)
IAS-16	Property, Plant and Equipment and IAS 41 Agriculture - Agriculture: Bearer Plants (Amendment)
IAS-27	Separate Financial Statements - Equity method in separate financial statements (Amendments)

The adoption of above accounting standards did not have any effect on the financial statements.

Annual Improvements

IFRS 5	Non-current Assets Held for Sale and Discontinued Operations - Changes in method of disposal
IFRS 7	Financial Instruments: Disclosure - Serving contracts
IFRS 7	Financial Instruments: Disclosure - Applicability of the offsetting disclosures to condensed interim financial statements
IAS 19	Employees Benefits - Discount rate: regional market issue
IAS 34	Interim Financial Reporting - Disclosure of information 'elsewhere in the interim financial report'

The adoption of the above amendments, improvements to accounting standards and interpretations does not have any material effect on the financial statements.

Further, the following new standards and interpretations have been issued by the International Accounting Standards Board (IASB), which are yet to be notified by the Securities and Exchange Commission of Pakistan (SECP), for the purpose of their applicability in Pakistan:

IFRS 1	First-time adoption of International Financial Reporting standards
IFRS 9	Financial instruments
IFRS 14	Regulatory Deferral Accounts

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

IFRS 15 Revenue from Contracts with Customers

IFRS 16 Leases

IFRS 17 Insurance Contracts

3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

3.1 Basis of consolidation

These consolidated financial statements include the financial statements of Shifa International Hospitals Limited and its subsidiary company Shifa Consulting Services (Private) Limited (100% owned) for the year ended June 30, 2017 (June 30, 2016: 60% owned). The accounting policies used by the subsidiary company in preparation of their financial statements are consistent with that of the parent Company.

Subsidiaries

Subsidiaries are all entities over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are derecognized from the date the control ceases.

The Group uses the acquisition method of accounting to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities (including contingent liabilities) assumed in a business combination are measured initially at their fair values at the acquisition date. On an acquisition-by-acquisition basis, the Group recognises any non-controlling interest in the acquiree either at fair value or at the non-controlling interest's proportionate share of the acquiree's identifiable net assets.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date; any gains or losses arising from such remeasurement are recognised in consolidated profit and loss.

Any contingent consideration to be transferred by the Group is recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration that is deemed to be an asset or liability is recognised in accordance with IAS 39 either in consolidated profit and loss or as a change to consolidated statement of other comprehensive income. Contingent consideration that is classified as equity is not re-measured and its subsequent settlement is accounted for within equity.

Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

3.2 Property, plant and equipment

Property, plant and equipment except freehold, leasehold land and capital work-in-progress are stated at cost less accumulated depreciation/ amortization and impairment in value, if any. Leasehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent accumulated depreciation and impairment losses while freehold land is stated at revalued amount being the fair value at the date of revaluation, less any subsequent impairment losses, if any. Any revaluation increase arising on the revaluation of such assets is credited in 'Surplus on Revaluation of Property, Plant and Equipment'.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

A decrease in the carrying amount arising on revaluation is charged to consolidated profit and loss to the extent that it exceeds the balance, if any, held in the surplus on revaluation account relating to a previous revaluation of that asset. Leasehold land is amortized over the lease period extendable up to 99 years.

The surplus on revaluation of property, plant and equipment to the extent of incremental depreciation/amortization charged on the related asset is transferred to unappropriated profit.

Capital work-in-progress and stores held for capital expenditure are stated at cost less impairment loss recognized, if any. All expenditures connected with specific assets incurred during installation and construction period are carried under capital work-in-progress. These are transferred to specific items of property, plant and equipment when available for intended use.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance costs that do not meet the recognition criteria are charged to consolidated profit and loss account as and when incurred.

Depreciation/amortization is charged to consolidated profit and loss account commencing when the asset is ready for its intended use, applying the straight-line method over the estimated useful life.

In respect of additions and disposals during the year, depreciation/amortization is charged when the asset is available for use and up to the month preceding the asset's classification as held for sale or derecognized, whichever is earlier.

Assets are derecognized when disposed off or when no future economic benefits are expected to flow from its use. Gain and loss on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized on net basis within "other income" in consolidated profit and loss account.

3.3 Intangible

Intangible assets are stated at cost less accumulated amortization and impairment losses, if any. Subsequent cost on intangible assets is capitalized only when it increases the future economic benefits embodied in the specific assets to which it relates. All other expenditure is expensed as incurred.

Amortization is charged to the consolidated profit and loss account on a straight line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Amortization on additions to intangible assets is charged from the month in which an item is acquired or capitalized while no amortization is charged for the month in which the item is disposed off.

All intangible assets with an indefinite useful life are systematically tested for impairment at each reporting date. Where the carrying amount of an asset exceeds its estimated recoverable amount it is written down immediately to its recoverable amount. The carrying amount of other intangible assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists then the assets recoverable amount is estimated. The recoverable amount is the greater of its value and fair value less cost to sell. An impairment is recognized if the carrying amount exceeds its estimated recoverable amount.

3.4 Leases

Leases are classified as finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the Group. All other leases are classified as operating leases.

Finance leases as lessee

The Group recognizes finance leases as assets and liabilities in the balance sheet at amounts equal, at the inception of the lease, to the fair value of the asset or, if lower, at the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to similar owned assets. In calculating the present value of the minimum lease payments the discount factor used is the interest rate implicit in the lease. Initial direct costs incurred are included as part of the amount recognized as an asset. The liabilities are classified as current and long term depending upon the timing of payment.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

Lease payments are apportioned between the finance charge and the reduction of outstanding liability. The finance charge is allocated to periods during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Finance charges are charged directly to consolidated profit and loss account.

Operating leases/ljarah contracts

As lessor

Rental income from operating leases is recognized on straight-line basis over the term of the relevant lease.

As lessee

Rentals payable under operating leases/ljarah are charged to consolidated profit and loss account on straight-line basis over the term of relevant lease/ljarah.

3.5 Impairment

Non - Financial assets

The Group assesses at each balance sheet date whether there is any indication that assets except deferred tax assets and inventory may be impaired. If such indication exists, the carrying amounts of such assets are reviewed to assess whether they are recorded in excess of their recoverable amounts. Where carrying values exceed the respective recoverable amounts, assets are written down to their recoverable amounts and the resulting impairment loss is recognized in consolidated profit and loss account except for the impairment loss on revalued assets, which is adjusted against the related revaluation surplus to the extent that the impairment loss does not exceed the surplus on revaluation of that asset. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use.

Where impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised recoverable amount but limited to the extent of the carrying amount that would have been determined (net of depreciation/amortization) had no impairment loss been recognized for the asset in prior years. Reversal of impairment loss is recognized in consolidated profit and loss account.

Financial assets

Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired may include default or delinquency by a debtor, indications that a debtor or issuer will enter bankruptcy.

3.6 Investments

All purchases and sales of investments are recognized using settlement date accounting. Settlement date is the date on which that investments are delivered to or by the Group. All investments are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership.

3.6.1 Investments held to maturity

Investments with fixed or determinable payments and fixed maturity that the SIHL has the positive intent and ability to hold till maturity are classified as investment held to maturity. These are initially recognized at cost inclusive of transaction cost and are subsequently carried at amortized cost using the effective interest rate method less impairment loss, if any. This method uses an effective interest rate that exactly discounts estimated future cash receipts through the expected life of the investment to its net carrying amount.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

3.6.2 Loans and receivables

These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the balance sheet date, those are classified as non-current assets. The Group's loans and receivables comprise 'Advances, deposits and other receivables'.

3.7 Stores, spare parts and loose tools

These are valued at cost, determined on moving average cost basis or net realizable value, whichever is lower, less allowance for obsolete and slow moving items. For items which are slow moving or identified as surplus to the SIHL's requirement, a provision is made for excess of book value over estimated net realizable value. The Group reviews the carrying amount of stores, spare parts and loose tools on a regular basis and provision is made for obsolescence, if there is any change in usage pattern and physical form of related stores, spare parts and loose tools.

3.8 Stock-in-trade

Stock-in-trade is valued at lower of cost, determined on moving average basis or net realizable value. The cost includes expenditure incurred in acquiring the stock items and other cost incurred in bringing them to their present location and condition.

3.9 Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, cheques in hand, balances with banks and highly liquid short term investments that are readily convertible to known amounts of cash and which are subject to insignificant risk of change in value with maturity of three months or less from the date of acquisition and short term borrowings.

3.10 Financial instruments

Financial assets and liabilities are recognized when the Group becomes a party to the contractual provisions of the instrument. These are derecognized when the Group loses control of contracted rights that comprise the financial assets and in the case of financial liabilities when the obligation specified in the contract is discharged, cancelled or expired. Any gain or loss on derecognition of financial assets and financial liabilities is included in consolidated profit and loss account.

The particular recognition methods adopted by the Group are disclosed in the individual policy statements associated with each item of the financial instruments.

3.10.1 Trade debts and other receivables

Trade debts and other receivables are carried at original bill amount less an estimate made for doubtful receivables based on review of outstanding amounts at the year end. Balances considered bad and irrecoverable are written off against provision.

3.10.2 Trade and other payables

Liabilities for trade and other payables are measured at cost which is the fair value of the consideration to be paid in the future for goods and services received.

3.10.3 Offsetting

A financial asset and a financial liability is offset and the net amount is reported in the balance sheet, if the Group has a legal enforceable right to set-off the recognized amounts and intends either to settle on net basis or to realize the asset and settle the liability simultaneously.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

3.11 Employee benefits

Defined benefit plan

The SIHL operates approved funded gratuity scheme for all its employees who have completed the minimum qualifying period of service as defined under the respective scheme. Provision is made annually to cover obligations under the scheme on the basis of actuarial valuation and is charged to income. The most recent valuation was carried out as at June 30, 2017 using the "Projected Unit Credit Method". The actuarial gains or losses at each evaluation date are charged to consolidated statement of other comprehensive income. The results of actuarial valuation are summarized in note 9.5 of these financial statements.

The amount recognized in the balance sheet represents the present value of defined benefit obligations as reduced by the fair value of plan assets.

Calculation of gratuity requires assumptions to be made of future outcomes which mainly include increase in remuneration, expected long term return on plan assets and the discount rate used to convert future cash flows to current values. Calculations are sensitive to changes in the underlying assumptions.

Compensated absences

The Group provides for compensated absences of its employees on unavailed balance of leaves in the period in which the leave is earned. Accrual to cover the obligations is made using the current salary levels of the employees.

3.12 Provisions

Provisions are recognized when the Group has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount can be made. However, provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

3.13 Taxation

Taxation for the year comprises current and deferred tax. Taxation is recognized in the consolidated profit and loss account except to the extent that it relates to items recognized directly in equity or in consolidated statement of other comprehensive income.

Current

Provision for current taxation is based on taxable income at the current rates of tax after taking into account applicable tax credits, rebates, losses and exemptions available, if any.

Deferred

Deferred tax is accounted for using the balance sheet liability method in respect of all taxable temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are recognized for all taxable temporary differences and deferred tax assets are recognized to the extent that it is probable that taxable profits will be available against which the deductible temporary differences, unused tax losses and tax credits can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that is no longer probable that the related tax benefit will be realized.

Deferred tax is calculated at the rates that are expected to apply to the period when the differences reverse, based on tax rates that have been enacted. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets and they relate to income taxes levied by the same tax authority on the same taxable entity or on different tax entities but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

3.14 Foreign currencies

Transactions in currencies other than Pak Rupees are recorded at the rates of exchange prevailing on the dates of transactions. At each balance sheet date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rate prevailing on the balance sheet date. Gains and losses arising on retranslation are included in consolidated profit and loss account for the year.

3.15 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts received or receivable for goods and services provided in the normal course of business. Revenue is recognized in the accounting period in which the services are rendered and goods are delivered and it is probable that the economic benefits associated with the transactions will flow to the Group and the amount of the revenue can be measured reliably.

Interest income is accrued on time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount.

Rental income is recognized on a straight line basis over the term of the rent agreement.

Scrap sales and miscellaneous receipts are recognized on realized amounts.

3.16 Borrowings

Borrowings are recognized initially at fair value net off transaction cost incurred and are subsequently measured at amortized cost using the effective interest rate method. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of liability for at least twelve months after the balance sheet date.

3.17 Borrowing costs

Borrowing costs which are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of that asset. All other borrowing costs are charged to consolidated profit and loss account.

3.18 Earnings per share

The Group presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholder and weighted average number of ordinary shares outstanding for the effects of all potential ordinary shares.

3.19 Dividend

Dividend is recognized as a liability in the period in which it is declared.

3.20 Non-current assets held for sale

Non-current assets are classified as held for sale when their carrying amounts are expected to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount immediately prior to their classification as held for sale and fair value less cost to sell. Once classified as held for sale, the assets are not subject to depreciation or amortization. In case where classification criteria of non-current asset held for sale is no longer met such asset is classified on its carrying amount before the asset was classified as held for sale, adjusted for depreciation/revaluation that would have been recognized had the asset not been classified as held for sale. The required adjustment to the carrying amount of a non-current asset that ceases to be classified as held for sale is charged in consolidated profit and loss account.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

4 SHARE CAPITAL

Authorized capital

This represents 54,537,900 (2016: 54,537,900) ordinary shares of Rs. 10 each amounting to Rs. 545,379 thousand (2016: Rs. 545,379 thousand).

Issued, subscribed and paid up capital

2017	2016		2017	2016
Number			(Rupees in '000')	
54,537,900	50,513,800	Opening balance: Ordinary shares of Rs. 10 each	545,379	505,138
-	4,024,100	Addition: Right issue of ordinary shares of Rs. 10 each	-	40,241
<u>54,537,900</u>	<u>54,537,900</u>	Closing balance: Ordinary shares of Rs. 10 each fully paid in cash	<u>545,379</u>	<u>545,379</u>

4.1 The SIHL has only one class of ordinary shares which carries no right to fixed income. The shareholders are entitled to receive dividend as declared from time to time and are entitled to one vote per share at meetings of the SIHL. All shares rank equally with regard to the Company's residual assets.

4.2 The SIHL has no reserved shares for issuance under options and sales contracts.

5 CAPITAL RESERVE

This represents premium of Rs. 5 and Rs. 250 per share received on public issue of 8,000,000 and 4,024,100 ordinary shares of SIHL of Rs.10 each in 1994 and 2016 respectively. This reserve cannot be utilized except for the purposes mentioned under section 81 of the Companies Act, 2017.

6 SURPLUS ON REVALUATION OF PROPERTY, PLANT AND EQUIPMENT

	2017	2016
	(Rupees in '000')	
Balance at beginning of year	742,191	751,182
Realization of revaluation surplus on disposal of assets	(6,441)	-
Transferred to unappropriated profits in respect of incremental depreciation charged during the year	(8,990)	(8,991)
Balance at end of year	<u>726,760</u>	<u>742,191</u>

6.1 SIHL has Surplus on revaluation of fixed assets in respect of leasehold and freehold land, which were revalued in 1999, 2004, 2009 and 2014 as disclosed in note 12.1, cannot be utilized directly or indirectly by way of dividend or bonus. As the surplus on revaluation is on leasehold and freehold land, the incidence of related deferred tax does not arise.

7 LONG TERM FINANCING-SECURED

	2017	2016
	(Rupees in '000')	
From banking companies:		
Syndicated Islamic Finance Facility	7.2 500,000	833,333
Diminishing Musharakah Facility	7.3 3,992	6,332
	<u>503,992</u>	<u>839,665</u>
Less: Current portion	335,764	335,674
	<u>168,228</u>	<u>503,991</u>

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	As at July 1, 2015	Profit and Loss	Other Comprehensive Income	As at June 30, 2016
	----- (Rupees in '000') -----			
Deferred tax liabilities / (assets)				
The balance of deferred tax is in respect of the following temporary differences:				
Effect of taxable temporary differences				
Accelerated depreciation allowance	497,566	(17,232)	-	480,334
Effect of deductible temporary differences				
Provision for doubtful debts	(9,082)	(16,546)	-	(25,628)
Retirement benefit obligation	(31,084)	23,189	(23,205)	(31,100)
	<u>457,400</u>	<u>(10,589)</u>	<u>(23,205)</u>	<u>423,606</u>

	Note	2017 (Rupees in '000')	2016
9 TRADE AND OTHER PAYABLES			
Creditors		740,612	568,706
Accrued liabilities	9.1	342,545	258,335
Advances from customers		199,926	85,111
Medical consultants' charges		376,156	329,544
Payable to related parties - unsecured	9.2	28,285	6,289
Security deposits	9.3	109,332	85,875
Compensated absences	9.4	90,189	84,736
Unclaimed dividend		27,052	42,724
Retention money		10,479	11,911
Payable to Shifa International Hospitals Limited (SIHL) Employees' Gratuity Fund	9.5	35,308	35,113
		<u>1,959,884</u>	<u>1,508,344</u>

9.1 During the current financial year the subsidiary rendered consultancy services to SIHL, which is a teaching hospital. The management of subsidiary is of the opinion that the principal of exemption under the Sales Tax Act 1990 available to goods supplied to a teaching hospital is equally applicable to services rendered to a teaching hospital under the Islamabad Capital Territory (Tax on Services) Ordinance 2001 because the provisions of Sales tax Act 1990 are mutatis mutandis applicable. This opinion of the management is confirmed by the tax advisor of the subsidiary due to which no sales tax liability in respect of the referred services has been recorded in these consolidated financial statements. Had these services been chargeable a tax liability of Rs. 2.48 million would have been recorded.

9.2 This represents payable to Tameer-e-Millat Foundation, Shifa Foundation and Shifa Tameer-e-Millat University having common directorship with the Group. Maximum amount due at the end of any month during the year was Rs. 6,076 thousand (2016: 4,138 thousand), Rs. Nil (2016: 4,042 thousand) and Rs. 22,949 thousand (2016: 6,053 thousand) respectively. Detail of balances of each related party is as under:

	2017 (Rupees in '000')	2016
Tameer-e-Millat Foundation	5,336	3,923
Shifa Foundation	-	709
Shifa Tameer-e-Millat University	22,949	1,657
	<u>28,285</u>	<u>6,289</u>

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

9.3 This represents customers' and employees' security deposits that are repayable on termination of respective agreements.

	Note	2017	2016
		(Rupees in '000')	
9.4 Compensated absences			
Balance at beginning of the year		84,736	66,243
Provision made for the year		34,565	44,902
		119,301	111,145
Payment made during the year		(29,112)	(26,409)
Closing balance as at year end		90,189	84,736
9.5 The amounts recognized in the balance sheet are as follows:			
Present value of defined benefit obligations	9.5.1	424,984	373,317
Fair value of plan assets	9.5.2	(389,676)	(338,204)
		35,308	35,113
9.5.1 Movement in the present value of funded obligation is as follows:			
Present value of defined benefit obligation at beginning		373,317	298,538
Interest cost		25,324	26,627
Current service cost		82,427	62,265
Past service cost		-	(18,192)
Benefits paid		(47,343)	(48,995)
Benefits payable		(710)	(1,882)
Non refundable loan to employees adjustable against gratuity		(2,540)	(1,399)
Remeasurement (gain)/loss on defined benefit obligation		(5,491)	56,355
Present value of defined benefit obligation at year end		424,984	373,317
9.5.2 Movement in the fair value of plan assets is as follows:			
Fair value of plan assets at beginning		338,204	266,510
Expected return on plan assets		25,559	29,122
Contributions		76,017	113,347
Benefits paid		(47,343)	(48,995)
Benefits payable		(710)	(1,882)
Non refundable loan to employees adjustable against gratuity		(2,540)	(1,399)
Remeasurement gain/(loss) on plan assets		489	(18,499)
Fair value of plan assets at year end		389,676	338,204
9.5.3 Charge for the year is as follows:			
Current service cost		82,427	62,265
Past service cost		-	(18,192)
Interest cost		25,324	26,627
Expected return on plan assets		(25,559)	(29,122)
		82,192	41,578
9.5.4 Remeasurements recognized in other comprehensive income (OCI) during the year			
Remeasurement (income)/loss on obligation		(5,491)	56,355
Remeasurement (income)/loss on plan assets		(489)	18,499
Remeasurement (income)/loss recognized in OCI		(5,980)	74,854

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	2017	2016
	(Rupees in '000')	
9.5.5 Movement in liability recognized in balance sheet:		
Balance at beginning of year	35,113	32,304
Cost for the year	82,192	41,578
Total amount of remeasurement recognized in OCI during the year	(5,980)	74,854
Contributions during the year	(76,017)	(113,347)
Other adjustment	-	(276)
Balance at end of year	35,308	35,113
9.5.6 Plan assets comprise of:		
Accrued mark up	2,947	1,997
Term deposit receipts	231,000	231,000
Cash and bank balances	158,321	107,089
Payable to outgoing members	(2,592)	(1,882)
	389,676	338,204

9.5.7 The principal actuarial assumptions used in the actuarial valuation are as follows:

	2017	2016
Discount rate used for interest cost in profit and loss	7.25%	9.75%
Discount rate used for year end obligation	7.75%	7.25%
Expected rate of salary growth		
Salary increase FY 2017	N/A	6.25%
Salary increase FY 2018 onward	6.75%	6.25%
Mortality rate	SLIC 2001-2005 set back 1 year	SLIC 2001-2005 set back 1 year
Withdrawal rates	age based	age based
Retirement assumption	Age 60	Age 60

9.5.8 Sensitivity analysis

The calculation of the defined benefit obligation is sensitive to assumptions set out above. The following table summarizes how the impact on the defined benefit obligation at the end of the reporting period would have increased/decreased as a result of a change in respective assumptions by one percent.

	Defined benefit obligation	
	Effect of 1% increase	Effect of 1% decrease
	(Rupees in '000')	
Discount rate	395,473	459,282
Future salary increase	459,951	394,338

9.5.9 The average duration of the defined benefit obligation as at June 30, 2017 is 8 years (2016: 7 years).

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

10 MARKUP ACCRUED

This represents markup accrued on long term financing.

	2017	2016
Note	(Rupees in '000')	

11 CONTINGENCIES AND COMMITMENTS

11.1 Contingencies

Claims against the SIHL not acknowledged as debts:

Patients	11.1.1	111,000	111,000
Others	11.1.2	20,000	20,000
Letter of guarantee	11.1.3	34,600	34,600

11.1.1 This represents claims lodged by patients and their heirs against SIHL for alleged negligence on part of the consultants/doctors. The management is contesting the claims which are pending in courts and believes that the contention of the claimants will not be successful and no material liability is likely to arise.

11.1.2 This represents the penalty imposed by Competition Commission of Pakistan to each Gulf Cooperation Council's (GCC) Approved Medical Centers (GAMCs) including SIHL on account of alleged non-competitive practice/B363 arrangement of territorial division and equal allocation of GAMCs customers. Management of the Company and other GAMCs are jointly contesting the matter and firmly believe that the case will be decided in favor of the GAMCs including SIHL.

11.1.3 This represents letters of guarantees issued by bank in favor of Sui Northern Gas Pipelines Limited (SNGPL) and Ministry of Economy U.A.E. in ordinary course of SIHL's business.

11.1.4 The Assistant Commissioner inland Revenue under section 221 of the Income Tax Ordinance, 2001 has amended the SIHL's assessment for a tax year 2014 which resulted a tax demand of Rs. 11.77 million. Being aggrieved, the SIHL has filed an appeal before the Commissioner Inland Revenue which is pending adjudication. The SIHL is confident for a favorable outcome and therefore, no provision in respect of this matter has been recorded in these consolidated financial statements.

11.1.5 During the year Deputy Commissioner Inland Revenue (DCIR) concluded an ex-party assessment against the subsidiary Company under the Islamabad Capital Territory (Tax on services) Ordinance 2001 (the Ordinance) and charged sales tax on the entire receipts of the subsidiary for tax year 2016 representing consulting income. The above assessment results in a demand of Rs. 2.48 million against which a provision of Rs. 2 million has been recorded. The subsidiary intends to pay the balance amount of Rs. 0.66 million considering that the tax authorities have recovered Rs 1.35 million from the bank accounts. The un-provided balance represents a calculation error and management of the subsidiary intends to file a rectification application with the DCIR for correction of the same while also challenging the error in appeal before the Commissioner Inland Revenue.

	2017	2016
	(Rupees in '000')	

11.2 Commitments

11.2.1 Capital expenditure contracted	96,548	282,614
11.2.2 Letters of credit	59,055	22,333

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

12. PROPERTY, PLANT AND EQUIPMENT

Particulars	Owned assets										Capital work-in-progress (note 12.6)	Total	
	Freehold land	Leasehold land	Building on leasehold land	Leasehold improvements	Biomedical equipment	Air conditioning equipment and machinery	Electrical and other equipment	Furniture and fittings	Construction equipment	Computer installations			Vehicles
Cost/Revalued amount	(Rupees in 000)												
Balance as at July 01, 2015	257,350	960,959	1,930,894	-	2,269,693	186,098	372,971	123,382	8,671	216,520	100,076	54,515	6,481,129
Additions	66,402	-	-	-	290,421	40,796	40,196	17,067	-	37,557	17,320	29,975	539,734
Disposals	-	-	-	-	(13,860)	-	(3,024)	-	-	(263)	(2,844)	-	(19,991)
Write offs	-	-	(221)	-	(5,130)	-	(49)	(214)	-	(789)	-	-	(6,403)
Transfer	-	-	29,245	-	-	-	-	-	-	-	-	(29,245)	-
Balance as at June 30, 2016	323,752	960,959	1,959,918	-	2,541,124	226,894	410,094	140,235	8,671	253,025	114,552	55,245	6,994,469
Balance as at July 01, 2016	323,752	960,959	1,959,918	-	2,541,124	226,894	410,094	140,235	8,671	253,025	114,552	55,245	6,994,469
Additions	565,777	-	-	-	387,034	20,969	34,015	25,353	830	62,097	7,320	246,552	1,349,947
Disposals	(22,010)	-	-	-	(81)	-	(470)	-	(7,614)	(266)	(7,247)	-	(37,688)
Write offs	-	-	(29,479)	-	(2,377)	-	-	(185)	-	(436)	-	-	(32,477)
Transfers	-	-	102,941	35,295	-	-	-	-	-	-	-	(138,236)	-
Balance at June 30, 2017	867,519	960,959	2,033,380	35,295	2,925,700	247,863	443,639	165,403	1,887	314,420	114,625	163,561	8,274,251
Depreciation/amortization													
Balance as at July 01, 2015	-	12,987	401,385	-	1,003,487	114,500	208,667	54,567	8,639	120,695	67,983	-	1,992,909
Charge for the year	-	18,671	61,272	-	208,606	15,376	41,957	11,084	9	45,158	13,619	-	415,752
On disposals	-	-	-	-	(13,860)	-	(3,024)	-	-	(174)	(2,095)	-	(19,152)
On write offs	-	-	(221)	-	(3,800)	-	(42)	(160)	-	(766)	-	-	(4,989)
Balance as at June 30, 2016	-	31,658	462,436	-	1,194,433	129,876	247,558	65,491	8,648	164,913	79,507	-	2,384,520
Balance as at July 01, 2016	-	31,658	462,436	-	1,194,433	129,876	247,558	65,491	8,648	164,913	79,507	-	2,384,520
Charge for the year	-	18,671	59,180	3,951	240,925	18,556	44,349	13,010	23	53,434	11,621	-	463,720
On disposals	-	-	-	-	(53)	-	(25)	-	(7,614)	(124)	(5,146)	-	(12,962)
On write offs	-	-	(17,736)	-	(978)	-	-	(138)	-	(436)	-	-	(19,288)
Balance at June 30, 2017	-	50,329	503,880	3,951	1,434,327	148,432	291,882	78,363	1,057	217,787	85,982	-	2,815,990
Carrying value as at June 30, 2016	323,752	929,301	1,497,482	-	1,346,691	97,018	162,536	74,744	23	88,112	35,045	55,245	4,609,949
Carrying value as at June 30, 2017	867,519	910,630	1,529,500	31,344	1,491,373	99,431	151,757	87,040	830	96,633	28,643	163,561	5,458,261
Annual rate of depreciation %	-	1.34-3.03	2.5-10	20	10	10-15	10-15	10	10-20	25	20	-	-

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

- 12.1** SIHL had its leasehold land revalued in 1999, 2004, 2009 and 2014 and freehold land in 2009 and 2014 by independent valuers, using fair market value. These revaluations resulted in net surplus of Rs. 180,873 thousand, Rs. 63,891 thousand, Rs. 392,360 thousand and Rs. 184,284 thousand respectively. The revaluation surplus amounting to Rs. 821,408 thousand has been included in the carrying value of the respective assets. Out of the revaluation surplus, an amount of Rs. 726,760 thousand (2016: Rs. 742,191 thousand) remains undepreciated as at June 30, 2017.

Had there been no revaluation the carrying value would have been as under:

	Cost at June 30	Accumulated amortization at June 30	Carrying value at June 30
	(Rupees in '000')		
Leasehold land			
2017	325,065	52,755	272,310
2016	325,065	43,074	281,991
Freehold land			
2017	779,078	-	779,078
2016	228,870	-	228,870

- 12.2** Property, plant and equipment include items with aggregate cost of Rs. 843,756 thousand (2016: Rs. 639,721 thousand) representing fully depreciated assets that are still in use of SIHL.

- 12.3** Property, plant and equipment of SIHL are encumbered under an aggregate charge of Rs. 3,014.67 million (2016: Rs. 3,064.67 million) in favor of banking companies under various financing arrangements as disclosed in notes 7, 11.2.2 and 30.

- 12.4** The depreciation/amortization charge for the year has been allocated as follows:

		2017	2016
	Note	(Rupees in '000')	
Operating costs	25	463,713	415,746
Capital work-in-progress		7	6
		463,720	415,752

- 12.5** Detail of property, plant and equipment disposed off during the year, having carrying value of more than fifty thousand rupees:

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

Sr. No.	Asset Particulars	Cost	Carrying Value	Sale Proceed	Purchaser	Mode of Disposal
(Rupees in '000')						
1	Freehold land	11,005	11,005	13,800	Dr. Saeed Zameer	Negotiation
2	Freehold land	11,005	11,005	13,800	Mr. Abdul Wahid	Negotiation
3	Honda City	276	161	276	Mr. Afzaal Ahmed	As per Group policy
4	Honda City	252	75	254	Mr. Wazir Muhammad	As per Group policy
5	Honda City	271	140	270	Mr. Malik M. Uzair	As per Group policy
6	Honda Civic	2,021	1,650	1,010	Mr. Sohail Ahmed Siddiqi	As per Group policy
7	Laptop	84	63	65	Mr. Wazir Muhammad	As per Group policy
		24,914	24,099	29,475		
	Other assets having carrying value less than 50,000 rupees	12,774	627	5,918		
2017		37,688	24,726	35,393		
2016		19,991	838	3,162		

12.6 Capital work-in-progress

Construction work-in-progress
Stores held for capital expenditure
Installation of equipment in progress

Note	2017	2016
	(Rupees in '000')	
12.6.1	68,932	-
12.6.2	47,286	49,998
12.6.3	47,343	5,247
	163,561	55,245

12.6.1 Construction work-in-progress

This was cost of civil works mainly comprising of cost of materials, payments to contractors, salaries and benefits pertaining to different blocks of hospital building in H-8/4 and F-11 Hospital. Given below was the break-up of civil works:

Block "C"
F-11 Hospital
Other constructions

Note	2017	2016
	(Rupees in '000')	
	21,939	-
	35,334	-
	11,659	-
	68,932	-

12.6.2 Stores held for capital expenditure

Stores held for capital expenditure
Less: provision for slow moving items

12.6.2.1	50,365	53,105
	3,079	3,107
	47,286	49,998

12.6.2.1 Balance at beginning of the year
(Reversed)/charged during the year
Balance at the end of the year

	3,107	2,657
	(28)	450
	3,079	3,107

12.6.3 Installation of equipment in progress

Mobile C-Arm
Steam Sterilizer
Auto Washer Disinfector
Plasma Sterilizer
Fire Doors

	-	5,247
	7,000	-
	6,116	-
	10,853	-
	23,374	-
	47,343	5,247

13 INTANGIBLE

This represents the cost of Oracle financials software being capitalized during the current year. Amortization of intangible for the year has been charged to operating costs at a rate of 25% (2016: Nil).

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
14 LONG TERM DEPOSITS			
ljarah key money deposits	14.1	6,844	4,009
Less: current portion of ljarah key money deposits	19	3,300	304
		3,544	3,705
Security deposits	14.2	41,729	36,282
		45,273	39,987
14.1	This represents ljarah key money deposits adjustable on expiry of respective ljarah financing arrangements against transfer of titles of relevant assets.		
14.2	This represents security deposits given by SIHL to various institutions/persons and are generally refundable on termination of relevant services / arrangements.		

	Note	2017 (Rupees in '000')	2016
15 STORES, SPARE PARTS AND LOOSE TOOLS			
Stores		76,107	64,234
Spare parts		20,391	19,748
Loose tools		202	638
		96,700	84,620
Less: provision for slow moving items	15.1	15,505	20,027
		81,195	64,593
15.1	Balance at beginning of year (Reversed) / charged for the year Balance at the end of year		
		20,027	16,078
		(4,522)	3,949
		15,505	20,027

16 STOCK-IN-TRADE

This represents medicines being carried at moving average cost.

17 TRADE DEBTS - CONSIDERED GOOD

Considered good			
Related party - Shifa Foundation	17.1	12,979	9,020
Others		437,077	336,475
Considered doubtful			
Others		55,078	47,559
Considered bad			
Others		33,630	-
		538,764	393,054
Less: provision for doubtful debts	17.2 & 35.1.3	55,078	47,559
Bad debts written off	35.1.3	33,630	-
		450,056	345,495

17.1 Maximum amount due to SIHL from Shifa Foundation at the end of any month during the year was Rs. 29,327 thousand (2016: Rs. 24,406 thousand).

17.2 Trade debts are provided on estimated irrecoverable amounts, on the basis of past experience of the management of the Group.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
18 LOANS AND ADVANCES - CONSIDERED GOOD			
Considered good - unsecured			
Executives	18.1	10,709	11,556
Other employees		27,034	27,890
		37,743	39,446
Consultants		9,911	13,836
Suppliers		291,974	104,298
		339,628	157,580
18.1 Reconciliation of carrying amount of advances given to executives:			
Balance at beginning of year		11,556	5,555
Disbursements during the year		41,311	40,871
		52,867	46,426
Less: Repayments during the year		42,158	34,870
Balance at end of year		10,709	11,556

The above advances were given in accordance with the Group's service rules. The maximum amount due from executives at the end of any month during the year was Rs. 12,945 thousand (2016: Rs. 13,612 thousand).

19 TRADE DEPOSITS, SHORT TERM PREPAYMENTS AND OTHER RECEIVABLES

	Note	2017 (Rupees in '000')	2016
Current portion of Ijarah key money deposits	14	3,300	304
Other deposits		2,560	2,560
Short term prepayments		14,011	16,552
Other receivables		19,463	-
		39,334	19,416
20 OTHER FINANCIAL ASSETS (Held to Maturity Investment)			
Meezan Bank Limited	20.1	-	75,222
Faysal Bank Limited	20.2	89,022	89,068
Al Baraka Bank (Pakistan) Limited	20.3	-	780,006
JS Bank Limited	20.4	-	101,460
Dubai Islamic Bank Limited	20.5	50,238	50,485
MCB Islamic Bank	20.6	50,191	-
		189,451	1,096,241

20.1 This represented term deposit receipt (TDR) having face value of Rs. 75 million with three month maturity, encashed on March 08, 2017. TDR carried an effective interest rate of 4.69% per annum.

20.2 This represents three TDRs having face value of Rs. 50 million, Rs. 25 million and Rs. 13 million with three month maturity (2016: three TDRs having face value of Rs. 50 million, Rs. 25 million and Rs. 13 million) due on July 10, 2017, August 02, 2017 and August 02, 2017 respectively. These TDRs carry an effective interest rate ranging from 5.4% to 6.1% per annum respectively (2016: 5.5% and 6.15 % per annum).

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

- 20.3** This represented five TDRs having face value of Rs. 200 million, Rs. 200 million, Rs. 200 million, Rs. 102 million and Rs. 75 million respectively with three month maturity. These TDRs were encashed during the year. These TDRs carried effective profit rate ranging from 4.7% to 6.4% per annum (2016: 5% to 6.4% per annum).
- 20.4** This represented TDR having face value of Rs. 100 million with three month maturity, encashed on July 08, 2016 with effective interest rate of 6.5% per annum.(2016: 6.5% per annum).
- 20.5** This represents TDR having face value of Rs. 50 million (2016: Rs. 50.32 million) with three month maturity, due on August 30, 2017 carrying effective interest rate of 5.5% (2016: 5.35%) per annum.
- 20.6** This represents TDR having face value of Rs. 50 million (2016: Nil) with six month maturity, due on November 30, 2017 carrying effective interest rate of 5.06% (2016: Nil) per annum.

		2017	2016
	Note	(Rupees in '000')	
21 TAX REFUNDS DUE FROM THE GOVERNMENT (NET OF PROVISION)			
Balance at beginning of year		25,737	52,154
Income tax paid / deducted at source during the year		341,962	264,259
		367,699	316,413
Provision for taxation for the year	27	(270,156)	(290,676)
Balance at end of year		97,543	25,737
22 CASH AND BANK BALANCES			
Cash at banks in:			
Current accounts:			
Local currency		63,536	71,585
Foreign currency		4,333	3,466
		67,869	75,051
Saving accounts:			
Local currency		565,546	400,400
Foreign currency		587	47
	22.1	566,133	400,447
	22.2	634,002	475,498
Cash in hand		9,133	11,203
		643,135	486,701

22.1 These carry effective profit rates ranging from 1.79% - 4.9% and 0.1% (2016: 2.4% - 6% and 0.1%) per annum in respect of local and foreign currency accounts respectively.

22.2 Balances with banks include Rs. 109,332 thousand (2016: Rs. 85,875 thousand) in respect of security deposits (note 9.3).

		2017	2016
	Note	(Rupees in '000')	
23 NET REVENUE			
Inpatients		3,899,266	3,677,215
Outpatients		2,077,565	2,154,542
Pharmacy	23.1	3,025,970	2,657,462
Cafeteria		312,703	261,084
Rent of building	23.2	19,655	31,593
Other services		8,290	45,371
		9,343,449	8,827,267
Less: discount		81,086	83,209
Net revenue		9,262,363	8,744,058

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

23.1 This includes revenue of Rs. 315,066 thousand (2016: Rs. 124,822 thousand) from external pharmacy outlets.

23.2 This mainly includes rental income on operating leases to related parties.

24 OTHER INCOME	Note	2017 (Rupees in '000')	2016
Income from financial assets:			
Profit on investments and bank deposits		58,130	37,314
Income from other than financial assets:			
Gain on disposal of property, plant and equipment		10,667	2,324
Liabilities written back		7,362	2,301
Sale of scrap		10,399	7,351
Miscellaneous	24.1	49,293	36,873
		135,851	86,163

24.1 This mainly includes sale of Shifa News (magazine of Shifa Publications) and related advertisement income from Shifa News.

25 OPERATING COSTS	Note	2017 (Rupees in '000')	2016
Salaries, wages and benefits	25.1	3,396,068	3,071,527
Utilities		294,355	292,955
Supplies consumed		1,161,211	1,018,454
Medicines		2,225,568	1,970,891
Communication		26,778	23,133
Travelling and conveyance		22,142	24,769
Printing and stationery		70,121	57,826
Repairs and maintenance		349,389	373,955
Auditors' remuneration	25.2	2,500	2,497
Legal and professional		15,819	14,979
Rent		132,563	99,622
Rates and taxes		6,316	59,851
Advertising and sales promotion		39,338	35,445
Fee, subscription and membership		15,356	38,421
Vehicle and equipment rentals	25.3	7,775	7,612
Cleaning and washing		77,538	62,387
Insurance		12,399	11,451
Property, plant and equipment written off	25.4	13,189	1,414
Provision for doubtful debts		41,149	19,179
Provision for slow moving stores		(4,550)	4,399
Depreciation/amortization	12.4	463,713	415,746
Amortization intangible	13	225	-
Donation	25.5	52,400	50,000
Other expenses		47,245	37,679
		8,468,607	7,694,192

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

- 25.1** This includes employee retirement benefits (gratuity) of Rs. 82,192 thousand (2016: Rs. 41,578 thousand), expense for compensated absences of Rs. 34,565 thousand (2016: Rs. 44,902 thousand) and provision for bonus to employees of Rs. 147,375 thousand (2016: Rs. 140,856 thousand).

	2017	2016
	(Rupees in '000')	
25.2 Auditors' remuneration		
Annual audit fee	1,517	1,515
Half yearly review fee	633	635
Other certifications	350	201
Out of pocket expenses	-	146
	<u>2,500</u>	<u>2,497</u>

- 25.3** This includes ujarah payments under an Ijarah. As required under Islamic Financial Accounting Standard (IFAS 2) "Ijarah" (notified through SRO 431 (I)/2007 by Securities & Exchange Commission of Pakistan) ujarah payments under an Ijarah are recognized as an expense in the consolidated profit and loss account on straight line basis over the Ijarah term.

The amounts of future ujarah payments and the periods in which these will be due are as follows:

	2017	2016
	(Rupees in '000')	
Within one year	6,987	5,986
After one year but not more than five years	7,412	3,134
Total ujarah payments	<u>14,399</u>	<u>9,120</u>

- 25.4** This mainly includes the written down value of store building of SIHL, which has been demolished during the current year. While the balance represents assets written off that were determined to be irreparable after carrying out detailed physical verification exercise by the management.

	2017	2016
	(Rupees in '000')	
25.5 Donation		
Shifa Foundation	2,400	-
Shifa Tameer-e-Millat University (STMU)	50,000	50,000
	<u>52,400</u>	<u>50,000</u>

Shifa Foundation and Shifa Tameer-e-Millat University (STMU) are related parties due to common directorship and related information is as under:

Name of common directors	Interest in donee	Name & address of the donee
Dr. Manzoor H. Qazi	Director	Shifa Foundation and STMU, H-8/4, Islamabad
Dr. Habib ur Rahman	Director	Shifa Foundation and STMU, H-8/4, Islamabad
Dr. Mohammad Salim Khan	Director	Shifa Foundation, H-8/4, Islamabad
Mr. Muhammad Zahid	Director	Shifa Foundation, H-8/4, Islamabad
Dr. Samea Kauser Ahmad	Director	STMU, H-8/4, Islamabad

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
26 FINANCE COSTS			
Markup on:			
Long term loans		50,418	82,235
Running finance and murabaha facilities		267	159
Credit card payment collection charges		14,594	12,340
Loss on foreign currency translation		419	493
Bank charges and commission		692	13,771
		66,390	108,998
27 PROVISION FOR TAXATION			
Current			
- for the year		259,553	313,865
- Prior year		10,603	(23,189)
	21	270,156	290,676
Deferred		(11,754)	(10,589)
		258,402	280,087
27.1 Reconciliation of tax charge for the year			
Profit before taxation		863,217	1,027,031
Applicable tax rate		31%	32%
Additional tax		3%	3%
Total		34%	35%
Add: Tax effect of amounts taxed at lower rates/others		20%	10%
Less: Net tax effect of amounts that are deductible for tax purposes		24%	18%
Average effective tax rate charged on income		30%	27%
28 EARNINGS PER SHARE - BASIC AND DILUTED			
Profit after taxation for the year		604,920	751,978
			(Number of shares in '000')
Weighted average number of ordinary shares in issue during the year	4	54,538	51,781
			(Rupees)
Earnings per share - basic and diluted		11.09	14.52

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

28.1 There is no dilutive effect on the basic earnings per share.

28.2 The corresponding weighted average number of ordinary shares were adjusted for a right issue fully subscribed and allotted during the last quarter of the previous financial year.

29 CAPACITY UTILIZATION

The actual inpatient available bed days, occupied bed days and room occupancy ratio of Shifa International Hospitals Limited (SIHL) are given below:

	2017	2016	2017	2016	2017	2016
	Available bed days		Occupied bed days		Occupancy Ratio	
SIHL H-8/4 Islamabad	162,356	166,579	113,927	118,698	70.17%	71.26%
SIHL G-10/4 Islamabad	8,110	8,110	3,050	2,795	37.61%	34.46%
SIHL Faisalabad	16,514	15,330	5,095	4,596	30.85%	29.98%

29.1 The under utilization reflects the pattern of patient turnover which is beyond the management's control.

30 UNAVAILED CREDIT FACILITIES

Unavailed credit facilities at year end are as under:

	2017	2016
	(Rupees in '000')	
Running/Murabaha financing	124,055	136,900
Letter of credit	50,000	84,709
Ijarah financing	1,935	10,000
	175,990	231,609

31 NUMBER OF EMPLOYEES

The Group had 4,585 employees (2016: 4,471) at the year end and average number of employees during the year were 4,524 (2016: 4,328).

32 RELATED PARTIES TRANSACTIONS

The related parties comprise of directors, major shareholders, key management personnel, SIHL Employees' Gratuity Fund and the entities over which directors are able to exercise influence. The amounts due from and due to these undertakings are shown under trade debts, loans and advances and trade and other payables. Other transactions with the related parties are given below:

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

	Note	2017 (Rupees in '000')	2016
Shifa Foundation: (Related party by virtue of common directorship)			
Revenue from services earned by the SIHL	32.1	113,702	66,353
Revenue from rent earned by the SIHL		44	44
Expenses paid by and reimbursed to the SIHL		3,508	-
Other services provided to the SIHL	32.2	15,840	15,840
Donation given by the SIHL		2,400	-
Tameer-e-Millat Foundation: (Related party by virtue of common directorship)			
Revenue from services earned by the SIHL	32.1	-	19
Revenue from rent earned by the SIHL		311	177
Other supplies provided to the SIHL		21,301	16,631
Other services provided to the SIHL	32.2	5,515	6,121
Expenses paid by and reimbursed to the SIHL		169	-
Rent paid by the SIHL		5,060	2,192
SIHL Employees' Gratuity Fund			
Payments made by the SIHL during the year		76,017	113,347
Shifa Tameer-e-Millat University: (Related party by virtue of common directorship)			
Revenue from services earned by the SIHL	32.1	26,865	27,928
Revenue from rent earned by the SIHL		13,613	24,494
Other services provided to the SIHL	32.2	24,066	17,209
Expenses paid by and reimbursed to the SIHL		14,291	25,537
Other supplies provided to the SIHL		-	1,300
Donation given by the SIHL		50,000	50,000
Remuneration including benefits and perquisites of key management personnel			
	32.3	283,382	240,486

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

- 32.1** Revenue earned from related parties includes medical, surgical, clinical and lab services rendered to referred inpatients and outpatients, sale of medicines and provision of cafeteria services. These transactions are based on commercial terms which are approved by the Board of Directors.
- 32.2** Other services are received by the SIHL for nursing education/training, employees' children education and consultancy services. These transactions are based on commercial terms which are approved by the Board of Directors.
- 32.3** Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the SIHL, including directors of the Company. There were no transactions with the key management personnel during the year other than their terms of employment/entitlements.

33 REMUNERATION OF CHIEF EXECUTIVES, DIRECTORS AND EXECUTIVES

The aggregate amount charged in these financial statements in respect of remuneration and allowances, including all benefits, to chief executives, directors and executives of the Group are given below:

	Chief Executives		Executive Directors		Non Executive Directors		Executives	
	2017	2016	2017	2016	2017	2016	2017	2016
 (Rupees in '000')							
Managerial remuneration	49,772	40,670	34,115	26,252	7,177	8,400	227,519	193,702
Rent and utilities	8,872	7,187	2,958	2,957	1,407	1,407	48,505	40,282
Bonus and incentives	2,657	2,196	2,880	-	430	430	21,467	19,328
Gratuity	-	-	-	-	-	-	12,071	10,863
Medical insurance	-	-	323	157	54	79	5,944	5,167
Leave encashment	763	500	-	-	-	-	6,039	5,585
	62,064	50,553	40,276	29,366	9,068	10,316	321,545	274,927
Number of persons	2	2	2	2	6	6	100	89

- 33.1** The chief executives are provided with a Company maintained car, while two other directors and forty executives of SIHL availed car facility.
- 33.2** Managerial remuneration includes Rs. 2,571 thousand (2016: Rs. 3,509 thousand) paid to directors of SIHL in respect of meeting attending fee.
- 33.3** Travelling expenses of directors for official purposes are reimbursed by the Group.

34 CASH AND CASH EQUIVALENTS

	Note	2017 (Rupees in '000')	2016
Cash and bank balances	22	643,135	486,701
Other financial assets (excluding TDR having maturity more than three months)	20	139,451	1,096,241
		782,586	1,582,942

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

35 FINANCIAL RISK MANAGEMENT

The Group has exposure to the following risks from its use of financial instruments:

Credit risk
Liquidity risk
Market risk

This note presents information about the Group's exposure to each of the above risks, the Group's objectives, policies and processes for measuring and managing risk and the Group's management of capital. Further quantitative disclosures are included throughout these consolidated financial statements.

The Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework and policies.

The Group's risk management policies are established to identify and analyze the risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Groups activities. The Group through its training and management standards and procedures aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Audit Committee oversees how management monitors compliance with the Group's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee.

35.1 Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Group manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Group has credit policy in place to ensure that services are rendered to customers with an appropriate credit history.

The Group is also exposed to credit risk from its operating and short term investing activities. The Group's credit risk exposures are categorized under the following headings:

35.1.1 Counterparties

The Group conducts transactions with the following major types of counterparties:

Trade debts

Trade debts are essentially due from government companies/institutions, private companies (panel companies) and individuals to whom the SIHL is providing medical services. Normally the services are rendered to the panel companies on agreed rates and limits from whom the Group does not expect any inability to meet their obligations. The Group manages credit risk in trade debts by limiting significant exposure to the customers not having good credit history. Furthermore, the Group has credit policy in place to ensure that services are rendered to customers with an appropriate credit history.

The Group establishes an allowance for impairment that represents its estimate of incurred losses in respect of trade debts. This allowance is based on the management's assessment of a specific loss component that relates to individually significant exposures.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

Cash and investments

The Group limits its exposure to credit risk by investing in liquid securities and maintaining bank accounts only with counterparties that have a credit rating of at least A-2 and A-. Given these credit ratings, management does not expect any counterparty to fail to meet its obligations.

35.1.2 Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	2017	2016
	(Rupees in '000')	
Long term deposits	41,729	36,282
Trade debts - considered good	450,056	345,495
Loans and advances - considered good	47,654	53,282
Trade deposits and other receivables	22,023	2,560
Markup accrued	1,165	1,501
Other financial assets	189,451	1,096,241
Bank balances	634,002	475,498
	1,386,080	2,010,859

The maximum exposure to credit risk for trade debts at the reporting date by type of customer was:

	2017	2016
	(Rupees in '000')	
Government companies	247,581	136,105
Private companies	127,979	134,412
Individuals	47,999	63,904
Related parties	12,979	9,020
Others	13,518	2,054
	450,056	345,495

35.1.3 Impairment losses

The aging of trade debts at the reporting date was:

	2017		2016	
	Gross debts	Impaired	Gross debts	Impaired
	(Rupees in '000')		(Rupees in '000')	
Not past due	204,301	-	198,836	-
1 - 4 months	195,486	-	80,936	-
5 - 7 months	8,868	443	3,496	92
8 - 12 months	34,427	143	61,902	1,302
13 - 18 months	43,866	36,306	28,434	26,715
19 - 23 months	18,186	18,186	19,450	19,450
	505,134	55,078	393,054	47,559

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

The movement in the allowance for impairment in respect of trade debts during the year was as follows:

	Note	2017 (Rupees in '000')	2016
Balance at beginning of year		47,559	28,380
Provision made during the year		41,149	19,179
Less: bad debts written off		33,630	-
Balance at end of year	17	55,078	47,559

The allowance account in respect of trade debts is used to record impairment losses where the Group is satisfied that recovery of the due amount is doubtful, and when the amount considered irrecoverable it is written off against the financial asset.

35.1.4 The Group believes that no impairment allowance is necessary in respect of loan and advances, markup accrued, deposits and other financial assets as the recovery of such amounts is possible.

35.2 Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. For this purpose the Group has credit facilities as mentioned in notes 7 and 30 to the consolidated financial statements. Further liquidity position of the Group is monitored by the Board through budgets, cash flow projections and comparison with actual results.

Following is the maturity analysis of financial liabilities:

	Carrying amount	Six months or less	Six to twelve months	One to two years	Two to five years	Above five years
----- (Rupees in '000') -----						
2017						
Long term financing	503,992	167,870	167,894	168,228	-	-
Trade and other payables	1,759,958	1,759,958	-	-	-	-
Markup accrued	398	398	-	-	-	-
	2,264,348	1,928,226	167,894	168,228	-	-
2016						
Long term financing	839,665	167,826	167,848	335,764	168,227	-
Trade and other payables	1,423,233	1,423,233	-	-	-	-
Markup accrued	483	483	-	-	-	-
	2,263,381	1,591,542	167,848	335,764	168,227	-

35.3 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, markup rates and equity prices will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return on risk. The Group is exposed to currency and markup rate risk.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

35.3.1 Foreign currency risk

Exposure to foreign currency risk

Foreign currency risk arises mainly where receivables and payables exist due to transactions with foreign undertakings and cash in foreign currency bank account. The transactions and balances in foreign currency are very nominal therefore the Group's exposure to foreign currency risk is very minimal. The Group's exposure to foreign currency risk is as follows:

	2017			2016		
	(Amount in '000')			(Amount in '000')		
	GBP	USD	AED	GBP	USD	AED
Bank balances	-	5.61	151.89	-	0.45	121.83
Letter of credit	-	(490)	-	(9.09)	(124.09)	-
	-	(484.40)	151.89	(9.09)	(123.64)	121.83

	2017			2016		
	(Rupees in '000')			(Rupees in '000')		
Bank balances	-	587	4,333	-	47	3,466
Letter of credit	-	(51,352)	-	(1,276)	(12,992)	-
	-	(50,765)	4,333	(1,276)	(12,945)	3,466

The following significant exchange rates applied during the year:

	Average rate		Closing rate	
	2017	2016	2017	2016
	----- (Rupees) -----			
USD 1	103.76	103.39	104.80	104.70
AED 1	28.24	28.14	28.53	28.45
GBP 1	131.60	154.22	136.42	140.38

Foreign currency sensitivity analysis

A 10 percent variation of the PKR against the USD and AED at June 30 would have effected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular markup rates, remain constant.

	Change in Foreign Exchange Rates	Effect on Profit	Effect on Equity
	%	(Rupees in '000')	
2017			
Foreign currencies	+10%	(4,643)	(4,643)
Foreign currencies	-10%	4,643	4,643
2016			
Foreign currencies	+10%	(1,076)	(1,076)
Foreign currencies	-10%	1,076	1,076

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

35.3.2 Markup rate risk

The markup rate risk is the risk that the fair value or future cash flow of a financial instrument will fluctuate due to changes in the market markup rates. Sensitivity to markup rate risk arises from mismatches of financial assets and liabilities that mature in a given period. The SIHL exposure to the risk of changes in market markup rates relates primarily to SIHL long term debt obligations with floating markup rates.

The SIHL analyses its markup rate exposure on a dynamic basis. Various scenarios are simulated taking into consideration refinancing, renewal of existing positions, alternative financing. Based on these scenarios, the SIHL calculates the impact on profit and loss of a defined markup rate shift. For each simulation, the same markup rate shift is used for all currencies. The scenarios are run only for liabilities that represent the major markup-bearing positions.

The SIHL adopts a policy to ensure that markup rate risk is minimized by investing its surplus funds in fixed rate investments like TDRs.

Profile

At the reporting date the markup rate profile of the SIHL markup-bearing financial instruments is:

	Note	2017 (Rupees in '000')	2016
Financial assets			
Other financial assets	20	189,451	1,096,241
Bank balances	22	566,133	400,447
		755,584	1,496,688
Financial liabilities			
Long term financing - secured	7	503,992	839,665
		251,592	657,023

The effective markup rates for the financial assets and liabilities are mentioned in respective notes to the financial statements.

Markup rate sensitivity analysis

If markup rates had been 50 basis points higher/lower and all other variables were held constant, the SIHL profit for the year ended June 30, 2017 would decrease/increase by Rs. 3,547 thousand (2016: decrease/increase by Rs. 5,209 thousand). This is mainly attributable to the SIHL exposure to markup rates on its variable rate borrowings.

35.4 Capital management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern so that it can continue to provide returns for shareholders and benefits for other stakeholders and to maintain a strong capital base to support the sustained development of its business. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividend to ordinary shareholders. There were no changes to the Group's approach to capital management during the year.

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

36 FINANCIAL INSTRUMENTS

Fair value of financial instruments

Fair value is the amount that would be received on sale of an asset or paid on transfer of a liability in an orderly transaction between market participants at the measurement date. Consequently, differences can arise between carrying values and fair value estimates. Underlying the definition of fair value is the presumption that the Group is a going concern without any intention or requirement to curtail materially the scale of its operations or to undertake a transaction on adverse terms.

IFRS 13, 'Fair Value Measurements' requires the Group to classify fair value measurements using fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the assets or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

Financial instruments by category

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy for financial instruments measured at fair value. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

	Carrying Amount		Fair Value						
	Loans and receivables	Available for sale instruments	Fair value through profit or loss	Other financial instruments	Total	Level 1	Level 2	Level 3	Total
(Rupees in '000')									
June 30, 2017									
Financial assets not measured at fair value									
Non-current assets									
Long term deposits	41,729	-	-	-	41,729	-	-	-	-
Current assets									
Trade debts - considered good	450,056	-	-	-	450,056	-	-	-	-
Loans and advances - considered good	47,654	-	-	-	47,654	-	-	-	-
Trade deposits and other receivables	22,023	-	-	-	22,023	-	-	-	-
Markup accrued	1,165	-	-	-	1,165	-	-	-	-
Other financial assets	189,451	-	-	-	189,451	-	-	-	-
Bank balances	634,002	-	-	-	634,002	-	-	-	-
	1,386,080				1,386,080				
Financial liabilities not measured at fair value									
Non-current liabilities									
Long term financing - secured	-	-	-	168,228	168,228	-	-	-	-
Current liabilities									
Trade and other payables	-	-	-	1,759,958	1,759,958	-	-	-	-
Markup accrued	-	-	-	398	398	-	-	-	-
Current portion of long term financing	-	-	-	335,764	335,764	-	-	-	-
				2,264,348	2,264,348				
June 30, 2016									
Financial assets not measured at fair value									
Non-current assets									
Long term deposits	36,282	-	-	-	36,282	-	-	-	-
Current assets									
Trade debts - considered good	345,495	-	-	-	345,495	-	-	-	-
Loans and advances - considered good	53,282	-	-	-	53,282	-	-	-	-
Trade deposits	2,560	-	-	-	2,560	-	-	-	-
Markup accrued	1,501	-	-	-	1,501	-	-	-	-
Other financial assets	1,096,241	-	-	-	1,096,241	-	-	-	-
Bank balances	475,498	-	-	-	475,498	-	-	-	-
	2,010,859				2,010,859				
Financial liabilities not measured at fair value									
Non-current liabilities									
Long term financing - secured	-	-	-	503,991	503,991	-	-	-	-
Current liabilities									
Trade and other payables	-	-	-	1,423,233	1,423,233	-	-	-	-
Markup accrued	-	-	-	483	483	-	-	-	-
Current portion of long term financing	-	-	-	335,674	335,674	-	-	-	-
				2,263,381	2,263,381				

Notes to the Consolidated Financial Statements

For the year ended June 30, 2017

37 OPERATING SEGMENTS

The consolidated financial statements have been prepared on the basis of single reportable segment.

37.1 All revenue of the Group is earned from customers located in Pakistan.

37.2 All non-current assets of the Group at June 30, 2017 are located in Pakistan.

37.3 There is no customer with more than 10% of total revenue of the Group for the year.

38 RECLASSIFICATION

Following corresponding figures have been reclassified for the purpose of comparison.

<u>Consolidated Balance Sheet</u>		2016
<u>Reclassification from</u>		(Rupees in '000')
<u>Current Assets</u>	<u>Reclassification to</u>	
Stores, spare parts and loose tools	Current Assets	
	Stock-in-trade	80,931
		<hr/>
<u>Consolidated Profit and Loss</u>		
<u>Reclassification from</u>		
Inpatients revenue	<u>Reclassification to</u>	
Supplies consumed	Pharmacy revenue	675,968
	Medicines	402,371
		<hr/>
		<hr/>
<u>Consolidated Balance Sheet</u>		2015
<u>Reclassification from</u>		(Rupees in '000')
<u>Current Assets</u>	<u>Reclassification to</u>	
Stores, spare parts and loose tools	Current Assets	
	Stock-in-trade	119,476
		<hr/>

No other major reclassifications were made during the year.

39 GENERAL

Figures have been rounded off to the nearest one thousand Pak Rupees unless otherwise stated.

40 EVENTS AFTER BALANCE SHEET DATE

The Board of Directors of SIHL in their meeting held on September 11, 2017 have proposed a final dividend of Rs. 5 per share.

41 DATE OF AUTHORIZATION FOR ISSUE

These consolidated financial statements have been authorized for issue by the Board of Directors of SIHL on September 11, 2017.


CHAIRMAN


CHIEF EXECUTIVE


CHIEF FINANCIAL OFFICER

Pattern of Shareholding

As at June 30, 2017

Number of shareholders	Size of holding of shares		Total shares held
	From	To	
136	1	100	5,792
1,141	101	500	546,786
316	501	1,000	261,242
258	1,001	5,000	580,971
73	5,001	10,000	587,489
57	10,001	15,000	693,540
29	15,001	20,000	540,983
20	20,001	25,000	444,411
14	25,001	30,000	392,327
11	30,001	35,000	357,929
9	35,001	40,000	346,633
8	40,001	45,000	336,939
10	45,001	50,000	484,790
6	50,001	55,000	314,419
5	55,001	60,000	296,510
2	60,001	65,000	123,950
2	65,001	70,000	134,800
1	70,001	75,000	70,772
4	75,001	80,000	315,306
3	80,001	85,000	247,271
6	85,001	90,000	527,260
2	90,001	95,000	184,597
11	95,001	100,000	1,094,757
1	100,001	105,000	100,266
5	105,001	110,000	539,908
6	120,001	125,000	739,928
3	125,001	130,000	382,825
2	130,001	135,000	266,890
3	135,001	140,000	411,267
1	140,001	145,000	140,700
1	145,001	150,000	150,000
2	150,001	155,000	306,230
1	155,001	160,000	159,600
1	160,001	165,000	161,040
1	165,001	170,000	167,410
1	170,001	175,000	170,300
3	190,001	195,000	578,879
1	195,001	200,000	200,000
1	200,001	205,000	204,925
2	205,001	210,000	415,317
1	215,001	220,000	219,755
2	225,001	230,000	454,675
1	240,001	245,000	243,840
2	250,001	255,000	506,294
1	255,001	260,000	259,119
1	265,001	270,000	266,560

Number of shareholders	Size of holding of shares		Total shares held
	From	To	
1	275,001	280,000	278,358
1	285,001	290,000	285,436
2	295,001	300,000	597,474
3	300,001	305,000	904,622
2	305,001	310,000	616,663
1	325,001	330,000	327,548
1	330,001	335,000	332,852
1	340,001	345,000	343,307
1	345,001	350,000	347,260
1	350,001	355,000	354,370
2	415,001	420,000	832,304
1	440,001	445,000	442,364
2	455,001	460,000	915,909
1	515,001	520,000	515,157
1	525,001	530,000	527,850
1	530,001	535,000	533,400
1	555,001	560,000	557,500
1	565,001	570,000	567,846
1	585,001	590,000	588,229
1	665,001	670,000	670,000
1	920,001	925,000	922,511
1	1,450,001	1,455,000	1,451,747
1	1,465,001	1,470,000	1,465,343
1	1,595,001	1,600,000	1,598,100
1	1,765,001	1,770,000	1,768,307
1	1,775,001	1,780,000	1,775,068
1	1,885,001	1,890,000	1,885,205
1	2,170,001	2,175,000	2,172,451
1	2,230,001	2,235,000	2,234,528
1	2,400,001	2,405,000	2,400,995
1	5,110,001	5,115,000	5,110,425
1	5,275,001	5,280,000	5,279,569
2,205			54,537,900

Categories of shareholders	Number of shareholders	Shares held	Percentage
INDIVIDUAL	2,130	38,656,803	70.88
FINANCIAL INSTITUTIONS	2	92,171	0.17
JOINT STOCK COMPANIES	14	193,901	0.36
OTHERS	59	15,595,025	28.59
Total	2,205	54,537,900	100.00

Disclosure in Connection with the Pattern of Shareholding as Required by the Code of Corporate Governance

As at June 30, 2017

Categories of shareholders	Number of shareholders	Shares held	Percentage
Directors, Chief Executive Officer, and their spouses and minor children *	11	7,483,493	13.722
Associated Companies, Undertakings and related parties **	2	8,450,487	15.495
Banks, Development Financial Institutions, Non Banking Financial Institutions	2	92,171	0.169
Shareholders holding 10% or more voting interest ***	1	7,880,564	14.450
Joint Stock Companies	14	193,901	0.356
Executives	10	50,028	0.092

* No. of Shares held by Directors, CEO and their spouses

Dr. Manzoor H. Qazi	1,465,343	2.687
Dr. Habib-Ur-Rahman	456,589	0.837
Mrs. Shahida Rahman W/o Dr. Habib-Ur-Rahman	13,117	0.024
Mr. Muhammad Zahid	431,942	0.792
Dr. Mohammad Salim Khan	227,975	0.418
Mr. Shafquat Ali Chaudhary	1,768,307	3.242
Shah Naveed Saeed	13,528	0.025
Mr. Qasim Farooq Ahmad	2,053,426	3.765
Dr. Samea Kauser Ahmad	1,030,594	1.890
Syed Ilyas Ahmed	11,336	0.021
Dr. Prof. Shoab Ahmed Khan	11,336	0.021

** Shares held by related parties

Shifa Foundation	569,923	1.045
*** Tameer-e-Millat Foundation	7,880,564	14.450

Shareholders with 5% or more voting interest

*** Tameer-e-Millat Foundation	7,880,564	14.450
Mrs. Kulsoom Zaheer Ahmad	5,383,594	9.871

Form of Proxy


31st Annual General Meeting
Shifa International Hospitals Ltd

I/We _____
of _____
being a member of Shifa International Hospitals Limited. Folio No./CDC A/c No. _____
No. of Shares _____ hereby appoint _____
of _____ Folio No./CDC A/c No. _____
or failing him/her _____
of _____ Folio No./CDC A/c No. _____

who is a member of the Company as my/our proxy in my/our absence to attend and vote for me/us and on my/our behalf at the 31st Annual General Meeting of the Company to be held at 1030 hours on Friday, October 27, 2017, and at any adjournment thereof.

As witness my hand this _____ day of _____ 2017

Signed by the said _____



(Signature must agree with the
SPECIMEN signature
registered with the Company)

Witnesses:

1 Signature _____

Name _____

Address _____

CNIC/Passport No. _____

2 Signature _____

Name _____

Address _____

CNIC/Passport No. _____

Important:

1. This form of Proxy, duly completed, signed and stamped must be deposited at the Company's Registered Office, Sector H-8/4 Islamabad, not less than 48 hours before the time of holding the meeting.
2. If a member appoints more than one proxy and more than one instruments of proxy are deposited by a member with the Company, all such instruments of proxy shall be rendered invalid.
3. CDC account holder, sub account holder/shareholder may appoint proxy and the proxy must produce attested copy of his/her CNIC or original passport at the time of attending the meeting.

AFFIX
CORRECT
POSTAGE

The Company Secretary
Shifa International Hospitals Limited
Sector H-8/4, Islamabad,
Pakistan

پراکسی فارم
۳۱ واں سالانہ اجلاس عام
شفا انٹرنیشنل ہسپتال لمیٹڈ

میں / ہم _____ ساکن _____ شیئر ہولڈر شفا انٹرنیشنل
ہسپتال لمیٹڈ فولیو نمبر / سی ڈی سی / اکاؤنٹ نمبر _____ شیئرز کا شمار _____ بذریعہ ہذا تقرر کرتا ہوں
_____ ساکن _____ فولیو نمبر / سی ڈی سی اکاؤنٹ نمبر _____ یا اس
کی عدم دستیابی پر _____ ساکن _____ فولیو نمبر / سی ڈی سی
اکاؤنٹ نمبر _____ جو کہ میری / ہماری غیر موجودگی میں میرے / ہمارے پراکسی (نمائندے) کے طور پر کمپنی کے ۳۱ ویں سالانہ
اجلاس عام میں جو ۲۷ اکتوبر ۲۰۱۷ بروز جمعہ دن ۱۰:۳۰ بجے یا اس کے التوا کی صورت میں منعقد ہو گا میں میری / ہماری جگہ شرکت کرے گا
اور ووٹ استعمال کرے گا۔

میں بطور گواہ اس _____ دن _____ ۲۰۱۷

دستخط مذکورہ بالا: _____

ریونیو
مہر

(دستخط کمپنی کے پاس موجود نمونہ
کے دستخط کے مطابق ہونا چاہئے)

گواہان:

۱۔ دستخط _____

نام _____

پتہ _____

شناختی کارڈ / پاسپورٹ نمبر _____

۲۔ دستخط _____

نام _____

پتہ _____

شناختی کارڈ / پاسپورٹ نمبر _____

خصوصی ہدایات:

۱۔ یہ پراکسی فارم باقاعدہ طور پر مکمل کر کے، دستخط اور مہر کے بعد میٹنگ کے انعقاد سے کم از کم ۴۸ گھنٹے پہلے کمپنی کے رجسٹرڈ آفس واقع سیکرٹریٹ ایٹ فور اسلام آباد پہنچ جانے چاہئیں۔

۲۔ اگر ایک ممبر ایک سے زائد پراکسی یا پراکسی کے فارم مقرر کر کے کمپنی کے پاس جمع کرواتا ہے تو ایسے تمام پراکسی کے فارم کو غیر قانونی تصور کیا جائے گا۔

۳۔ سی ڈی سی اکاؤنٹ ہولڈر، سب اکاؤنٹ ہولڈر / شیئر ہولڈر اپنی پراکسی مقرر کرنے کا مجاز ہے۔ اس پراکسی کو میٹنگ میں شرکت کے وقت اپنی اصلی / تصدیق شدہ کمپیوٹرائزڈ قومی

شناختی کارڈ یا پاسپورٹ کی کاپی لازمی دکھانا ہوگی۔

AFFIX
CORRECT
POSTAGE

The Company Secretary
Shifa International Hospitals Limited
Sector H-8/4, Islamabad,
Pakistan

INVESTORS' EDUCATION

In Pursuance of notification No. SRO 924(1)/2015 dated September 9, 2016 issued by Securities and Exchange Commission of Pakistan (SECP), the following informational message has been reproduced to educate investors:

www.jamapunji.pk

Jama Punji
سرمایہ کارانے سمجھنا اور نیکو بنانا

Be aware, Be alert, Be safe
Learn about investing at www.jamapunji.pk

Key features:

- 📄 Licensed Entities Verification
- 🔍 Scam meter*
- 🎮 Jamapunji games*
- 📊 Tax credit calculator*
- 🏢 Company Verification
- 📋 Insurance & Investment Checklist
- 👉 FAQs Answered
- 📈 Stock trading simulator (based on live feed from KSE)
- 📖 Knowledge center
- 📊 Risk profiler*
- 📊 Financial calculator
- 📧 Subscription to Alerts (event notifications, corporate and regulatory actions)
- 📱 Jamapunji application for mobile device
- 📖 Online Quizzes

The Securities and Exchange Commission of Pakistan (SECP) logo, featuring a globe and the text 'The Securities and Exchange Commission of Pakistan'.

jamapunji.pk @jamapunji.pk

*Not for investment advice. Please consult your broker for investment advice.



Sector H-8/4, Islamabad, Pakistan.

Ph: +92-51-846-4646

www.shifa.com.pk